var title_f13_8_13440="Scheuermann kyphosis";
var content_f13_8_13440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Scheuermann kyphosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with Scheuermann kyphosis have a rigid kyphosis with a relatively sharp angulation when the child bends over, best viewed from the side of the patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13440=[""].join("\n");
var outline_f13_8_13440=null;
var title_f13_8_13441="Bimatoprost and timolol: International drug information";
var content_f13_8_13441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bimatoprost and timolol: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ganfort (AT, BE, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MT, NL, NO, PL, PT, SE, SI, SK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4145810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Timolol and Bimatoprost",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4145811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta Blocker, Nonselective",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Antiglaucoma",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Prostaglandin, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4145812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4145814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Adults: Instill 1 drop into affected eye(s) once daily in the morning",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4145815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic: Bimatoprost 0.03% and timolol maleate 0.5% (3 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10443 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-2A8E9B1E90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13441=[""].join("\n");
var outline_f13_8_13441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302624\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145810\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145811\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145812\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145814\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821222\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145815\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10443\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10443|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_8_13442="Inflammatory breast cancer with peau d orange appearance";
var content_f13_8_13442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clinical presentation of inflammatory breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The characteristic \"peau d'orange\" appearance of the breast skin, which is similar to the appearance of the skin of an orange, is apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Giordano SH. Update on locally advanced breast cancer. Oncologist 2003; 8:526. Copyright &copy; 2003 AlphaMed Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.TheOncologist.com\">",
"      file://www.TheOncologist.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13442=[""].join("\n");
var outline_f13_8_13442=null;
var title_f13_8_13443="Lupus erythematosus tumidus on face";
var content_f13_8_13443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lupus erythematosus tumidus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDRi5kLZ4Y4/Cn8M5JPPQD2qPkEbhxTfLZmwSc15zPoUizu3KxcZA6E/wBKbNvAG3h8jPtTgwSIs/TsOwFV7WYzB2PCg8d80m+g0upbCjdlicnjPrUkigQqS3JOPamRfOFL5C+9WCE7AE9h6VSQDYlxHg4HbFSoSFG3oOgNCr8uNpzTwMBcDFFrCbGgM4AJJIpXZ1UhMFjxz0FKflU4P41D5uSwPYc9qdxxV2WUcgHnAqVWLDGSoPvWbvJkU9D2FXEnAwSD83OBTG4MmGB3OT61KcNxngCq6Nuf5jmrAzglhx2xSWhDjYZkEfex7VajJZAPTpzVF5EjPUE9KsWu503jhaNxuOheBYFeO2KcgOCOeDSRxkpuwQw68dKcoGeQWz79apGQ9OFJ3ZHbilOdoOSPxqORSCDub124zimuykgg4H16mgYrk4Jydv8AKowVDYBz3zTjjJOCPbqKaxi3DK7eM9aYDXIGT1Pr7VXmcYHQZP5ilnnjGCuSo4PFZ00mHON2MdSMipbNIRJppkAJ5GPSqjzByCDyDkc0EEDqSc9O1Vpo2LFcfLgk4qWzVRQvmbzgMMA896gnmUEeZKNo7AUscMiqDgAep6iljtcKzuGkY92paoqyMqeVpd22MhegJzTRaTSMrYMg28bxgCtpLdyTggAc9an8lCRjepX070cjYc6WxkPpzZXJ25HAVQaq3mnkS8xuZGOGLd66pWCNhcoD1NQYSW4c45Xj61py3MeZnn2u6RI0qtMmQqtsXHAPsKw/Een7rlBFH5jpAcMDyXJA/rXqGqWyTSIzZ24YY98d6yUtY7jXfMVFEUMSouBxuxyam2tilLQ861XQZbbQba1Kfv4ZGkOeA+QKoaJZG/jW22iNnYeYD/Ao/wDrmvT/ABlaRmwMwCsFxkDuMjIHvVLTNGEaTTuwQS4IUdcemap6C3PKtTtJLe6vIEZiUAJIOdwB6in3cD2ZiVCNs0IlBPc9a9F1nSLebUvMQfMYCoAHYdc1zF1ppuNDN4wxJakwIp/uZ60JoOW5i6svkJCDIflVZV29MEVAryxF5ZDtWRgAO+RzW7Y2C3unH7pdbYD1wwPSq91aC40NZFwJNxOT6qMUcyJ5bGR5kn2i525xG3zDPY+lUrJWuDIVY/u16euK0UES3hXcRFdQ4LEfdYf/AF6Z4Wt3jvLsbd6ocMvfB700yeXVFW7uGit7dy25+cYPBU9vwNZ8MgZvKflDJtP41vappqrEJYV/crIQw68GsC2tVGpJbEnDtgN7ZqkyJRcZInu42jLW5Ztmcq38qdp0crIxOCrHDKeoPqK3brTUkARgfNPy7u2Oxqm1kYAkruV/vjONw/oaOa5bpcruVI4nhnCyJ35z0rd0+3hEkctozxSY+aDrk+o7EVY09EnjxMCrkBVbAxIvbPpW7pOlgBA0UbxjgZHT/wCvUc3c0UFa6LemCKZU81cH/nog6n6dq67T4EjCbX3q3Qk55rFs7O3+0EwFoHBA254NakKyBdn3tpzuUYI/xppBI24iFVcbAxB5HSrscoURmTDKRxmsRGHTfkdRmrSzgwbGXBHQg1rEzcehLczgsGU4BPIpY5CzZKkE9hVEyIHwWBz3XnFWIWwoJJrJ7lJWJuWLbi3+FShd3Dk4x1JpikoS3TPr3pzAjLFhk/j+VI0HSKAQFJC+9WHx5KjcQ3XBNRW4BQTSZPbFNZ/MGf4+mT0pjWug5JhnAwcdRinNId/HTFV1hw28MRzz71MVOAVZueoNJXLdiQs5AwQB6YpcuCPT0FOjG3luT3BqUvtPQbTxVpEsTDgnHTuTzj6UVI288R4YdjRVEanNbuC7evSlMqIAWzuPSmHai/Nzk8D1NSqgZQ0uCOwrnd2SkhYyJAd/SnpGvCJwvfHU02PJb5sAd6miOOTgHsKaVtwEZmBUYAHpUkRVwzN8oHBpxG5iDn3PrTjGhYAn5U64oKuTAArjPNKQfxApkfrnk8EUHIXaWU5OSfSm3oRYSdl2HHJIrKZ33N8zEHj6VfeLaMgkjPHpVSVJJME8HsKVr7m8EkJCxVdpUtknr3q9buQMMuO/XpUEMZdRu4UHr71cSIqp28A+tVYqdiW3UtIW2kLjipCWA+Ubh71HGOPn59AKlOGwB+RqDB7lUxkzDJBDdhWrbfIuAdgNVI4SxOQABVyOMKOck47DrTi7DlLSxMZeCpPHU9h+NBnOVAIYf7vSo5CxRVCgL1INISzx9SoP4AU7mVkOeRs/M2D2wKYGKrvXbg8dKjMw2kEKD6g9abIxdgdrFT03HAo3HYlE5xyeT2FQPKzL+7xn0PNLkg/KFw3v0pcJtBJy35ZqdRqyKhYsFBBDEZz0oWIqvBJOfmxzUrFd+07VAGRxmmjdjg5GSciml0ZVyMhQ5LA89D6GjZ0J+bI5yc00Z3MSMIR3qRkB4ABJ9qpAiOKNWJz8ozx3p7Q7HyzfQjvT0BUDjA6YqZghYg/dp2Qm9SAqoBOCSaYNpBPJ5xU4iYhtvIPHvSAgyHOCRxmgCPy8Ej+EUwR/MwOQev1qZl/jXp0xSKoGCecdc0EkF1AJF8shQMZJPcVTs7NEBxxjge1aLbMDJIB6U1kLKwPYcUWW5Sb6GfqNrHNbMGAJ6ciqyWG2DDdDxzWoygRkFT071EobaMk4P6UWQ1dIw7yzjkXaUwP7wPP4Vm/2SG0qVMBsgjHrg8CutkgDLkkcdMiqjW58gqn3hyPSp5NRpnn+h6Wltq8sIQtFcrlG7IR1FTRaMj2FzCoyscz9Rzz2rohZN8jFsOhJyKdaoyyyblGZG3jHSo2KODn0MNbsY1DOMPtYYB7Yqt4asmi1W+CxEupVwD1Gf6V372pEjZ67sgex61imxMOurcRFl3DyiQOPbNNOzHYp31jFMrvCuCxGRj35zXIa9oTWN5HLCW8ssCxUZKD2FeoeQfPbcoRmwCB0+oqhrFgCA+3BVhmqvbYFFS3MK3ijurdWjfdJFgEj+lWH0mKSZmdd6svKkcZxViKzeHDxqMEkEDqD6471q2yZhVCOR1Iqdylocza6ctnceWqAw43Af0rpdOt43RjASGP8J/iqa9swAjqAdvzEipYNsTjYhw+CVx/KqSJsuhZghEkKCRQecBwOn1qUq0LRbJGZ14+gpkZKxyAH5mxx6e4qxGD94KFK8fWtSGPICn5CGzyeKZl2O0Ec/pUigEDBLYGMe9PiiwR5e76GmyRLZFYFQo3kY6datxkwrtGB2zjOKcg2xfKo9SPSpCox1Lcjio6Be4gwuBuJYjk4qXHmKAOcdMcD8aRgQMlRg9felT/WtnOAOBSLROoCjgjaP4RTMYJ24z9ORSytjAQqPoaaNwO772eopjQ1lbndlcdsVMEwV7jGeaUIXT72PY1FLIIkwQ+ccsOaFoVe5YKfL1A5yTTtwbAxkL0NNjUGFWyc4qJtzzgfwAdB0qxJXLO9mRjjpRTFfCAMAM+/AopEnNAksp9T8vtUqnEgyDj2qNFDc457D2qaPhSNwwo4FYJWFoSfeVlUZ3ck0qjywDy1MhwVBJPB+Y+tTsd2Q2QoHGKfmFiWInAYj6ZpInV5cAnbnlgMikIPlANwT2HpTiu2P5iMDnHt2psEydDtz0OOhPeowpJAPU88HNR7jwzAY64NSgEDIIB6n1peoJDguSRnoMgVEUyCzKSTxxT9sgOeFLU7bnKnoOp70xoaiDkoAB/FVlSNvzAgn15yKhXaDg5PfbU29UBZ8gmhsHcjVpS52qAo79KtRggndy2KbGysg5GD0qb5WA+Y474pJCb7jY0JPIOD3qfnA2n8zTVQMhYnA7AdTUmwFRjGMUyLjVfKfeBbtjrQwH3pN5PoaUYDBVznGKikQEgluPXsPoKGIijwW+VBuPGP/r04hjgyHJB+71/WnOwTuVB9OaRydicAnr1oSsN3HbQXbkbfaopWznysL/tGjzBJxkKF7L3ppPzt8uT29KNAQ0KWHB56lj6VJhguCcL296EAXgHJ9j0qWOMNhm46AA0wuRRxBm3fMw6AdqsFBt3KAOcYzTxkEjnPXjpTMZIDtnPQ9MUxbkTLlSuMnqDmkTGFIID9zUhOCQ0Yz6nvULggkLu9wBSKQrt0YNk9+1Mf5xgdQeKASFAx9OM5FHpgcflSHYUkqBuJwTUTtnPAqRxk5JJPHeoZuMk4Bz2p3BIYAHKjnH5UTowzgk9hzmhclRkAD1oIIDAA7exzQirEedgAY57cU0MFOPXiq13G0iARMUfHWpYiFRQwJIHX1pXbY7DiTuYE4A9qYCCP6U51JYFeaayA8Z5Bp2sFiCOHMRHXnPHamRxlGcDoTn6VaXZjjOAfvUuFCELgn3osBm3EZV0YruHT61Dc2qlSwLA9hjitEqGUlhkg9KhcB0JHJzkZ7UrdRlM/Mquy59u4qF49wwV3JnAyORU7dSAc49O1MSQeYQ3B7ihq5SRQltSMODgg4B9KmgYEqcBW6Hj731qzcsDgA5B6gVEYgrMRgcfLQkO90OMbyrh+CeQPWkKddgwyGnqxJ9SBwakt1UoJG+9uINWQ9BcZkMgGDjj/AApy7lQqASM5J9KU5WPb69/apIiWZucnv700Qwi3jmNRg856VOqkDC8Z6E96E6HjAHAP+NWUiDAEhenGOMUNksApwpGVHQmrEinGcKCMEEUvJ+UZb03CkUNvAcYGfyqb9AQmAr5PzZ7ZpkbsWdRkKasFQRyoyDxxTAg3b+Rt6A9KbNEyRF3LkYA6YI5FDowIOcZ7ClVcjA4Hc9ak3bULDBx0z2oDYRAxB4J/lT3ZQwRsM+MgdhSsQyjHyqfTvSeUgZXAII/Wmr9Cb6j1UFsHJ+hxg0hURgjv6U5wIwnGS35Cojw7Kx5PIIPNDuNETiOVcqTjHTrk0USQ7ioUldvPSipd+xV0YXIfK8jpz6UD+4Dz6Y4p4CjdlsA9fYVJGgEZyOW5HsKRkmOjVcDK8fwr/WrMa7GHmY9T7U2z24AYfMeMHtUrfNJnOQelFtBXb0HOVKqSBkjIpmQHG3DZx1pssg/1n93gD1NMhJDFn+83b0qd9ikh0x3RuwGTnaDUUTkuwYH5R1qZQS4UkADrQoUqQOQOntRbUtBuZlyeQO57VMEKqMnn9ahRgp9T3NWUwRnoT3qkgeg3Z8429PWnTKrId3TuaQDaDnJ71Ii7MbzkddtKwriW8WFJ6d+ewqcOXUhUx7+oqExszBv4T0FTnjthvbtQkJkwB+UN+n9acJNrMO3So96BQv8AnNRb97sFPPXrTJSuSlh5mQScHp3pkjBj8w2p3qNj5agliPXHNKcuDgk9+aB8o4kFOCcE9T3pu3OQf3YH61Mh3BSAB6CkkJ34P0amS2RRFQMKuT34pzOWzsGB6UoCoTjlvfilPCEcHPNIQ2FN2SRz7VKHKvgcY4GO9Q7CNrF1AP8ADnOKlACsz449zQh2JD975iMeg5NQycodwwM9qdkMgGcAnqBinCMA9CF9qY0iNZMKRk49DTXfaBnn6daftXkYx7ikCg5BXPuaRSSIUbeuQMY4p+0Mo3A0qo6cKwAPalwxIOenakNkbY2YCnPqKa6qB8vX3qUsqhgQOvB9aQj0I+gppAVcNHhWGFHOacHBPYDHFOIJLBmye1QY2Z2k7u5I6Ua3KWok4AG5MYPbvUbLvAG0jH6U7G4ktwT1pjE564x3HOaZXLcjE2yUxsMDGMgU8Bdyk5weM1CItsiv1cjoanYA8uCT3I7Ukn1BgB8rZwPUetKVBAK9fpSBiODjdjApjkkHDYPU59aBWK0+4EEYznkVX3kvtT72OvappXJVsqPeoHw6kD5WPXFD12KSG7SMEZI746VGwLru6L0qfhYxjgngAc/nTZEY7c8c7c+tFguRbVDcYxu/HFATBDkny84x7UjlkcbBn1NWlIYKqgKo5OaEyX5Ff/Vs4UcMPlz2FKkeAAxyOv4VJKf9G5UMWP5VJ5fK5XA284707ktkbFtqkqWA4H0qZCduEzkd8U4KcKoJx3GO1WbaMAZwzZOfqKCWLboDgrgt3q3Gg44AUdjSwQgFsjGfvD0FTlFG0hj6U7ENkZVSPvEHqKR8AndzkdRU6xtzjaQajC8kKMr3B9aLBFjEwVB+beD19KXnkLggHn0pfK5xzg84p6oi4HJAFFi07bEcZUNtLE59KecjaBuVD/ETwKBDumDBeD1zTxGQRuAwD0osO4w7wp2EZHOfWrEL4Qk8seuRTlg3nI4+tIQGby8cA84qrCvcjcsx4wwI4qORfu8n321IzhDtKgAdzULAhAeoPvU3uikOXfvPcfSimAlyEXOfUUU0mgaTMMRksFBG3qc1OAoV2JyehOP0qGEEEnIAHrU6DKBGOx+ufWoZkIrkxbkP3uuKkd8wFV6gcY600KoRmXp0A9aSKPBAzgLyTSs2WrCR5VEUZJxlh6VKXwNx6EcA1FDn52wCvvUucMFZQSRjmmlYoVc7ATjc35ims7RrthJZicMetMly0pEZJY9PQVIh2ZjXGT94+nrRa+gbBEXBPGV6N71ZJ2kZYKo6CoVcKyggknOAeg96QsuNw5x0HrSWhSVy1FLzkdW6e9KU6/NiSqcJLsSpwx5Y96lVxtYnceOg7/jTDlLSygcAEjHOaUy5O7aSTxj0qpbTKGLMPlxgA0sUgOGI2lhwM9KOgnEu7WkxnaCOuDTlWNGGMZqj5yRSbM5Pt3+tN8zLEkkOeBTQ1BsvswcHYwUKe9Kc7Rk7RVeBductliepqZUO5QPmHuaLEtWZO6gBT1HbFMDkxFWQgA9aUcMQmdop7MI4ySeaasZ21K7s0gXjr0J61KgZE+fBB6+tV4y4kDHLPyA2MAVdVQQpI5PUgVKdxyVtCIRZYOFXJ71JsC8YLMe5qQIsZJYbzRIWLEKMD2ppWERBXdSAu09MU7jAEmR75pSCAdoIzyCaYAFI3DnuRyaY7D9sSnBySePxqPy2Lqpc45AHp70s4YoNvBHehUdCGkyWFJaspIdsIf8AeNn0461G5EfzL26inOTuyD26dxUMrsq/dxHjqOpoY0hlyASCTkHqRUGCZwCx4GeKsB1chRxxzkUxshSPxGO9JlpdGOZgSQhwfUiqXmoS4BIA5+tTeYjSbGcbvQmoDGoO0DAHSpu3sVGNgILSfMQy9hTlUAcjAHp3oZFVsnOafMPlUb85PPFWDZCwURY3HOfxFCKSMEkkfrUTMA56hakRyF45agTjYdHtGdgJPTmoJFQ7vMJGT1qZhmLOQpznioJVUL855zzg0mJIi3DjeQR1B7fjVVsYZQdrjkVK6kJsVcgd88ZqOQxtGXVWBx26UnoUQux5YDO7lTT13NCWzk9Oe1IhjDNu3HC/IO1SkPEoyq4xxjt3pLTUliRozAqowD39aWUA8RqSAvzexoVZCxCkrnkipwhWMLnLkc+9UmtiGRhQy4BAYdfalh3MVB4Hc1IsJU/O3UZwB0+tSqiu6qOB1z2FMQ2OLaCCD97itCGPDY3YwOMCo0IX5cZHYd6sRxAj5MqT3JoRDeg+MAyYVs8dzzTwMMAMH3pRhRz1xzS7dygHaufQ00SNDLvORlvQUp5BAXGPSjDeZt7r0IHFOIHOTtPen6jsCKu4kA9OeaMA4ULg9cVMqqFJXkkcD1NRKsj7Eyp5yQO1K+oXsNijljlZT93+8P5VaWJiwwMk8nPSk4JILbjjaABxUgRhIFY5PpVqwmxXGVPHJ/So3A27goz0wKnA3Fs8e/biqxJBfH4CkOJXaLfMXLZIHTtUU43Eg/jipSSGPbI5xVSWRgwVQTng1DNFcbJNsYKMgd8UVC8TbsnkdhRUtM1XL1KqJgFuoHNQxfPKzFiTnvSq5KtH3pkUZErDI2noaLHMupZjlAyPQYX60FhtO3Jb0P61BjbLx26D0ojYxycudpBGTQjRIsNIgjzgbcgDPeoZptyBgeSQAfQ1WZwXKNwvAA/vGnIQIT3Ibdj0q0rmsYlyJvnZfft3FL5gBO3gZxzVC13Yxlsklmx0Aqw4Mh2KvygcdhRZ2uVKJMkpKvyGZuAD6etSDDRbW6dSwPJqi2/7QScCNRwBxmp5pQLdXUZHQY7VKE1YkaVQSMFU4HXqakEnkxBACGb+H2rOkkVSfNYg+gHNOMjttJ+XyxjA649PrTSK5C/I5k34xnI4HaodzCEtHjapxz61WlkOBneseeQvY06KbOVPyjPC/wBadi1AdCxjGGyWb1HJqyDIrABev41FGkbSM7kvKeAB0FXVTdGUHGBkn1qlEcnYmtphIVTkt0JI71cVx5mx+SveqYG0qFOBj+Ht9KsRsF4GMcf/AKzQznmupYxtySRjIwKaUBc5GcclqYOJGZmOPX0qzCCcbee+TUozkrDki+Qh147KO1ERK4Urgg5/CpNzd+h9+KQowJ43MPSmjMdnc3IOOwHUUyaPy8EkZbtmlJ2pkllyOmOvtTVyFIZCM9d3rRcaT3JGTCBQePQd6ifnodpPGB6UuGEeF5x36YpSVMeMfN60mNaEIwr4diSehFMkMiuMMXVu+OlSMeS20ZxzjtSRtxtXPFLqWQb1WTLE78c55pPNViQwPPSo7gN5oY9CeKad27cU/KmtTZR01FOFXJIbPBGOlKjjaclTjpTckYxhhn0qBnWE5BBOemKS3DluBgXzzImM9QKVwFJPLeuaSSb94AMBRTWlO85GT/CB3oSS0RXKxjiRiNhx9aeSyjDciomlJO0kgjjHehlYJvJIA9aLA4DkhLgsGG3360KqqChHJ6EVSS53yEM/yDgGpQDu2IcAc7ietK4ODW48qUySCEHIIqPYn8QZvcGnMCwDEsBnAWoy7xuwWP8Adj7xz3pPuKxDIpD4j3GMZ+U9RSzSCIRJ5W3Pf1qUKXO/lRjLDoaS4zuG4g5+7k0dCZEBX5lGQFA6+tOGBEoHDnuTUieQG/eZYZyAecUSFpG/cxho+g96EyGNhRVBz68981OoUBgFYyMOM84oRRjaUCt6k1MFIyVUHP8AF0piZHHG8WckM3vzVlYgSADgg8gDvTQGckgDpxzxUgGH46igljkQKe+8jOasK3y8At9OtR5JXJHPOKcN6KSMZNMzJchlywBUAjjrUcm5NinDd1INM3tvPzgkDmpdv3ORycigEtSwJAyKwOAf4RTkUDGV+XOeahiQI5JACFvmUDjNWgrMTuJxnBx1qkJ6bDQoOTnJPOCOlPkQQoWAwQvX1zSkqmcdMcepp6twpBwM5INNakkEf3ORk44xU0ZZlI24U9/X8akWJVyy/Nnp7UgYguu0g+3QfSqW2oc1yDGWJ34Vei+tQyud/wAoAPXnpTnU9Ceff+dQzlQSBz659azZaI5JAdpUcMfmqnnbIyBiSamkckEKf8BUTgDDLyRzkVDNUSM+VUkjI44oqrkqPmOMnpRTTHYoRnaexNKCFVt3BJ61HCobB+6ec/hSyP0VMFu+fU0XMkKQJJVOcHqRT7kb2VVGKYBj3K9TUkq5YqDuIAwfSmjRblcxfMSOWI6ntUM7mOIA4Yscehq0/IIDbeMDHtWdOkpeFuGVR1PeqT6G9MtwOY9qgDJOOtSySOM9CByATxUNrIUjJwC4PU9s+lTYVvl3kuRyMdKoH5kDysFycY6k/wBBVeedlCyMw+YfKo7mpLhwxEaAso4I9fxqMK9xICApYDC9gKhq+xol1IXml3KhAMj9T1wK0IyYtxizJhduD1//AF1Xt4FiYkEtJ71LKWhdQjZO7gjvVJWKdmSszTFUCBD7dBj+tPWM4Kx/Mcdc1CWcIFxk/eYg9fapYQww2SmOD700CL0Ee1htxuI5qzghSVwcHnPaq8AGwNyc856VIkm+ParKqA/MT0qtEZtNkwZWDL1OcgjipN/8QYMDx+PtVRnDKEUcHkkdx9akgVnJjjjCrxuIOcVD1DlL1iWK4Ix6k1oxhVCgHr0FUIxh0Vk+UdQOpq7HGwYu2D6Y7UWsc1Rak7jYCqocDt70krERsQBvx0HenxksPnPTnNEgZWHA2+3Wixl1IlDSqFYHcBg4/lUjxDcOpZTipDKVTAXaMfeNNL4yyYIznFNWHrYh3lAwcYz0Bph/e8HAUde2KfIXJ45bOST/AEpzKvzBhkkZGelJajRUnDLEpUgo3Q+tReYCSqEbqS6djIFU8n8hVYwuuWXr/Eam2uh0Rirak1wR5bBeWAyR71GJyyjaCDjo1JEoABkByOvPWpQiuM7fZfaq3LaSKd2jAK6kAE9jUToBjjOat3OSMY4HGapGYkumPmJwPQUWSNIXaK9wxwgPGOTUJuCJDsBYHvjpVkW0bozsTnpVdkZAqDG0c59aLGsbMbve5kLbWjVT3PJ96lm81I8bgFztye9RgkS7QGH1qwVJKMcMAMAYqJIJ6MgkijREQLnjKgdzTo4HFxjJK9SCOlNi2Rz+YAWycdOlaEWAWJIKnue1LlW5lNsQqZDnZhR0HpUYhbcAoHyjkHuasM8eN2SD2PrVco8oPlqVGcE5oaMUQ4MpwwA55A6UhEe7DgggcA9KcVweW2knpT4ssw3jI9TSsFupHFAqLtU7j1Leg9Kkij67RxnAA7VLIieYMlhU0ShZQ/8ACeCKdjNvQjZFVlZly38qQhiue5bkY6CpW2ZYZBzSQIwJG0MR+tK/QjbUBGSxC8ADNCo24AjPNWIvnXI+8Dgg0gbB6DaSe1VYlsYhyzKchc4ApWaQZUAY6tn+lPDqAykEOvSlAJRW4zQmgIFPBLD8frV63B2bTgp+tQKuZtgwQRyelWGYDhTkgcgd6BNEiSqRhQMencU5fmyWJVeg5qIKGj4RTzznqtLBE205c5x0YUybE0Y5bem854I6VZUEKGJTOcYAzVeEuSzSEKg4VVHI+tP8wlwibVA5PHWrukQ/InLBiwwxwOdvAFV5VJbsDUkjkKUiBI9fWoMs67n+Vf4h6UmxJDJTnG0YCjHPSqU7BSM9+1WJX/dnJwCelVJWWMAsN3PArOT0NoxIjIGbC4H1ppLZODnjpU3l7iSAMN1ppTj5cj3pF3REI/4sE/WipWyOo+U96KCrmSq7F3EHjse5qFmRWZ9ucmnHLJl+4OD7+lD7VEcf4n2pmS0JlXZtLHk8mmRufM2jv94+1NY7wXHUnAH9aQyhWwyhRjp60+pcVcfKCxbaNo6cVBhig3jgLwakklVEQoeT0A6GkR/NADjCAZ59KqJrFNIhSMLbrI5GSTgetNkZxDGBglj071byGRWUKNv3ar3EAfyiOhPJzVM0UrvUrOx8oLGWwT1A6mpIF2ypGcA/xY5xUqxGIO+5QAuenOPalt90meAoAAGOtJblOV0KVY5IwEPt2FM45jIKjqBjoPepi2UVT9xTxn+KoY5l3OZOWB+6apjje1ybySNiM3AAJx0x6VPJtKhVOMY47k1WjlEuCH46tU8EOZC+8qRjANNbD2LKFkhIkPJ61G214gmW8vsCKVpACFbIAJJI6mnxMrbn2ZTGF5xTa1BaCxlUVgfu4xj1HpWlZushA2CM9dpOMelVRGMFWGE4/OrkMYKFcAYHb2oSsRUasWsbIwcKGPerCMdpzkL2qrFuLgk5A7VYSRl+8oJPI+lKWxzSHopVN5JPOMepqcMWYkAk+/amq2WDuAoPHHarBVQuQeOoOalK+pkwYGROfugc0xFQdOCB0FSNKditgAkd6QKXBKkAnAxTsCGybsgbMnNV3QZLYJPfFWyvlk5PJ56dKBgnhPlzjnvRYdzLih3s5fC46CrTYWFlCjk8mrMoRp2RuPTA6Cql1lMs2CAOhHUU0kjRScnYoMqNJwCo96gmDqy7fug5A9KsFtwEijaD0BPBqrcYBPzYJ5HNTY6IkLsxO1s7ielRpamWQhB8w5JJxVklFnSNnO9hnOP5Va/dyL5eDvXIB7mmkU5OOqMp1227t/y0zjmqLiJIGYnD4+8fU1pRwmOR3IBzkAMc1nrbK0rM6r5ZOQc/pSknuawkhLSMNArJG7A/eqxKsjqViyiD25q1C6o2I2CkcEGpJnjwcknjnFLTqZuTvsUo0IX5sDHAx29qsBF8jL4OeMCo7YEjGSVz1NOO7JUEBexpImWpD5FwHJDgKB8oPaoZ2uBhlTGT6VaG8NlnAIP1FM892kaMBmAPUDik/MepWEU0xYzzDJ5GB0FaEce1FyR92mBEJ+bOT0NSqjKv7wAjHQfzqW7GU5XEYK2BkHA4p4eMgL2qpIgVg6EkjoBU6IyhiOc8HNF+pDirajnhVmJUgA9alVcKcdcU2Nm8sszA4HGB0pyPuJG3J+lPToQ07DfL3rt6EdAO9SrgRjj5v4qZIxRScAkHpTBITuGMZoRNiNbciZjuYtkHGavqf3ZHrUJb5T8mW9KAymPawO49jRsN6kx+ePLAbux9KTALhw4UHgHFMiYPIoU47bfapolVThx83QjsaFqFidkaVSVwSBtOOM06OUf8sxmQDDbjjmiNH8whj0PA71KY0GfmzIPve1Naozv0GhgQfkOTySF4pwysykKDkemBRFhSV5Ge+etSS5EYYH6mmS9xrhlXJ+XNQkYUkgbqdGwlQgHhT36Zol44LE5FDCxVmi8z5sZ/xqMwkqCeg6CrJjOF2k+9OdRjHFQaXsUljKkjrSlBg/pVl1AJ9TxUEmI8cj5Tmk9EC1IgMAL1oqc8845PSimUcijGV2ODgdAO9SSgrlQevXFJAGjJc8AnpSy7VRmXj+eaCEx8SgyKrH5ccmqd1KMKnHGeaezOQAvA7nHaq0kgjzkDezDnFO5vTWpYQgzIrgbcZxTrktsPAwOcDtVaJxLzg45x6mi4dN6xh225yWP0q9kbJakssn7hC4+8c/L/ACqRVJEQ5BPHFQuSz7sfLkKijuasgOoVQcEctR1E/Ic0eEIfBJ+XBoSMBn3YVE/iH86YMhxJcHGMsB9PWnhgLdc8K/IHU/jTCwIoZnkYknggZqO6hhELOy/MzYAXrn0pUZXYuDhUbpUErmSRWX7u7g9s+uKdzaKd7lq1iCRjAG5uTnt+FTXKNHD50j4PRfembkjYNI5yMEjH6VX1GdpniiIAIOdoPrQ9EVFOTJUfziASfKA3t7nsKvW8LMd0khBPBXpVVV3QxrGvzKMtn2rQgjLCNUJOBnJpx2FJlmFiEKld2OhY1PBIYkYFlMrnkegoSNkySAx44HarECiN920LuHPpim2c85D3G6MKuATyR6+1Sq/mbUdQuMZP9BUTRiST5DgL39aljAdu5Ze+P0qLmPQtJ82C3K9CT+lTx4PzKoIHA4/Wq6sWibzCAy9PSkRmP3Scfxe1NMzsT7PtPyg4PrmmxKY3UH5k70yGVfmUcDoT/SpElRZ/mGOOPrVIVnsFxnf5ig8clfahHYqFQ4wCMg96kc73yzBe2BTmEa24XjOcnFRbW7C5Tn3RjIJJHA96gkWRmyxGVH4VYeT75IO1SF+tQLFwzsxO5u1UjWJE6hlGAvlrzgnk1SmiVoGU7QTwFxVyRURmcENjj6/hVO6MWQHZkzyB3p30N4Mr+QWniZIyXUFeemKkjz9oBfKqvb/69TQrgN5bHnvjpSSpIpjD8KByRQlpqW5X0IbggjavXd97HSqElrIJ9/XJzt7GrbNMEdFyFJ4I6mo4VcZLq6op6scnNTqVHRXE2K2AV2gd/ellWNsBs8jHFWBInlbSCQ3NVixd/LKkrzggc0noJNtgojYMEbjtzQkhihZXQnPQjkVWMGyUg71T1HNWoANyhWLJ3U9qAkla5C7Dy1SL5mY5IAoEM2/KEgdj71eXajfKgOO4qaPY5JJxnqKhR1MnNrZFVEO3B+Y9qlALk7SQfSpPLCn5Dj39KY0fz5UnAOSaGrmV7jHi2AHnHdcVICfLO0d80skhGdwIp6uGTn5eOam1yXcijKldzY4NOXhtwOF7GmMQTwPrxikzhcnoeMelAWuSTBHXcGy3THpUIAyCpA/vN6U2NWX5wN2e+etSoqsNp6dcetPcLcojSASEY3kHGaSY74do5A5H1qcAAA8UYG1WAGR60rXC4eQqokgYFuw9KkALqSTwfT1psY2MyswA689qmiPlkycE9Co6Y9aTE2CMGUhXImUfnUuxmx3YrhlBpu3awcDLDqPapto8z5cYYcc1SJuLFuAC4UAY+lSptJIPKA87R0pka5yMng444q2ilmdflIIGAD2q0mZy0ITGWwwGFH8JqEoxfGPar7AKVVsDjbj3qGT+IKAGJwTmhoSZUbAx8uMVG24MCAcUoZxv3kYWoZZMjIYj2rOz3NLDugPP4VBcpHMmCML3pss6xW8krfdjBc468CqkU17PpyyrHAty43qhJK7TyAffFDV0F7F6B4nhR42VomX5WU5BFFQ2U0dxYQzRgIJF3bf7vqKKYXuc/OdpXP3h/OopOoLYwDwMd6fgM25unJyabFKrIxHP1oYkBcb1APynkj1HWqd1HHMGYkjdkhR2qy5HloRnfnFRCPPLZY9Pp6UG8HbUqW6PtBY8AYGO3NWvKAeMuAWGeO1GdkTAdW6VKQySnoECFsnnmqWxtdkZkSQqDtTB4qY7mlK9MZHPeqiiOQfN16LVrnzDhv4cK1UmJ6DVAZyHA2L69xToVLSFgMR4OB6UTK3JHIYAfWmGQqArtwPvADp7UFJXHL8hZGPysMnI6fWkiyTI5VVRB37dqmlIMZJB2gZGPWqbbkYRBCxHzMf72e1O1jSFy3axnapf51bJOP0p9/HG08JR8FVxkLRET9oiDghQ3QdPpVi9RUJcbQGHQjpTbuik3zENg+6ZRyQMk5/irUiD7V2cbzwPSsi0G/mMnd90H19a0bF2LKGbdsyOOtF7IVRGrbIAu1juy2S39KtqVdiWz6YHpWYLhs53DJ4HHStCANtIA5bJ59Km9zkkh5XJCA4BOT7GnxkIxVevbFVw0hUg7Qh+8wNWokKLG2AO+P5UEvQE+UkN/C2cH0p4cyHCkKCMnHpUcwcvs2kMwyxPem26tGgSReWNJaCtoW4So6qMZouG3YCjocggd6coT5Gf+LtSlcs3POatMm+oRupQgptA4/GlG0RhgDwMVCQQduCSDnNTK4YDgBRyN3c0XHYgfIUqFU7jxmq8jMkwjPO49+AKnuJJDCFAHXcTikkEdwA6kgcdab8jRFHMryB44xuL/wAXQD1p8oMsilVWQqcMSvWrhZYQB8pUeh/SlaJJlMicbh24NVyj57MrxRBkIJB9B0qK6UKpcEHj14FPWAiQiRi2BkHNQ3yOybfL+XqMcU7uwvtblSRh+7MbZGCOBzUSm5JZXj+Xt7D3p9tH5cu4l2cdSegq3IxJ3tJlj7dRU2drs25ktipDM3mbJkUEjAApl4qlFOSpJ4I7VFdCISeazFjjgg96FmVplKs3K8gngVEnfQpx6oMswKsN3GOlWLdV2LlDkdcd6i3bGPIdfUU2O5V5CqkqaWwpXlsWGDIzBSu00yFSnmfPndznGcfSqkl2sbOJep6Y9altpGMJMnyofTtU31uS4NIuoxGBlW+opNzFsoVU9OaiZAV3HbzyDT1KE4HJI4NSzJxIp3IjYs2DnBpluz5JTLBuGFSmHMbFuhPep4guwAnb3yKlp3uJvSwkajaCSfp6Gl2bVB4LU5WAJOQeeaevOcYK9apEakQBIJC8njioo0Kluc98GpXDAl1yCDxjpTwmGzzubvniga03KykPj5eM5q4irtWP2JJqFsb+uPftS/eJDYBHINIGriqCBgZcjkE+lPVl3Dbwcfd/pTVGZBjg9CB0p+w794wd1J3CxYjKhlD5IIJGO1Dq23KY4wRj0qO3HmAo2NoPY81cRAwAY/Mg6A4yKe5mx6Au5bOUZcYHQVZRGAO4AYAxjuKitlU22zO1hwN3OM9qe77I1PYrt/H1rSOhk22OdgFDsee9UJJQGYr37elTSc/McsRwPcVSuZOccZNNlpEczc4AG6q7OcHcB17UkrbjyaiyQvHPNZtmiCSRAreZt2Y+bPTHfNc5HdW6L5cF/qItPuhUiLcegbritu8Qy28qY3ZQjaOCePWseJ9RjgjD2BbYoUFZgBx7VF2tgauzoLZ4TZW/2cFIAuERhggehoqnazPPAjyxlJMcoTnBoo5mPlMycnLAHBzTQhVeW5Yk012LTlVOFFMDcMzsTgbRVN9TOK0FTLvjr82B7ChyDI4zhun0psO9Y3bPLEY+lKPmmAYfLyXPf2FNGqB9sYUAfe4BxShzNL85OD8v/wBamyE7NxGXU8f0qvI5DAquVxgEd6aZrHUV9pd2UAIDjFTKxYncvyADgHrVSJNqzMykqrbhjrS7/LKuoJDY2qfX1NUma8ty6txmElvlZgQPaoVibO0tyRliaIyojEsrZJbG3196IwTLu5YZ3Y9fSn0KWmxflO7yYs8qATx0qOZUhQlMknkfWnQqcsWZmZsZ4p3ls4YhRtByfanqC0Y6EMuwyMAeSOO1PTbMzA8+oPpUkcTAq0inGKmEW1/kIDdPmpA5IitrRXYRxjaOmfX3qylp5cowQBnBxQqPHnLMpPerMLBkBDZB9etFzOc3bQLfYJifvBQe1XrWffHvKlS2FHHaqkSopJBwM1biBLARcjPWoTM566FgqFbYq8HqfSpdqO534EQ/SqbMxLbGyVqWAvNBxzTUrmTRY8syKCScdSPQU+VCZI2xgDtQm8IoQf71SKWJyOccVSRFxzAFNu0bT1oBAAViDikaTnb2FMY4U5IwPTvRsCQrpgkgfX3pZIwVHUe57VEsmWIx8gPXvT3nUjao7fnTTKVxoYKMSE8DPAqKN1jRQQ2WJOfWpAAX3EjIHQ9qhKuZVCHPPK/1qy0WtiBBjGAeeO9RsgWM4ODnOPWo4HkJYMnAPAPelMgbJGVYHpTWommnYpi5KA/L37VKXJjfOGB9+lQSjKnAYoTyR61PDuWEKwyqnOPU0Lc0klYhaCRgJUzt7A+nrVR5WWTDg/Re31rS8wszNIWAUbdpP6VBNJPHLJII1U46YzgU5K5UW9jJWDzJXJ+VPpxTEjdMjaQD+tW2kM0PyAq5POO59arSh9pVmyOoFZWSN029CEhxI6biit2JqExCP5kfB7igRu8oeSUBjgBTVm4tcx+YvI6de9JRb1K20KwKkqXAL55B71oRFgmSnysKx7VWmlUv8xVtpOa0/tTHbGidBzzSbWwqsbFq0zja7ZTOQOtKQ6yZyAFOBx29ahllTywVYbyPur1FJFLI0RySxA/iGDUOPYw5Wy/PgKFjPzdR6VER1BByR60kO3yDsyTjoe1RhpH4RsrnHSixnyjiwBAwpb0BxmpBuBBX5vbpimBeF3/eFSfdCg9TxxR6ktixO5JOe/QipHPAToSc5pqkkKoGcHgijeNpUg5JyD3FBDEOCTuPGcdO9I+V4CkjGRSTMY+Bg55yOlSA4XchypwR6YoKIoyCoX+E/NkVNhlG0nB7VXVgX8teCp3e30qyoSQrliUzkD0NTe6BkkBAYNsCtxk9s1aQ7TvKgdNw9qgIZSN6jBp3mFHHfcOlMzeuxcjG0gDqSWU+1TuoX5XBwarRtuw3OMEHHan3Eu7Yu4gLz0rRMya1KtxLj5T1HHFUHZW3YB3d8mp7lsMzMcY71SlY5BXPPtUtmsEhHDfNk5qIMwIBzjkk1KWOwZO0+lNXc3QcetQzWxRurS2vJFMxkDAY+VyvH4VAuiWTOwBmIH/TZq0fJYsGxU9vHIUPK7+3bJpg4rcjtrVLeKOJFOxBtHOTiirlhHdFT9sSAMB0iJOPY5opWM+c4/ft2vwcgikCjygMjfzwKYmTCDj6UqkgblUenNAkLM2dgUcZ7dKRyWBAXndzmpIeUClenOKiMm1sY+cg9fU+tMuI6NT5DSyZK5woqNnPKwgDYM/U1YUhI0VyNiDnHc9qhjQxyKVTDn5jmg0iyFonhWXeSS4AUnpmpIojN98KVUcHNTGA3KYLkFfmNKiArsT5s8t6mq1NFMrId3KgEoOAR3q1Hl4xk7SODjjPtTkIQqQm2TofTFEYAG7kgnrjqaou/YvJHCsZ4y2zJGaWMjy1C/dI+7/nrTY2RPlA3cdTU0f8JC4IYbSe3uKdyLj0kAhKucDP51OipGBswXGCT1qBv3j4ILZPJ759alyVfaw5xgYqW2Jq4txKZ0fJJZjjHenwIqIvzAMf4alESoiMnLZPPqKcI8vwvOOtS9XcltbIfEoVWYnGOme9OEjJwAQRyMDpTAp247D0p8ZYkgH7vahENhbqQ7MeA1XHKxKNvQnge1QBcnAw2BwDTSjNIuWBzwB6UK/QW5eWT5Bz83QemKGlYSA/xDsKMBX28cc8U25mzsUjBxzWjdiLDo3LclevXmlZvnJ2nbiqyzgAAkbR1PvUyEzFWyAAOaNCrNbixqzBuBz3Bp6q2NoQD155NM3/ACY243cURw/P5jZyPWq8rDJSNylQMg9x/WmhdrkgkEj6YoaTbMqfeJ7CkPzA5zj0qrgR7x+8Eb7vTNDzCCPjqRyccmmTbFAVAfMxmo497AeZz60lIu3UiKvtjwCilic54GauA5XaNu7oT3pJDiNSmABwPrUaMxkcyAFkGcetUgeorYDlsZdPvVGinBkkYsXHA7//AKqcjLI2zJDH07n/AAofafMCsC6ccd6rcNiKa3ZEURgq7jcwHYVn3NujWjsHJcEcY6VoxvKwDP8Ae2/MD/DUN6A0JXICPgZ6c0mlY0g3Fq5iRoBDvbL8jmrDTsiSl/mDDAzxipHCw2mzbn5eeKhkUPHtGQSoPHrUanRdSK0cBZ3dWVAuGPOM0IMuUG8H+EetPjtHuFWL5sgFuvNQjak4kkJO0bMd1qfIrfqTFmWYuAqcbcH1q5BcGVQHGD0+tVFaORkcsSwPH+NTK7PuCJlTkZHUUOJlJFuKZdzIGx2BpUBOBESv4VnERqAyNtUdieSat27syB+QMcj6VLRk42LW4qynGTgg81C7ojLuwQTjr0plwwL7VI3YqGH95uLAEqe/elJCUVa7L3nbiVQjg8HsaXJwWGc9BupkCfuw/wAvB6VJK27fjjI59qmxDQRHZGQFD5/hNKhUJtAyDwc1HhY0RixyelKJV2DOAcc0xcvYWRTEcKB83epoHXBz9MVGygyLv5B6VJF+7JIXk8GpSsS1oWkO4AHv0qRdvy8ZxwahDAduvQelSxsCcAYJ4pozLEasFIxx1UetNujzwMECnuq7QrHIGMY7VW1E5jwpO3dnI9K02RC3M+eRhkDnPOaYrbgwbgd6GIBGBikRSxORx71mzdIZIBgcj6UsIx261MIw27pyODSxQ7Vwuc+nakUmmhs6yfZ5vIX96I22j3xXP2wgukjFw8rWlpB5kzsWBMrHp9R6V1AmWCKWZk3eUhYr64HSqVi+oSzMstzGWntPPUCMBIiTx9eO5qkjCozR0ASvpdsbrIuDGM7up9M++MUVNpV4LzSre4bAkkTJUdM5xx7UVWhmeerhvl5+nY1LkKfmIO3oO1C7TEFQYKjJzUMynyyVzycAY/Os9kaIsJMVDMxG7GBj1NI0CxxFn5Zu5PSmjCIFUjezAnNSk7lLPjA4FFykyOLAZd3IU52mnhScu2QvoO4pYRw3mdf61IwGxU9BuLGnYpvUZFIdjqo+YjqKiUSqrYHB4z6VZR0USFRjJpWO0gnOR7UtSk7ESrIYyrNy4ySOtSNk7FBO1fXvTyoYmTPPAAFSqoLhSOQOhq0rF8wlqMZMg6rwKsRqCRydw4HtTTGw3EHK4z9KtxIFjQngnv60xORGw2EbSckZJHXFGWlYNyGz0NEUe6Qk579PT0qRyqnKjlR0zUj5uhYt1YsfMOI8gYqx/sgD2Oeaq2oLkuT8vODVhWxw+cdqRk9yVwFRU3Dj06mpEQLG5A4Peo1Tdgg8GnuCclM7QMdaBDC4QkhPmBwKC+2Q9CSPSmSKSvI5HfvUxUCEOwU84xnnHrTHsSojDZuIz7U1tsh5AqF8mMbScnj6U1iUIJbGOnvTuCQ9kXZhyOOhNS23KLtHBPOahjkyNzgbemfWphw+5SMDOAfStPMqSexcm2gHdkgdqjVspg8DtVfzVkyWyWPYdqjdtkJ2tuAPJqhKJZG0gPkAj+Ko2uDj5AWzxntUanLKCPlVQT9alYIIgScE8YHrQU0luOCKBvckv1FV5SfM5H3uSfapDN5bFUG7K/gKhkTdGXJIB4zQNeYpbftV2+QN270SKxJDHHfNN2FkjH48Uxz+8YOcDru9famVbsRu+wqCd3T5h2oxg7h068HmmtbtNJuU7U9D/KmSEpmVWCoDjI7+tCNLJjywMT8l5ARgD+tE7hti7MHGTjsaihclJHyoz93jk1Iuwqgfg5ydvp6U76BbqMaRFRlZsSbTz2NVkWPyzk9BkYpbvM1wSuQfQDqBUKR7w0bYAPIINQ7miSsDXMyDdGTuUZGBzVfnyHldeWPOavpCLVEG7KMCpB6ioZgHUAg7hyCPSmOLXRFSVxCUZPmY4GR9KZ9plhIZ2CF+Bg85p7xIF3DdlDux6+1Vrt98SFYuUcOT6Coa6miSbsSXEqFUYo+XAZmAxg1Zgn8vJDjYTlVz2rPut8ksZDFlI3YHp3qQSQqMDgDAIHah7jcU0aO4TTLJtwv8OO9KXLShgPlzk4plsW8sbwCOdtNRhJcGI5A7+2aTsYNWLEsrSHbATtzz9amZ2CEE4AHI6mmlljcRx9AOcDigy7ZiNvXipt3M35BGS0LbOe/P8qjCOzqTxu6g9qlifa8ikBedy4pZgHT5W7Zx6moa1J2ZZhUdCdwHqamjO5SBzgZBqCNTsTatTfeQZ4A9OKDJkoY8qR8o796liUkE9BnNV0Yqct171Yhc5PIA6inHUzZYxujZcHAOQR3qlLIGwuCCBzV2AjIZvuEEYFU7tNpbA9q0ciYrUosuCd5+XtT1bBXnj2pm4k4bhRxUkaZJyPpWTZ0NE6guAAuPr3qa3jATJGcGo0DKRnOPX0FWYtq8KeOuaaMm7DmCrCWZdwAJ2gdu4rlHn0wr5sR1hLbaUKKnyBM52g9QPaunuQJIZYWJQyKV3DtkVgi51GC3FobSBmVPLEvnDZtxjJHX8Kd9DKau9S1ZajbXG2G2EkKogKRyJtyvYj1FFZUKSRSWuSjQ2sBjWQHmQnr9AKKlsuKdtignBIOCTwKinX5euBnIp0oEcitk5LY/SluduE28jAAFPYlCSRq67n4Y4Gc0R4ZdqseDnPpQm+QqDtwDuFKkZZNo+Uk0blIDl4VOeemaeDuLFs5PA5pjrscs2du3kdqdGQcHb0HHvmkMlZF8onGGDYxnrToxu3SN1zgD2pN4kHXocjPrT3HzSDnIxmnYpMfEryOM9O1SFhuf1PGf8KVBliF4YAfrSJk4IXGD1oGiZQxQhcnnmpFKpjJOzqQajEp39TsPJPrUsiqyYBJVugp3F1HRMpG8Dg8/WpkRUKlgPmPQ1WghEQB6qFwBnpViRHeSNjkOFxQO6uSQhUyDkKDwc1KoYneTleccdKgAG5fN3Kvv61ZDj5V5x3IpEyJDgxAg4IpFkGRkZxzUY+ZsscEcGnsyogAOcmgaQ9nBkYLyxHSkijdiwcECo2ACGQkBs9KUM5UFc++e1MdiQKdhGc47+lVZckDOSyjFWdwG3AyCMnPeqs6bhlFzv5Az0qlqVHcbA2EwxJPYGpXdnAYDG08H2qjvba6sOwGR7VNEwWIgsx4J5rQ2cepbiygLjGWBJNRiXc7ZXauOB61CzbYhjDAfw55qOOQmHcXYsTgU27DUeppYEbswJI4BOeKZKfkKL19qao/dKX+YqMkHuainYkHglh1xR0ISuxEWVHXJO3GT7VciuA8XIyB6CqsbfIOOnJyelOSUhggAJIye1BT94uWyiS23McYyMA9KqyJ5m6MZOOFI7UkfGxWbDMScUsr+QxcHI7fWnclJpiFnMXl5I5+Y96ruuxhg7lPQelPdhkBzjfyNveq9zMyjEarg988iguMWmXUj32xbYuSO/BPvVEwhFAkJGOfvVcimQWypJ94dMc4qA25LBzhh0XIpoUXZsImyxBGJGBANNeN0facHvnFLKnmbm3FGXjPrTkQyKTJzxgA0i79SnqUhEnzbeFyR71BAz/LuJ2KCQ1aMsJfYJB8oI5A9aqzKyThFHA7etK2ty1NWsiFQVkIPIYZJ71UlhkAkMqAxEALgVad1jZUKnzG5/GoL1HnYFiVP3RzwPrSSHGWuoscb+SzCPAXG1M/5xTZIjtHChz2HQitWGLYkaOyLgcOTwT71TlzukZ2y38WBgfhSZKm29AIkRFU5O0BsdhT4D5EpyNzE7s+lNkmLAr3Ip0L7z84AK8EVLDVomib5i0vCvyKCu/5j97+lL5IJQ8eXz39aJcCMbTg9/pStfRmTBY1EmXzgDjnrUsYVQGBwDk4qN4eVZjkinAjY4I7daTRLZMs3yK3TIFPEobPORVNG3EhVO0DrUwIVc7h9KghxsWlzjcanTkgjJxyKhiOeoyBU65XmmlbUyZLnaypltvXjsar3ZZJSFJOehNWUAySAOajuFJjYOMMpyOKq9xJ2ZQ2gkZOPSpo8j0NQt8hAJz71LCyqOT+FQbdCxGRtJ3Z9qkDjaO1Upc4JXg+1NRmH3v50rmbimS30r/Z5xCT5gRtv1xXHS2+mhLaR2ZYJrdg0rOciUdfx68V0l7dGGGZ1AZlUkD1IrmZ5bye1Vmu7co4D7RACFP496HKyJdO7sileaytnotuxAj+TAUfzorM1awk1KPZKS5UY3AYzRXO22ztjCKSR0sigkEjOHOM0xQN7Lu+h9KcSZBkZGPWmlQ7kLnPbHtXVuzgSFQsrnadwGQM0kjHcnLDJ49qcVVkDL3XpS3BVfL2DOEyT6UPQEPfk7c5AGTR96RFHGRSIcq5JGCB3qUuBO2FGEXrQMREBZlJyc59AKmjwCzsc45IqK2ZXJJJwadGQSqvgBs0h3JCz4Vl4LUqkgnJIb7tCncoVCQAOaicPJINpAPfNDdi0y7gRlj949sdqkR9iqGyx7n0qKF41ibzM+mafFIvXqMYwaAJ0kbcFbOGwBgVYBORu5JPHeoIwDxk8cingNjkg/SmSyfG+T5yRntTwpDN0NQDerKHPGM5qRZSme+f5UBZscn3eOTnnNOIBdU45OM+lQI7HACjd705wQBjkjnrQVYfKpAG0AtkjNSA7odqknJ+b61TMhU7icdgPSpIpMgjJ54G31ql3KUXYlZgELPwBxgVWuJRFGNh6jGKfKjMNpzlT1HWsy4Je4AyePvHtiqNIRVySGTORwrL81PBAyxGAe4NQEK1wWVBjsB0p+4kgMAAegA61Zu9RhuC0gQcbP4hTwCIx2x3+tSmLCJuGHLZ6fpUyIWcYb7p4x60ncTkuhI7uItobcxxzTeUDMx471JJiLbxyTn3qGdgSSvzEjGD396ZKdxib9mA3yfSnrIQhZly/r6ipIg5G9lwemB2pu3bEATnBOF9qLDbuVbRme8dizMgOB3xV+4G6PcfungkdBUECMrqACA3O0dvepJPuGNidhGeO9EVYTepDgrhI26Hr14pqL+/TcpIIyB6mnoGwSiqMgkj0FSmPeCBuB659OKphcfjdCVfqTgkdhTRyrMzHHG1T3+tEKCKIB8c9eelEO7cXIBRh6dqaIJTGqSruHEgGT6Uoj8uQbz82cg9ttF1cSkoPlMeNgGP1qJlG0Fsn+EnsKQld7ks0xcnYCxz09qp5jT5tpMme46DvVooPKDnJI52g4xVYgyOIWXZg7SB3/GlfqCsZ82HvCI9wP3j9KsvE7OECgKeSe5p8y7J8ImW6bj6Ui28vErA4PGQeuKLl8wAr91z+7B+6Odp96hLKVkRwGk9e1OAkhGVG7J+7j8jRK0kchk2qCRjNIIor30YWOKSORTuGCB1FQWYLO29iPYVamiK225imPX1qMI67MbT03Edqlo0TVrFtVzlduQDkVYiXcWbGT2B7VWiBZnjVjluc+gqwuQ4Gck1HmYSfQdOTs7fNwaZI3ybRgFajX5WyxOT0p7jHUDJ71NydiJSwOFYAAdPWnRgqMgZ96RVBOTjcTVoLhQCePSp6jlIIpCpIyeatQsW+XPQcmq8afMCRxUynCHGQwqlcx3LkRUZBPAH5U+fa0RK7t4HU1TiXcuOmeSO9SlyPu5PtVX01IasyhOvXbnHf1qJWKjJ5q84VgWbO41UmhK8moa6G0Z9GBnyTk/gO9RPJgYHc0xyR1B+tQyFjjAANItJFe/nf7PMUYI4U4Y9uK5W3XTJYY/NkdWwN+WbJPfpXR3a3zOptkgZD18wkYpIhqkeMQWR57saVrkSeun5FjS9MhktYfsx3REfKeTx75orX0yaUIBOqRy4G9Y/ug+1FVypifN0OYh/evhs4GCaaUIJbPOD0p9tIGlZScHrUm5mlAGMEfyoWuxhcZnhABjt+tR8Fk28kk8VMFyjMTj0qIgO2Cv3TwBTKQ6M7WcgDywfzNTKA7HaM8YJ9RVG6BRWIJA3everdmxkBwuPlNJb2H0uP2hRtHX29KVirMRzgcD2pWX5tpGMcUbhuZ9oIHAFHkA9V+6A2FB6nrT5IuML3Oc1HCQUJYHJPFSDIYMx4x+VFgRMeFVWXDE5Ap8aFGyw+U8mmlwWwVwx71MCSuOAuOc07FD4fnbI6dasq20jO3A/WqnAJXkcZHvUpJSPHU4Awe1AmSeYWO7HHf2qMcuGJHpipVHJyRjFChcLx0PH0pjWg8upXceucCm3DeWnHIzn61HKQzhkAyefah8PFg8v6UFLccyhpAWxgc1X8zY5CdfvcU9ypjfqCDiqtwhAKng4yQp5IqjWKLaSyIifNnOWzTdqglmB29h6k1FAcwAv0VQAPSrCrtQ5BCnkZq0O1tiHyiqsxyPpSOyvuzlQoyOO9PlDSAKWPGarMXGVB+U8EmjqXHzLImBjUyAlQPxzUjEAblIA6jAqhHt3FXb/6xrQQARhG4XGcU73BqweYXUMx+YdM96gcnbkjJB4x2q4i8q2VC4wM1EpGMAY+bINHUE+wtuW8sbsbh2PenKDK3yja3IOe1NK4y24l/WpYRyxBOMZA96oTIYyEJVSS3Ofm5qNXIDtxx+gqYoA5+XB28k0jw5YOv3u3pSs7BdChgYShB6HPFPhHyHYQ2R07YppB3IcYwOcdhU0aLGiIOD1HqKpIlsagWRwkhC9ge340ssZV9m/bt44OQR7VGE/feawKovr3NQu4Nxn/AJZg5AHWgLa6FlUMqMQQMHjPapnUJF8mTn72fSolkJIyGAIyOMAVKoLkBsFR05p2JdxGXOVBIbA5PX2AFRnaltvfGS2A3pUkrje0rDlRgZ9faoVdGfBJxnIB5FISRH54ec9SCMAjvUgZlbYSqLGvO4ZJNV5RtJKfePJ56CpJ4jFC8kWXVsEuTx9KkbSZAZXXemxmY8jFVCjplpO/UA1dM7tITK2AVA2gdBVa4kRZFyp24wM9BQVG5Vkt/OX7+0Z4B5FSQRtDAQZFIzyexqx5AePcucHgDsfWqcitvkVRjb1BFS9DRNy0uXowBljnkdh6U58qm5H2nHWoYH8wqpIG0cYqbG4/MQMcqKh67GUtxIy21Q45Hr/npSE5YY+6Owp24s2O5pjuFXAFQxbikrkbQcVYiPGQcg1XRh3BBXpUsBJByeKRMiyrg/Kep6+1WV2qQBySM4qqmHcZI45NWMjAYtTuZMlUevHepCAeD8vrioUcEg5qTOc4HNIRGy4Xrgj1prEqDu24NBc8hhketOTZnBY5x9407opIryWytj5mz1IqM26MVyp+o6VeOQoA59+1MXI68c5GKLoLsybuZbSZU8maQMM/ukLYqqmpQq4At70jqcwkGt64lMUM8sarvWNiFx3Arnlg1GaWCMao3mT2xnUhRt3cfL9OaLIlyaNuzdZoElQMFYZwwww+oopdCZbnTLchndygyWPOe/P1oqHcrnOT2jzQx6jjFPY4jReelEYAXJHfA+tSkdBjLL1q7GRG+XbryMcGovMBOB1znNSoAjbTyOSagOA0SgdBuJ/pSZSFkjMiIpPcnJp9m4QBectxTpYmw5PIHNNhjAkQ54Iz+NHUa2LTHK8jlmAB9qaFG4g9MZ4pdykISeMHOKYCQx3cKeKYkOjG7BJ4zyKeT8oz93GaZgbl2kgD9aVnJQEYxg5zSKLsQ5V+MY5Gaf8AOAcY245NQwDcikHlv1pXVk3YJx1K07iRYx5hDL8wHGal25PzE8cVBA2zlTj0FSnbkkN+PvQUx8PDMm8bfenFW3ZJwo6YpmcEcsc98VJvCJgc5poLiIRIjFgBjoKgZwrZ5B9anGFfcuAM9arSsHlw3TIyKEaRJGm3whY1ORktk9aq3P3kI5B680/jzSBk5zx6U7ZHmLODxwK0saRViKOZUUqEI9zzVpGaTMbElQMg+lQpFGWIJ59BViPMDFiMtjFCY20KpB8v5cHHzZqtKA3B+6DyTxVq4DtGcDvkmoSGwfMBYgZ4pPcmLKjRGV/lBCAj5T3q/Em5trqR6ZNMjkL4AXGOc+lTplWUk/Me5FCRTYvyqAgGCDgVG0Xz5H8J5HrT5ycrnGR1xSI4w56kjgnpVXCL0FKOHZRgdhnpSM2yT5CSRxnHFMdyUZix9Me9QrLtfJbjue2aq5STZc3p9pG4BGKcEninRIHkLkcAAH0NVbeaMEtITITyOKsW7O0HycAtyKohpol8sAbzkfN+dOQqcMCAZCQM9qZHKyqyswy33arn5jkMPlx7Ypk2LDFFD+eNyrxkH86aluu1ihATvjk59qWONjgPyD6dqdzGu1gAx/H8aA8hThEwfvEbQvanIRvZXXp3FRsdyk56DIGOppA3+jl1Jy3TPcU7oOg6cq3U/KOMVHGQJFY+nT1ppZCccFh1AqMurFWfIX09qRSjoNcDcz9Qe3enyZMAYDcuMgZ7+9OaP90kgyCM8Y7VSlklJwnzBmzjFJuwJXAhTGYyzAty3uamQPvIOx1C5wev0qO8R8xs/JPJwOgpLhZMLscLkbhg56VLY7X0JJ5Qq7huUqeR2qlPM0krSoML0I71KkW4na2doyTVOVSjBv4c9KllQSFt5OWLHGDgAd60Q2E4OTismVg5PBTbxitC0wYzkk4HWsr9B1FbUmJDL8vUevWo1YOcNx247U7GCG7mmCPEhIzk9aky0J4wG6ZJB5NTou3OO9MjUqOOlSQgk7TznmhsyZJb/vVBXPXqR3qYnnGV+h7mgHKkD5QPQU1gNpLdj1oIW5MpDZGOfSgnBG/7w7img7VBzyRkGjccoWGMdeOtJgOJXBUZUn1pkSk5JJ46in43dOnfNP3beM89jUp3HzdgkYBQFHBpnCjpz3NKxUgsxI7dKrFtjYUllpt9RokuGjQNJIDsVSzN2wBzmst7S3utEikSxkUKxeOFZtrbT1w3uO1Xpri2Ja3uSqh42JTdzt7msaO6RIBbR67aCBcKjNGS4X+VNa7ETdtzc02WJrGE2abYSg8sEYx7UUli1tFYW8Nqd9uF/dv13e9FDkC9DmSAWiGen61MSEj3DgtxUPmIDGxO3HqMUbuxO5Bk8VVzOzGOGExOM8EUGPkEjHIApYyHRyG+vtU0nPQZAxUpFkEbnzW3HIwVpkjEhWXtjj1p/RY9qdTuNKifvnz0AzzTYCxHZxIONvIFMllYqWCjAH41IkuDISRjGPrRJ/rEyATtpMY+3OcEnIIppKhsAbg3FKiFVXtkUrpsKBvxosCZZUbXAU529PpUoIkcq2ME8ioYtsYwTnd0qRdryYA53YNMFoPjUiMAc89amVc4xzmmQkoQp6DsKlGeO3NMbZIWAyT0x60xJx7HFBXG5c5U/nQiqGHGWHagaGl2VACMButV/lWQHBJwfzq3Mpkyeeneq8cbjBYc5pmkWQrGWOWJHzbuTUojYOAxAzyKeoAfOCe+COKHJkLMT34x2qrmilcI22yszDAPQVbkYyuPu9OnpVdcSxKDjgkZqWOIBSUJ4/WmhSt1LWflCP3FVrplwMEDseats++USNgbu1UbgMGJOc9wemabM47jYcOAnAHc0qmTOHwSOATUDggqVyCAGJ96mD4Cs2CD2HXNCaNrDyct87AAdqaswZj8vTrg4olIPKjI9aRFVmZiMAc4HpVLUZDcSADeBkdqijBbCyYG8/hmp5AqZIyR3FRxBvvNgL6YpotbCfKgZYxnHOBVqK4XyxggPnBA9KreXjOWwAPvD0oSMR/PkHjt3ovYGky6rCZUJUfIT0pQVAyVBLHJxVQSiRWV1IJ9OMUkShSAzFuOD2p3J5S6sjCQbFy3b0odl3LLLkZONv8AWpNirCqg7ScEk0jOpZDlfk7etUZ7vQUsDgleeeBxTiU2KGAAUcjPNQwEGTll5qxEgAkJIBA60A9CIqo37EGO3r70kkDFVbO/+79KkyY4ldSS54z/AHRUf7wKyLyNvB7kUMV2QzQyCJ/3jAgdB2qJG2PtJAwuOO9WjLG5ZWbGRnI5z7VnzXLSRhnG0oSBgYJFSyo3Y6R5Gi2owZVYEg8H86dConcBvkVeRjtTYWP3MhQwzxVyBXZFERyRwCeBSRUvdRHKEIYglccYHf8AGsm4d1ZAgy3PbtWxKMNtUlzgkqB1rOmJJJXgqDx/SpeoqbsZ0W9pGWYjnpWpaqCF2jA/iHvVWGLzZN5GD2rQt0B+4PxI71ky6sh2Nw+Y9D+dOCjBbH4U7Z9wYxS7cD5uh9Kk57jwAFx0J/WljB2lhx6U1V3sikmpwf3gVBwOpPpSIJYWAGH4Uc+9NYbh8245PGDSyMc54yeeKiHfDEHqKCESDCrjGQKckg6AE/7JoUHaN4weuGqMgNu6jHQg9KGVoyYZUDc2Dzx2pzyrn5iU9Cajj3JtwVIPPJprHLHPKnrx0qQsSSMGXAwT6iqhkKI3loWOO9TSpJjg4PVTTI87gH5PORQylaxFK6JFJNgDbGSWYZ7d/asxH1J7WKcW+nMWXeqbTux1rYcL5ckbqojcHOehHvXLxSLHERbXWoHTskFlhyAO4DdcUIzmbOn381zLClzFEomiMsLwjAOOoIPQiinW0Fqs8U6SSGLyhHCOqxr3IPqfeih2HG9tTHl5hZjhgBwOtRbVUP1BK5ABp/3YwmcZoTa5jJ9MGrtczQqQOqDb8xI7cU8thgMEcfrUluzduFFMBJcEnINMVyIndHyT8rflT3jbaecEqcH1pqqrNnBwc96VQ4ALYYYwBnGKm5VxjAMpJyDgZApGBYxY4IG01NuVpOhUgc05TlCF+8ehxTQ7iSbkcjrkA4pZHLHGcnA5pTh2bnJ6UrbgYwAMgZzT9BkqDaBISuOwNSoSUBXHXr61XQo0YU8kk4qygVdxzyOlAgiOWBHGB1Pepg5WRR175qsoLghsj8O9OQuZjggKOBQi9y0uCeW6D9adCwDknsCahQZBUkeuakRQCpFMQ4SEj5eGAzz3oUHjf3Gc06MAfL6+vaiQjeqnIyMc0DUiNclmYkkEYAp4AVQuOemO1NwUjzxkHFPRlYKCMMOTQnYtMRVUHav8Xb1qUAgcEcDHFJgbwwHCjPvTJBnkHGfu+1FwvcBIenRugBpAWmlDNlgBjjpikch3wBlhzn0p0TGGIhSMMKaZWm6IJItjlV7e+eagZD5oyxAPT61bnkXywT681TVi8iHIC1RpC7WpMGUQkMx3ZpBMEBXaST3pLhwpXKjcevtTWOw5x1Gcf1rQuOpLGQ+AVwV4570vzBiS21SOR6U2GdXChuBnGfWnSNHvRi2AOtNAI5XYpOducc96riJo5JGaTJPKqOg9qmK7VLK28dQD2otziLjtyc9Km92NabDM4i3dT19zUbyykRvtCqp4H+NSs6qu9cYJyRVWQj5nQcYp2KSNOOT7QXZmDOAOfaplT5ASEy/TJrNs3bopAJ6DHUVfwpRfOY7RwMVVzKSs9AtmCMDhWOcKPT3qbynyqkbj657UwpkDykO8dCP50sszo0auG9OO/vQiJasnbAUIykM3B9PrUM+90JVuAuFqO6updrbEyW4/Cq8fzZGWwTkgGhsFHuMQP5qhWBOMdOKNoMmOHbHK9vrRN8sqrCee9Pt0MnzICOx4xk1Jpe2ogtwZgRuMajlqsTSbDmAsQOvpUsMO3C7izevb6VA4ILKPv5yQOgpN2M2+Z2GNIysG4RsYH0qvjectyc9cdatDdJGN2D9RzSvD+8BIwMYAFQ2NNIYkG5RgAD+lToCFCgAhTnmpIAFiKnAJ6j+lPaPjaeCOmKzMnLoQ/e6561HGMs3vzgmp3yDn8KciBtqqBubipaF0HQLsBcjt8vvSqCgJyfm7HrTiF807zlU6Ad6Vg7YYnDMenWhEMidAzgKDnFSugDct94fnSkDnIIbtimhm6EZx0BouK9yX5doCLlgPrkVBCVVWchgCeN3apEyRleAegzRIVJXf5igDnFDFsMk+ZSFAIPO0etRW42tnkk9VznHtUufMQhGYcZIPTNRybS2UYoccgjrQykK28uNpwMfKD2pq7ufOXDA5/wDr0olZIwDHlQMc88etPZgQocqV4+YdhUDIL5TNayQofvIVDY9ay4rvULa1W1XTnMioEV42HlMQMZNXL+9t7F/JmuUj/iAYH5h7VVfWLAROReQsGGNuTQrpkNruWNNi+yaVBGx3lFwWQcZoqHRix0Ww9PL5P4mik3qCehljBjAFOAAX1wOlRNIucbeATnFIjNtUAdTWwi0hOxevPNNXO1PTBNMDkED07UiEBSOnGaExKIjPICdq8g9aVY55OpVRx2zmnJjIbnk7amh42gHIB5qVG+43sVwrFSCxLA9T6VbQAbMgZWm7VV/l5BznNCjj5gPzp2sPcRVIYuQM5p/LsQBzjFICWyD0Hf0oSREw3OcEmmgCIYJGMbTjNSgqSR1z2FQxsdpbrn9alVckY7CpQ2icgOGByAF/WkjUgrzg4x16UKBsG4ZpWK4GB857VSBbjsbyQpDDtThKQy8ZHemwqEbGeKcHGSQPmJ70MpljauCfTpS/eOTjcOv0phIDYxzSg4YNjAzQJCAb5PmA24781Ike0EnAPaowSG9BUu7hc9BzQNsV/lLbDk044MQfoajchl3A85pRnAB7dqYEHnbpehOO1LgfeJ5Az9aHXYCR93rSONyhgcA9cU0zVENyxddowVPPFZ0txGGjYZJQkjFX50OBt6dD9Kx508qTBPIPah3OikrlqKV5ivmH5m5I+lOld9pC846/jUNquFOQQAO/vUm0glSQBjqO9WmVpexPbsWhCSEEZ7cYFIs0cd0I5AfL5OR3NMSN+gboOKcNgePzOCP4vendjVrlosmCUb5SeBTFyf3ZGAw3cUhG6cKPTPoKmi+X5hyR0weaZOyIBEPTocYpI4nRmPQ464qRuX3EsG9/WnTRq8i/vCXxz6VS1C9txioWIbgEHp3p7ncTxnPp61G4ZSACW7Zx2qeAKqkSAqzdD6GnsRJ9SazmlhTeshD9Bnpimzu8sqBBkrUKbgeeVJ6VL9qCAxxgbwKLit1QwSzGUlxyRtwKdKXZgq/Kh44605WCBSf9YTgnPSpvLBbK5weMHn8aVxN9yNLdFZSOQB19atRJtQBuAfugUqLGB8uDjrU+wnaf4R3NSzKUr7kSoURiTtPb1qntLyn5gOMkkVbnUblJYN6A+tV9qGRuduB0Hc1DbCLW4+MnaiMuADzTmXG91Gd2APYUKMSIzcIe1SKpIY4ypPyj0qGS2MUHedvBxjPoBTjllDZ7U9gqgj+LuaI8HIYkZ6A1LFe5Go3A561JaL951GONq/WkceWBtGSflqyiCOLbt+brml1JctBnlggc807ZsTPUZ/KnhA3yjO7Gab82Qp4Pf2qkRdsjZjI64Jx70rL5h+9hhyBToQrK24Bxzz0xTTtbaCeACc9xSsNW6AqHaRIoLdeD3psgLH7rggYBA6UkhY8wsAein1qQtIsSrMxIxk96XkJrqVlbO9cFZF7t0NJMzsBjae7DpT4ihkJjYbmGDuGaa7dY3VcdQR60txjpBlDu4XHA7iqxEmDs+Z+654xU6cHBJAAwQaWb7odSUYcZx1+tDVwTtoVWVGC+dHkAYQ4zkelQCBPnBRAAR/CPu0zWpryGNXtjGEjwJFZNxC/3ge/0qBhqq5K3Nm0b/wDTA5x+dS0LmNAh4lxhVjUdAOooqKJpLeGNZXEjkfMyj5fyoqbrqUc5KNu/APXOKLViysMkkHgU1yRKm3uKdCWV3A65JrbqImKkMpBPpilYBQGK7ewpxbCq3cHmgOWjPGQelD0AacqPmxgN2qaAhPvfUYphGUYDrjnNSIMOo2j3oQh27cGbAHsO1Ix34OADjGfWmAESkds1YRFIYE9aYEZcbMAYJ7UhB3DgAhecVIsYZgB0xkmoihWVSTwaQ0xluHZiW6ZyParwAbZ6KMHFRQLvRY9oB5/Gnon744zxx9aSVht3HR9s+p4pzKrY2Hk+tKFyGU+nBFRq/kzxo3JxTbsJEqMEPIwB2qTO5QQB9KbIgI3EnjpQo4AboOc1RW5KwwATygPNKhxFIOhxkDFMRwwZRjA6j0qaPnGcZpCZWdnwu0nB9asBt4HGO+Kl+XI3DJFNABLEdux7UCTEGAMEdal2gpvGMioY8EEHd1znNDuUG0HGW6mgpahjdMABx2HpStFyoI/KnJ8pyfUCnOVUkBjTLuV50O1eBgnFY1xbuxj7Nnk9sVvyKPL29M9KoXC7EIJx6mrWprTnYzY98RfL8dOaUsxK9wR3qdoAQCec8nHenRwqrqTjYf0oSszdzQkJIQMR83p7UiktcLuX5H/SrQiBbGcHtTFjDsu7qDgmqFzDCzFl8sgHPU96lhVyyEuVJJPA4OKdIwVgAOM0OWkRdjdP7vFNCvdEN5GwgUphcuCA1WoIxKQN2wt0Y1RuzklZDnZ/E3apLWbayPNk4447fSmtBv4SeQSRMu4gqD1A/nTSSCwL5J796nmk+YlULKfXvTfIU5JAjJ7nvVPYhPTUiSPYqtuZ884NIqupYE4RuRkc09JCjsi5IGOlSsEJz0PU561Og27bhHEB/CxJ9anWNidrAAdTz0qSJQu3y1ZnwDuPaphsLqT8xPXtk0mZSmJBGi5CYUZzmpppBgLndxzjvUYYq5yFPX6D/wCvTlVT90bRjJJqDJ+YzkruI5HT0qMJG7g/mfU1ZRQ6AKx2+hpqIu446DqfT2pNBdCKpPygcg5JqVyOByWIPA7UwkEBhkLnC+9C8O2Mlm4Iz1pWJY1DkLH824/NnHGKV9vBHpnFOAyrInFNYMwVQuSePqKhgh8Y3ZfHA6Cn7GMhywPOPQZp0gMaABQMDGBShRgnIyF49jTXYkG4xuJLdPrRI4UAD5tw59qYvJxgkAdfSkB2ucAgHp3pi8yMAxliACjdRnr9KYCfNGBuRuTntVraGUMm3K8c96YBGJABhXP5VLVh8wRyKyE4UY4phdUUMGByccdqJl/eRpGxHPPoTUKgC6aNCF3DPPek7hoExxMPM4B6D0qrFIpZ1l5JYr1xip9pUuk7N977x6e1Uidt2fM5O7BK9Kzk2i4q5aDNsaPYSR2PcVA15sZkQtvHOwjINW0UyE7sqdueOlV2gMhXBGe7epo1Jur6le71G3ski+0rOGkG3CJuwfr/AEqumqxJMMQ3jhc/Kbc81Pqktqtrt1DiKQ7cDruH93HOagj1q0Rw3+kov96SNgOKt6md7dS/azLPEJVVkDJnY6YI5/Q0U5juRpEfdFIAT+PpRWfM1sXa5y+3BjYdc1GjYnYEkHJFHzO0eDgj1pzACQscZ61syUx6uRCwJyd2alUYTb2zxiqoyQhH3SSKtxrhWBPORtpj6Exiy7dhihshgcdqYkmHJ9OBTk4UkFs5784ouGvUVOdw7nmp1Xp/unIqtHwQeSHBx7VZRgrrjrmhCY1EHnDBwMYNIV3FQexyKl43knoTUe1lmQk5UmkwQ9RsO4kg5yKVH/els4wc80krdVxlc9aRATGWbrincZIpwrAnPPFDJ+83gDPehXH905HcUMxUPgfLnNDBaEm4sjL+VIAVOCeSOKjjYsmD06ip04lG3k47073dy1oIihCcA5xyfWnLlTnqDzTmwJlH97PNOYBVUY5NKwrgHwWY557ing7sEH86VVBJIHFMVcNkng9PY0IFZkgdTkdh0pjQ5ww6Zyc0yNfmwCOv5VZXlffdj2NN6lXsEDKQN3BPao5zmXaB14zUpQ8MfujrQ5Vo8HqOaLCTIJN2Byc54pkse6A7wAOuKnTaxCvx3+tRc78uDwcfhVXNEyCOLEZLjGTj6UxIiJDwD25qe4cF9rAjPNN27SpXk9qZpFhIEAXJ700kbV2jA7imzIWcMo5ByT61MkeFJP3v5U7lDJ0U25KZJxjB7VHt2IjKCHA5xTUY8huGyee1NLMWOzJyMYzTTLRH96VmwxB5PGaRZNjMcA88jvVm3DjckgHHpUItX+Y7cDsaLjUlsyZZzIoIBLdhnoKmjGAGYgtnAJPFQRYLKGyD0OKuW4JIGw8Dv60cxnJroISHdgDz61MgLN+7VQFGSxqWCM9AuQev1qc7d+12B4/hHAouZOQRAhcKC/fjv9aGflhwG9hQXHRQT7LxTW+SIkHaWPpkmldGfUhiZmJUjcP609kOeRj1BOaSBXdyqr5adSasqq4OTgD17UimxrsPkUYAxSIwLMiqcHqTQFLMAmcA9T0pxG1iqcBuMetS2ybiBV3qpJIH3QKkGBtK9Sec0uAp+VhnufShFO0k5J9aRDYEHkkjin265Jd+PYelRsBjGfw71KvOFUdByR2FJAxkxyyjHORjHenFSHPlAgAcnrSpIHLOqjf90Z7VGgZJnLtxjC4/WhK2oh7N5ZIHCHqTUcmCysPmDcU9/mX5xxjr61HIxRRtC5Y7RnsKNhksqqHSNckkdugqvccFdoG8AgGpGm2SSEjKRr19TUTAOQ7ArtGSKmTuJaPUWP8AeSMvJdO+eM9cUkhBkiUR/Meue1Niw0ZZPm3twOmBTZMsodR+9J+VfYVDbY2R3kanKOD8/Qk9KgjgWbYHc/MRtbtgdasuGnMbNna4OfY1HCu2EJ93yyeD/Oi2uo02kTZMShOWK5BwevpUeMsACFVsEgetPJYhTGRvIycjFMXkMoGOOfp7U9CdzNvklF/FdxQecFQo8WcHk/eXPGeKbPf3JRo49LuRkEDzSoAz6+1LqB82+tLSado7Uxs3yttLsDwM0zzJNOYRXUrtZSgiKWQ5ZGx9xj6HsaduhLLem2b2djbw7txRPm54J9vpRUHh8SnSbdm3SBUzyck5JoqWmUtjDC/OSDgYxTY4w64JPPGfWpmbEp7g1DF94jcRtNaMlMkOMqB6ZOPWnliVc87gABxTMASuCeo4IoiYtgcgA4NMpCxuQVPXI5qyjIM4IGaqSKVmXB4qZsjt8p5yO1JIbROB90noD0qVWBiGCO/bpUG7dDwc7e9SKcAc5zjOKZL1JUfG7OOOlRtvfynDbUVuQB19qc23DHJ9DiljUZAbBHXGaTBC7TuO85yOKRDkqvIA606VcYBJxjrTbbBYo33l7jmgaHKV8vIzjt705iFiY5I5HHrT/l+VSMqD1ppA+cKOvT0oGiRYwqqy460EMr78fJikgYlFjJ+VTgHHWkkXcNo+7mmwRYRgUU9uajkbDAj6iiFAnyk8rSyohyp5zRuNaD97FG2EZAzinwDeFPTNV4U2RnJGT2qdSUj4B64xQgt2DGBkDGKs2xypGKrEsVUKfrT4JMMRnJ9aAaui8QnIKnnvVaQAAeXz60k0mdoL9OpoI+hxz70xRInxvUE4B7mndCFU7scjIoc925J9qfyOwz2p31LuQEAsS/Jz09KRFAGRgEZ5FSOM5OOfWnAAR4Azmi5SZSdHJ3HJBGcjtViIHySzco3SpztTCrjGetJlRwBhc4oWmpTlcqyR5TgAdzxVdQizg7dnHBU960SqjOTwepqtNCPMxnnqKpMuMh9ui5BJz6k96shFaNg3zNjNV7cLhlJ+UfnVuHBYA52k8HFO5nO9yGBVVRE0YyeST2qeMqu4A9O/9KYd2DgFjnn0NEY+bgVIXJ1ySuMjvuNK5JJCgBR/FikO4lQVxx0zUgjfgkYA9eBTv0M7jCpkG0L8uMk+tSRoFQ4XIHVjzgUkjOW2jgdu9SYUJ87c+gpA77jAflZj9z1pqgP935R/eJp7KZiAxCoo5Pb8KinUyfKpGOgwO3rQJMerAKUiGT3NGD0H4k0YEKFVO4Drinn7nTA6+9JgCkEkHkdzjrUrD58gDbj5RTSCAQBkYx+NLz5Z6jnApMhjY1Lyfdzgc1JJ8vmFcgYohTCEty3b3pGbcw28sOQKSF1II3Vy7D5AoxgdyaSTJT5mKgDn1pYsYZeMk5JxwKcGVsscgLxjuaCxJ2PkKEGOA2T19qY6l9hbnv8AjSyACMc/Pjn/AAp4dBsjXGMYB9aTQJ6EKruQAE4zycdTUhBKsXAG84IBokdUUK5+UMMYphAdlJHq2M/lU3sTe48+WpKggBBkVWkfdADyMdPWnlsLJjbtOaRSdo2nOBjn1qR26g2FCMX+QnDe1RFwq+WpyCScnrTJWG2Pu27k0rJl1A6d6AF8zKhD0XqaUfeBHyk84NIy5ZiR1IGB9asLEx87GMjjFWokt2KtxaJcYinRXVGDIGGR61LLCJ4njfa8Y5ZSM1T1aZ1byjvWJUDyohwz5YKqA9sk8mqt9axQ+SsEC2js3lPLC5yjnpn+8M8GqUCebU1lhhhghW0OxF+QKONp9KKzbe+D2MMsqleMSgd2Bxmim0jRRbWhzwYttz6YpWXdI5U+lNg+8/8Av09eh+tSShl1lHBTuwqVOJUIYfMMke9En3m/3/6VGn34PrUvctaonkG05zkHkVLGCY2H40y9/wBTGfY/zpyf6pfoKrrYFqiQD5G/ulcilRwMerd6Qf8AHpFUZ6/jQJFuMiRZA3fvSR888Z6U1ep+lPj6LS6gPnPy7WHboKbboI5Dt6Y5JqVP46jj+8fpTFsSpg9uB2pcja2R1qMf6x6WL7v40XGSoCcjBz2wc1NGgUHd06iqiE7hzVn+BfpQhscyAevJzmkZeT6DnPennofpTP4j+FUCAjJJ2gUjudvy547VJN901Geq/UUPQpEgCmIFcbieabDvhO5ucnt6U5f4PqaeegouBKArhd4HNNmAXlQMUtsMn8afP96k+4loyOLD4yRg9s1K2cbSc55xUVsBzwOtLL9wULa4PR2DYdvXAHam4Gd3THH1qUf6sVE38f1plodjcUGMNjBHvShWO1D3pyf6wU5v9Yv1oQDNilGDEE+lRkKWIPJHAJqdR+8P0qqP9ZTb1HHqRrE6udx289RVnK4OTgninr98fhTXA8xaXUq9xyuYgwduPalQh/unAPPPQe1Rjmg/fQdsim2JlwttABPPrSx5bAbke9U3J+0N9Kvv0/AU1qZsSQKn3TjHXFRqoZumVU8jPU0i9D9KWP8A1S/571N9UC2JGDMOflTsP6UitlyF5PqOwol7U3uabJJlCk9CAevv71IqopyzH5u/tUK/63/gIp8fKnNITFbJJ5IyaRm+7GABzjjvRJ98/SoX+8PwpMCeRjGoYjGPQ9BURYOu8ZVW5/CmT/cf/dNI/wB1v90fypsSQ4OOWIznoB396hTe6hc7d38s1JJxbjH9w1DF0X/eFJldCeVwMKMADv3NKhdiWdQu3ge1QT/68fhU6fcl+tIliSuhIDcgnPSmKy4c4ywp0v8ArIvpTI/9W/8Av1DEiJyEY/3eAc9Oabu2oGIAAb1oi5jfP940+UfMfrSsWM2b4hlztZjkEVIjMUQ7QCmc4ph/1M/0/rUcP+rj/wB01pFGbZOny7wFOWwaQXCpt3EDAO4dc1BKT+65rMvifl5p3srhGHMyTWZBNKJkCs2wxujnaHXqRnseAQawLrUTG0csYuiUPyG4dSsZ9ePvEVPqJOH5/i/pXOXf3B9RQ5s6adCL3LEup+XCVhdtq/Lz1IorHuPut9KKybbZ2xhFK1j/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory plaques consistent with lupus erythematousus tumidus (tumid lupus erythematosus) are present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13443=[""].join("\n");
var outline_f13_8_13443=null;
var title_f13_8_13444="Mometasone (topical): Pediatric drug information";
var content_f13_8_13444=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mometasone (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43748?source=see_link\">",
"    see \"Mometasone (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/61/13268?source=see_link\">",
"    see \"Mometasone (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8775141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elocon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8775142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elocom&reg;;",
"     </li>",
"     <li>",
"      PMS-Mometasone;",
"     </li>",
"     <li>",
"      ratio-Mometasone;",
"     </li>",
"     <li>",
"      Taro-Mometasone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10502886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10502932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43748?source=see_link\">",
"      see \"Mometasone (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply sparingly, do not use occlusive dressings. Discontinue therapy when control is achieved; reassess diagnosis if no improvement is seen in 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, ointment: Children &ge;2 years and Adults: Apply a thin film to affected area once daily; do not use in pediatric patients for &gt;3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Children &ge;12 years and Adults: Apply a few drops to affected area once daily; massage lightly into skin",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8775347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as furoate: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elocon&reg;: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as furoate: 0.1% (30 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elocon&reg;: 0.1% (30 mL, 60 mL) [contains isopropyl alcohol 40%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as furoate: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elocon&reg;: 0.1% (15 g, 45 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8775144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10502933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply sparingly; avoid contact with eyes. Do not apply to face, underarms, or groin, unless directed by physician. Do not wrap or bandage affected area unless directed by physician. Do not use for treatment of diaper dermatitis or in diaper area.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lotion: Hold nozzle of bottle close to affected area and gently squeeze bottle.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10502929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Store between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Store between 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10502924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of the inflammation and pruritus associated with corticosteroid-responsive dermatoses (medium potency topical corticosteroid);",
"     <b>",
"      Note:",
"     </b>",
"     Due to lack of established safety and efficacy in specific age groups, the cream and ointment are not recommended for use in children &lt;2 years of age and the lotion is not recommended for use in children &lt;12 years of age",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8775128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Elocon&reg; lotion may be confused with ophthalmic solutions. Manufacturer's labeling emphasizes the product is",
"       <b>",
"        NOT",
"       </b>",
"       for use in the eyes.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8775241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Bacterial skin infection, burning, furunculosis, pruritus, skin atrophy, tingling/stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Decreased glucocorticoid concentrations (pediatrics), folliculitis, moniliasis, paresthesia, rosacea, skin depigmentation, skin atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cataract formation, reduction in growth velocity, and HPA axis suppression have been reported with other corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10502925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mometasone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10502927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA axis function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose; these adverse effects (as well as intracranial hypertension) may also occur with topical use and have been reported in pediatric patients. Do not use topical mometasone products for the treatment of diaper dermatitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10502926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse systemic effects may occur when topical steroids are used on large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in infants or small children; infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to a larger skin surface area to body mass ratio; use with caution in pediatric patients and for no longer than 3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8775244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8775245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8775231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8775232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies following topical and SubQ administration. Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy. Monitor these infants closely after birth. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10502934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor growth in pediatric patients; assess HPA axis suppression in patients using topical steroids applied to a large surface area or to areas under occlusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10502930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10502931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: 0.4% of the applied dose of the cream and 0.7% of the applied dose of the ointment enter the circulation after 8 hours of contact with normal skin (without occlusion); absorption is increased by occlusive dressings or with decreased integrity of skin (eg, inflammation or skin disease)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10502935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/61/13268?source=see_link\">",
"      see \"Mometasone (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition being treated persists or worsens. Do not decrease dose or discontinue without physician approval. Avoid contact with eyes; do not use occlusive dressings or other corticosteroid-containing products, unless directed by physician; do not use for longer than directed; contact physician if no improvement is seen in 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10502936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Several studies conducted in children 6-23 months of age with atopic dermatitis demonstrated a high incidence of adrenal suppression when topical mometasone products were applied once daily for ~3 weeks over an average body surface area of about 40%. Of the patients with normal baseline adrenal function, adrenal suppression occurred in 16% of patients using the cream, 27% of patients using the ointment, and 29% of patients using the lotion. Follow-up testing 2-4 weeks after discontinuation of therapy demonstrated suppressed HPA axis function in 1 of 5 patients who used the cream, 3 of 8 patients who used the ointment, and 1 of 8 patients who used the lotion.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16023 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13444=[""].join("\n");
var outline_f13_8_13444=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775141\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775142\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502886\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502932\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775347\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775144\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502933\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502929\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502924\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775128\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775241\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502925\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502927\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502926\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775244\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775245\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775231\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775232\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502934\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502930\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502931\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502935\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502936\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16023\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16023|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/23/38261?source=related_link\">",
"      Mometasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/4/7236?source=related_link\">",
"      Mometasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/20/42307?source=related_link\">",
"      Mometasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/11/34998?source=related_link\">",
"      Mometasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7654?source=related_link\">",
"      Mometasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/6/28773?source=related_link\">",
"      Mometasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43748?source=related_link\">",
"      Mometasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/61/13268?source=related_link\">",
"      Mometasone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_8_13445="Acanthosis nigricans on the nipple";
var content_f13_8_13445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperpigmented plaque with a verrucous surface is present on the nipple.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13445=[""].join("\n");
var outline_f13_8_13445=null;
var title_f13_8_13446="Carbamazepine: Patient drug information";
var content_f13_8_13446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carbamazepine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     see \"Carbamazepine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     see \"Carbamazepine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbatrol&reg;;",
"     </li>",
"     <li>",
"      Epitol&reg;;",
"     </li>",
"     <li>",
"      Equetro&reg;;",
"     </li>",
"     <li>",
"      TEGretol&reg;;",
"     </li>",
"     <li>",
"      TEGretol&reg;-XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Carbamazepine&reg;;",
"     </li>",
"     <li>",
"      Dom-Carbamazepine;",
"     </li>",
"     <li>",
"      Mapezine&reg;;",
"     </li>",
"     <li>",
"      Mylan-Carbamazepine CR;",
"     </li>",
"     <li>",
"      Nu-Carbamazepine;",
"     </li>",
"     <li>",
"      PMS-Carbamazepine;",
"     </li>",
"     <li>",
"      Sandoz-Carbamazepine;",
"     </li>",
"     <li>",
"      Taro-Carbamazepine Chewable;",
"     </li>",
"     <li>",
"      Tegretol&reg;;",
"     </li>",
"     <li>",
"      Teva-Carbamazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700477",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe blood cell count problems may happen. Report any fever, sore throat, mouth sores, infections, easy bruising, or purple \"splotches\" on your skin to your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad rashes have been reported. People of Asian descent are most likely to get these. Talk with your doctor right away if you get a rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat restless leg syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carbamazepine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703726",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bone marrow disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other liquid drugs within 2 hours of this liquid drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake it well before use. Mix with an equal part of water before you drink it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11711 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13446=[""].join("\n");
var outline_f13_8_13446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026975\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026977\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026976\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026981\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026982\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026984\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026979\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026980\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026985\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026986\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=related_link\">",
"      Carbamazepine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=related_link\">",
"      Carbamazepine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_8_13447="Ventricular demand pacemaker tutorial";
var content_f13_8_13447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventricular demand pacemaker tutorial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 118px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A single pacemaker spike (marked by red lines) is followed by a QRS complex which is wide and bizarre and resembles a ventricular beat. There are some normal intervening QRS complexes that suppress the pacemaker when they occur faster than the rate set for the pacemaker.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13447=[""].join("\n");
var outline_f13_8_13447=null;
var title_f13_8_13448="Overview of breech presentation";
var content_f13_8_13448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of breech presentation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13448/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13448/contributors\">",
"     G Justus Hofmeyr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13448/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13448/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13448/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/8/13448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breech presentation describes the fetus whose buttocks are adjacent to the birth canal. There are three types of breech presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the frank breech position, both hips are flexed and both knees are extended so that the feet are adjacent to the fetal head (",
"      <a class=\"graphic graphic_figure graphicRef71398 \" href=\"UTD.htm?34/7/34943\">",
"       figure 1",
"      </a>",
"      ). At term, 50 to 70 percent of breech fetuses are in this position.",
"     </li>",
"     <li>",
"      In the complete breech position, both hips and both knees are flexed (",
"      <a class=\"graphic graphic_figure graphicRef77224 \" href=\"UTD.htm?34/27/35263\">",
"       figure 2",
"      </a>",
"      ). At term, 5 to 10 percent of breech fetuses are in this position.",
"     </li>",
"     <li>",
"      In the incomplete breech position, one or both hips are",
"      <strong>",
"       not",
"      </strong>",
"      completely flexed (",
"      <a class=\"graphic graphic_figure graphicRef68254 \" href=\"UTD.htm?14/18/14624\">",
"       figure 3",
"      </a>",
"      ). At term, 10 to 40 percent of breech fetuses are incomplete.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One or both feet are the presenting part in a footling breech. The presenting part is smaller than the buttocks of the frank or complete breech, and can slip through an incompletely dilated cervix. Rarely, one or both knees are the presenting part; this is called a kneeling breech.",
"   </p>",
"   <p>",
"    When breech presentation is identified, the major concerns are (1) whether the fetus has adopted this position because of an underlying abnormality and (2) avoiding maternal and fetal harm during delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/1\">",
"     1",
"    </a>",
"    ]. The breech fetus is at increased risk of harm during delivery because cord compression between the cervix and body must occur as the breech crowns and because the aftercoming shoulders, head, and arms are at greater risk of harm from dystocia than in the cephalic presenting fetus. Cord prolapse is also more common in breech presentation. The magnitude of these risks, whether they can be reduced by use of management guidelines, and how the fetal risks compare with maternal risks from cesarean delivery, has been a matter of debate for decades.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of breech presentation decreases with increasing gestational age. It is a common occurrence in early pregnancy when the fetus is highly mobile within a relatively large volume of amniotic fluid. While 20 to 25 percent of fetuses under 28 weeks are breech, only 7 to 16 percent are breech at 32 weeks, and only 3 to 4 percent are breech at term [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous version may occur at any time before delivery, even after 40 weeks of gestation. A prospective longitudinal study using serial ultrasound examination reported the likelihood of spontaneous version to cephalic presentation after 36 weeks was 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/4\">",
"     4",
"    </a>",
"    ]. Characteristics that lower the likelihood of spontaneous version include extended fetal legs, oligohydramnios, short umbilical cord, primiparity, and",
"    <span class=\"nowrap\">",
"     fetal/uterine",
"    </span>",
"    abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is hypothesized that a normally proportioned active fetus in a normal volume of amniotic fluid adopts the cephalic presentation near term because this position is the best fit in the intrauterine space. If any of these variables are disrupted by underlying maternal, fetal, or placental conditions, then breech presentation becomes more likely. In most pregnancies, however, breech presentation appears to be a chance occurrence. Abnormalities of the uterus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetus account for less than 15 percent of breech presentations.",
"   </p>",
"   <p>",
"    In addition to preterm gestation, the following uterine and fetal factors have been associated with an increased risk of breech presentation:",
"   </p>",
"   <p>",
"    Altered intrauterine contour or volume:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uterine anomalies (eg, bicornuate or septate uterus) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Space occupying lesions (eg, uterine leiomyomata)",
"     </li>",
"     <li>",
"      Placental abnormalities (eg, placenta previa, cornual placenta) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multiparity resulting in a lax abdominal wall and more rounded intrauterine space",
"     </li>",
"     <li>",
"      Extremes of amniotic fluid volume (polyhydramnios, oligohydramnios)",
"     </li>",
"     <li>",
"      Contracted maternal pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Altered fetal shape:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal anomaly (eg, anencephaly, hydrocephaly, sacrococcygeal teratoma, neck mass)",
"     </li>",
"     <li>",
"      Extended fetal legs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Impaired fetal mobility:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crowding from multiple gestation",
"     </li>",
"     <li>",
"      Neurologic impairment",
"     </li>",
"     <li>",
"      Short umbilical cord [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fetal asphyxia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other purported risk factors include primiparity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/4\">",
"     4",
"    </a>",
"    ], female gender [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/11\">",
"     11",
"    </a>",
"    ], maternal anticonvulsant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/12\">",
"     12",
"    </a>",
"    ], older maternal age, fetal growth restriction, and previous breech presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of data from a population based registry showed that the risk of breech presentation in a second pregnancy was 9 percent if the first infant was breech and 2 percent if the first infant was nonbreech [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/13\">",
"     13",
"    </a>",
"    ]. After two consecutive breech deliveries, the risk of another breech presentation rises to 21 to 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and after three consecutive breech deliveries the risk is 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, men or women who were delivered at term from breech presentation were twice as likely to have firstborn offspring in breech presentation as parents who were delivered in cephalic presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/15\">",
"     15",
"    </a>",
"    ]. This suggests there may be a heritable component to fetal presentation that can be transmitted from either parent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mother is more likely to report subcostal discomfort when the breech is presenting since the fetal head occupies the fundus rather than the lower uterine segment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/16\">",
"     16",
"    </a>",
"    ]. She may perceive kicking in the lower, rather than upper, abdomen if the breech is in a nonfrank position.",
"   </p>",
"   <p>",
"    The diagnosis of breech presentation is usually based on physical examination (Leopold maneuvers). Clinical assessment of fetal presentation should be a routine part of prenatal examination in late pregnancy. On transabdominal palpation of the lower uterine segment, breech presentation should be suspected when the presenting part lacks the hardness of the fetal skull and the normal recess between head and shoulders is not palpable. Ballottement of the breech is characteristically sluggish because it is accompanied by movement of the entire trunk. By comparison, the fetal head is readily balloted since it is relatively small and pivots on the neck.",
"   </p>",
"   <p>",
"    Nevertheless, clinical diagnosis is not infallible. This was illustrated in a study in which an experienced clinician examining 138 women in the third trimester detected only three of eight breech presentations, and falsely diagnosed six [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If breech presentation persists near term or the diagnosis is uncertain, ultrasound examination is recommended to confirm presentation and type of breech, estimate the fetal weight, and exclude the presence of a fetal or placental abnormality or an extended fetal head.",
"   </p>",
"   <p>",
"    Occasionally, vaginal examination in labor suggests a previously unsuspected breech presentation. Differential diagnosis includes the possibility that an edematous face presentation is being palpated. A useful distinguishing characteristic is that the greater trochanters and anus form a straight line, whereas the malar bones and mouth form a triangle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged umbilical cord compression and delivery-related trauma are greater concerns during vaginal breech birth than during vaginal cephalic birth. To reduce these risks, the fetus in breech presentation can be turned to a cephalic presentation to increase the likelihood of cephalic vaginal birth, or the mother can undergo cesarean delivery. Because the risks are small, however, the mother may choose to labor and undergo a vaginal breech birth.",
"   </p>",
"   <p>",
"    Our preference for women with breech presentation is external cephalic version, with planned cesarean delivery for women with persistent breech presentation. An acceptable alternative is planned vaginal delivery by an experienced clinician for women who meet selection criteria for safe vaginal delivery and choose this option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     External cephalic version",
"    </span>",
"    &nbsp;&mdash;&nbsp;External cephalic version can be used to convert a breech presentation to cephalic presentation and thus increase the likelihood of vaginal birth (",
"    <a class=\"graphic graphic_figure graphicRef63535 \" href=\"UTD.htm?20/38/21092\">",
"     figure 4",
"    </a>",
"    ). A meta-analysis of randomized trials showed that external cephalic version at term was associated with significant reductions in both noncephalic birth (RR 0.38, 95% CI 0.18-0.80) and cesarean delivery (RR 0.55, 95% CI 0.33-0.91) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/18\">",
"     18",
"    </a>",
"    ]. Performing the version at 34 to 35 weeks of gestation and using a tocolytic drug increase the likelihood of success. This technique is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8281?source=see_link\">",
"     \"External cephalic version\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cesarean versus vaginal delivery at term",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, cesarean delivery for breech presentation rose from 12 percent in 1970 to 87 percent in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/19\">",
"     19",
"    </a>",
"    ]. Similar increases have been reported worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. This change in clinical practice was largely due to evidence from randomized trials, particularly the Term Breech Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/23\">",
"     23",
"    </a>",
"    ], that showed a policy of planned cesarean delivery for term breech presentation was associated with a large decrease in",
"    <span class=\"nowrap\">",
"     perinatal/neonatal",
"    </span>",
"    mortality and neonatal morbidity, with only a modest increase in short-term maternal morbidity, compared with a policy of planned vaginal delivery. There are limited data that the worldwide change in clinical practice has also led to a reduction in the morbidity and mortality of breech presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H8\">",
"     'Evidence'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    This evidence should be applied with due consideration to specific health care environments, individual women, and the limitations inherent in the trials evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. A policy of planned cesarean delivery may not be affordable or feasible in resource-poor settings. On an individual case basis, there may be clinical situations in which the risks of cesarean to the mother, or the mother's desire to avoid cesarean delivery, may outweigh the short-term risks of vaginal birth to the baby. Both routes of delivery have similar long-term maternal and childhood outcomes and some data suggest some long-term health benefits to being born vaginally [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In addition, cesarean delivery has implications for women planning future pregnancies including repeat cesarean delivery and increased risks of placenta accreta and uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/34\">",
"     34",
"    </a>",
"    ]. Lastly, the randomized trials that were the basis of current policies for planned cesarean delivery included fewer than three thousand women. Increasing the magnitude of planned cesarean deliveries worldwide will increase the absolute number of women who develop rare but life-threatening complications of this major operative procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists Committee on Obstetric Practice recommends use of external cephalic version and planned cesarean delivery for persistent singleton breech presentation at term [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/37\">",
"     37",
"    </a>",
"    ]. However, they also state that a planned vaginal delivery of a term singleton breech may be reasonable with detailed patient informed consent, under hospital specific protocol guidelines, and by a health care provider experienced in vaginal breech delivery.",
"   </p>",
"   <p>",
"    The Society of Obstetricians and Gynecologists of Canada also allows for selective vaginal breech delivery; this follows an eight-year period during which vaginal breech delivery was discouraged based on the results of the Term Breech Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Evidence",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15336833\">",
"    <span class=\"h4\">",
"     Systematic review",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence supporting planned cesarean delivery was provided by a 2003 systematic review including three randomized trials of planned cesarean delivery versus planned vaginal delivery for term breech presentation (n = 2396 participants) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/39\">",
"     39",
"    </a>",
"    ]. In two of the trials, which were from the same unit, women with frank [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/40\">",
"     40",
"    </a>",
"    ] or nonfrank [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/41\">",
"     41",
"    </a>",
"    ] breech presentation were randomly assigned to undergo scheduled cesarean delivery or a protocol allowing vaginal delivery within prescribed limitations, including the absence of diminished pelvic dimensions on X-ray pelvimetry. The third trial, the Term Breech Trial, was a large (n = 2088 participants) multicenter, international trial comparing planned cesarean delivery with planned vaginal delivery by an experienced clinician following agreed upon clinical guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/23\">",
"     23",
"    </a>",
"    ]. The participating countries were classified as having low or high perinatal mortality rates (low = less than 20 per 1000 live births plus late fetal deaths, high = 20 or more). Cesarean delivery was performed in 550 of 1227 women (45 percent) allocated to the vaginal delivery protocol.",
"   </p>",
"   <p>",
"    The key findings were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with attempted vaginal birth, planned cesarean delivery of breech presentation was associated with a reduction in perinatal or neonatal death (RR 0.29, 95% CI 0.10-0.86), after excluding fatal anomalies.",
"      <br/>",
"      <br/>",
"      This result was largely driven by the Term Breech Trial, where",
"      <span class=\"nowrap\">",
"       perinatal/neonatal",
"      </span>",
"      mortality associated with planned cesarean and planned vaginal breech birth was 0 and 0.6 percent, respectively, in countries with low national perinatal mortality rates, and 0.3 and 1.3 percent, respectively, overall [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with attempted vaginal birth, planned cesarean delivery of breech presentation was associated with a reduction in the composite outcome of perinatal or neonatal death or serious neonatal morbidity (RR 0.33, 95% CI 0.19-0.56), after excluding fatal anomalies.",
"      <br/>",
"      <br/>",
"      Again, this result was largely driven by the Term Breech Trial, where serious short-term neonatal morbidity associated with planned cesarean and planned vaginal breech birth was 0.4 and 5.1 percent, respectively, in countries with low national perinatal mortality rates, and 1.4 and 3.8 percent, respectively, overall [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15336847\">",
"    <span class=\"h4\">",
"     Term Breech Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the findings reported as part of the systematic review described above, the Term Breech Trial also found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At two years of age there was",
"      <strong>",
"       no",
"      </strong>",
"      significant difference in the combined risk of",
"      <span class=\"nowrap\">",
"       death/neurodevelopmental",
"      </span>",
"      delay between the planned vaginal and planned cesarean groups, even though neonatal morbidity and mortality were reduced in the short-term (first six weeks of life) by planned cesarean delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/31\">",
"       31",
"      </a>",
"      ]. One infant death occurred in each group after the neonatal period; neurodevelopmental delay was diagnosed in 12 children from the planned cesarean birth group and 7 children from the planned vaginal birth group. Despite the large number of study subjects, the trial was underpowered to find a difference in composite",
"      <span class=\"nowrap\">",
"       mortality/morbidity",
"      </span>",
"      at two years of age since there were relatively few serious adverse events and most children with neonatal morbidity develop normally. For example, 17 of 18 neonates with serious early morbidity were neurologically normal at two years of age.",
"     </li>",
"     <li>",
"      Compared with attempted vaginal birth, planned cesarean delivery of breech presentation was associated with a small increase in short-term maternal morbidity (eg, hemorrhage, transfusion, infection) (RR 1.29, 95% CI 1.03-1.61). The prevalence of urinary incontinence at three months was lower in the planned cesarean group and incontinence of flatus was less troublesome [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, maternal morbidity at two years was similar in both groups, with no significant differences in incontinence, relationship with partner or child, or distressing memories of the birth experience [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/43\">",
"       43",
"      </a>",
"      ]. Constipation was more common in the planned cesarean delivery group:",
"      <span class=\"nowrap\">",
"       124/457",
"      </span>",
"      (27 percent) than in the planned vaginal delivery group:",
"      <span class=\"nowrap\">",
"       93/460",
"      </span>",
"      (20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prelabor cesarean delivery had a lower risk of adverse perinatal outcome than cesarean performed anytime during labor, especially if the labor was complicated (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      augmentation, pushing for more than 60 minutes) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Planned cesarean decreased the risk of adverse perinatal outcome due to both problems of labor and problems of delivery compared with planned vaginal birth [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A policy of planned cesarean delivery did not appear to be more costly than planned vaginal birth. In the Term Breech Trial, when all costs related to maternal and neonatal physician services and hospitalization from randomization to six weeks postpartum were taken into account, the overall cost of planned cesarean was significantly lower than for planned vaginal birth, $7255 versus $8042 (in 2002 Canadian dollars) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/46\">",
"       46",
"      </a>",
"      ]. However, there were wide cost variations among the various centers involved in the trial; therefore, generalizability of these findings is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A disadvantage of scheduled cesarean delivery was that it decreased the opportunity for spontaneous version. In the Term Breech Trial, cephalic presentation was present at delivery in 19 of 1041 (1.8 percent) of the planned cesarean delivery group compared to 39 of 1042 (3.7 percent) of the planned vaginal birth group (p &lt;0.02) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Furthermore, a policy of planned cesarean delivery did not eliminate the problems associated with breech presentation. In the Term Breech Trial, 22 of 1041 (2.1 percent) women randomly assigned to planned cesarean birth experienced difficult deliveries and 6 neonates (0.6 percent) experienced birth trauma. One hundred women (9.6 percent) gave birth vaginally, usually because the birth took place before cesarean delivery could be arranged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15336854\">",
"    <span class=\"h4\">",
"     PREMODA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2006, the PREsentation et MODe d&rsquo;Accouchement (PREMODA) study, a prospective observational multicenter study conducted in 174 centers in France and Belgium and including 8105 singleton breech fetuses at term, evaluated the safety of vaginal breech birth using strict criteria (",
"    <a class=\"graphic graphic_table graphicRef86649 \" href=\"UTD.htm?4/32/4619\">",
"     table 1",
"    </a>",
"    ) for selecting patients for a trial of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/48\">",
"     48",
"    </a>",
"    ]. The composite outcome of",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    mortality or serious neonatal morbidity was not significantly different for planned vaginal versus planned cesarean delivery: 1.60 versus 1.45 percent; (OR 1.10, 95% CI 0.75-1.61), after adjustment for the geographic origin, gestational age less than 39 weeks at birth, birthweight less than the 10th percentile, and an annual number of maternity unit births of less than 1500 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/49\">",
"     49",
"    </a>",
"    ]. Approximately 70 percent of the 2502 patients in the planned vaginal birth group delivered vaginally, and 165 (6.6 percent) had an adverse perinatal outcome, including but not limited to brachial plexus injury (five infants), skull fracture (one infant), genital injury (two infants), intraventricular hemorrhage (one infant), seizure (four infants), and fetal death (two infants) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/49\">",
"     49",
"    </a>",
"    ]. Factors associated with adverse perinatal outcome were geographic origin, delivery at &lt;39 weeks of gestation, birthweight &lt;10th percentile, and annual number of maternity unit births &lt;1500.",
"   </p>",
"   <p>",
"    This study is often cited as a counterpoint to the findings of the smaller Term Breech Trial and to support offering vaginal breech birth using specific guidelines for managing labor and delivery to selected women. The results of this observational study are less robust than those of the Term Breech Trial, but provide additional information illustrating the magnitude of morbidity of planned vaginal birth in patients managed using the authors' protocol. Subsequent smaller prospective observational studies have also reported low rates of adverse outcome from planned vaginal breech delivery that followed strict protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cesarean versus vaginal delivery preterm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is generally preferred for the preterm breech fetus because the fetal head circumference-to-abdominal circumference ratio is larger than that of a mature baby, thus, the premature breech head is more likely to be caught in a partially dilated cervix, resulting in birth trauma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute asphyxia from compression of the umbilical cord [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. This recommendation is based on limited data.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials evaluating cesarean versus vaginal delivery of the preterm breech enrolled too few women for meaningful statistical analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of women delivering breech infants at 26 to 29 weeks of gestation found that head entrapment was two-fold higher in the planned vaginal delivery group than in the planned cesarean delivery group",
"      <span class=\"nowrap\">",
"       (11/84",
"      </span>",
"      [13 percent] versus",
"      <span class=\"nowrap\">",
"       5/85",
"      </span>",
"      [6 percent]) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/53\">",
"       53",
"      </a>",
"      ]. Four neonatal deaths were attributed to head entrapment; three of these infants were delivered vaginally and died within an hour of birth (neonatal death related to head entrapment",
"      <span class=\"nowrap\">",
"       3/45",
"      </span>",
"      vaginal deliveries versus",
"      <span class=\"nowrap\">",
"       1/124",
"      </span>",
"      cesarean deliveries). The single infant that died after cesarean delivery complicated by head entrapment died five days later because of sepsis and grade 3 IVH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, 84 women planned vaginal delivery and 85 women planned cesarean delivery, but approximately 50 percent of planned vaginal deliveries ended in cesarean birth, while 6 percent of planned cesareans ended in vaginal birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABOR AND DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery is generally spontaneous or assisted (the fetus delivers to the umbilicus without any intervention and then the clinician performs gentle maneuvers such as rotation of the trunk, suprapubic pressure, or gentle traction on an elbow or knee to help with delivery of the shoulders, limbs, and head). Complete manual extraction is reserved for delivery of the second twin because in singletons it is associated with a relatively high rate of birth injury.",
"   </p>",
"   <p>",
"    Labor and delivery are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=see_link\">",
"     \"Delivery of the fetus in breech presentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetuses in breech presentation are at increased risk of developing mild deformations (eg, frontal bossing, prominent occiput, upward slant and low-set ears), torticollis, and developmental dysplasia of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=see_link\">",
"     \"Congenital muscular torticollis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breech presentation has been associated with higher perinatal mortality and morbidity than cephalic presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/58\">",
"     58",
"    </a>",
"    ]. The following factors appear to account for most of the difference in reported outcomes: increased risk of birth trauma, increased prevalence of breech presentation among low",
"    <span class=\"nowrap\">",
"     birthweight/preterm",
"    </span>",
"    deliveries, and increased prevalence of congenital anomalies and neuromuscular disorders among fetuses in breech presentation. Fetal presentation does not appear to affect adult intellectual performance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13448/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/62/18402?source=see_link\">",
"       \"Patient information: Breech pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breech presentation may be frank, complete, or incomplete (",
"      <a class=\"graphic graphic_figure graphicRef71398 \" href=\"UTD.htm?34/7/34943\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef77224 \" href=\"UTD.htm?34/27/35263\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef68254 \" href=\"UTD.htm?14/18/14624\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breech presentation complicates 3 to 4 percent of term pregnancies; the prevalence is inversely associated with gestational age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breech presentation may be associated with an underlying fetal or uterine abnormality and has a tendency to recur. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of breech presentation is usually based on physical examination, which can be confirmed with ultrasound examination if the diagnosis is uncertain. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fetus in breech presentation can be turned to a cephalic presentation to increase the likelihood of cephalic vaginal birth, or the mother can undergo a vaginal breech birth, or she can undergo cesarean delivery of the breech fetus. Women with breech presentation should be counseled about the risks and benefits of each of these options. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend external cephalic version (ECV) for women with breech presentation at term to reduce the rate of breech birth and cesarean delivery (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8281?source=see_link\">",
"       \"External cephalic version\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For persistent breech presentation, we suggest planned cesarean delivery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Cesarean delivery is associated with a reduction in short-term adverse outcomes (perinatal mortality, serious neonatal morbidity) compared with vaginal birth, but no significant difference in long-term maternal or child morbidity or mortality. Randomized trials have not evaluated the risks of cesarean delivery in subsequent pregnancies. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cesarean versus vaginal delivery at term'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There may be clinical situations in which the risks of cesarean to the mother, or the mother's desire to avoid cesarean delivery, may outweigh the risks of vaginal birth to the baby. Vaginal delivery, if elected, should be performed by an experienced provider and meet specific criteria. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cesarean versus vaginal delivery at term'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=see_link&amp;anchor=H3#H3\">",
"       \"Delivery of the fetus in breech presentation\", section on 'Criteria for an optimal situation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/1\">",
"      Thorngren-Jerneck K, Herbst A. Perinatal factors associated with cerebral palsy in children born in Sweden. Obstet Gynecol 2006; 108:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/2\">",
"      Scheer K, Nubar J. Variation of fetal presentation with gestational age. Am J Obstet Gynecol 1976; 125:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/3\">",
"      Hickok DE, Gordon DC, Milberg JA, et al. The frequency of breech presentation by gestational age at birth: a large population-based study. Am J Obstet Gynecol 1992; 166:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/4\">",
"      Westgren M, Edvall H, Nordstr&ouml;m L, et al. Spontaneous cephalic version of breech presentation in the last trimester. Br J Obstet Gynaecol 1985; 92:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/5\">",
"      Ben-Rafael Z, Seidman DS, Recabi K, et al. Uterine anomalies. A retrospective, matched-control study. J Reprod Med 1991; 36:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/6\">",
"      Michalas SP. Outcome of pregnancy in women with uterine malformation: evaluation of 62 cases. Int J Gynaecol Obstet 1991; 35:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/7\">",
"      Fianu S, V&aacute;clav&iacute;nkov&aacute; V. The site of placental attachment as a factor in the aetiology of breech presentation. Acta Obstet Gynecol Scand 1978; 57:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/8\">",
"      Ranney B. The gentle art of external cephalic version. Am J Obstet Gynecol 1973; 116:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/9\">",
"      Soernes T, Bakke T. The length of the human umbilical cord in vertex and breech presentations. Am J Obstet Gynecol 1986; 154:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/10\">",
"      Moessinger AC, Blanc WA, Marone PA, Polsen DC. Umbilical cord length as an index of fetal activity: experimental study and clinical implications. Pediatr Res 1982; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/11\">",
"      Hall MH, Carr-Hill R. Impact of sex ratio on onset and management of labour. Br Med J (Clin Res Ed) 1982; 285:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/12\">",
"      Robertson, IS. Breech presentation associated with anticonvulsant drugs. Am J Obstet Gynecol 1984; 4:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/13\">",
"      Albrechtsen S, Rasmussen S, Dalaker K, Irgens LM. Reproductive career after breech presentation: subsequent pregnancy rates, interpregnancy interval, and recurrence. Obstet Gynecol 1998; 92:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/14\">",
"      Ford JB, Roberts CL, Nassar N, et al. Recurrence of breech presentation in consecutive pregnancies. BJOG 2010; 117:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/15\">",
"      Nordtveit TI, Melve KK, Albrechtsen S, Skjaerven R. Maternal and paternal contribution to intergenerational recurrence of breech delivery: population based cohort study. BMJ 2008; 336:872.",
"     </a>",
"    </li>",
"    <li>",
"     Hofmeyr, GJ. Abnormal fetal presentation and position. Chapter 34. Turnbull's Obstetrics 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/17\">",
"      Thorp JM Jr, Jenkins T, Watson W. Utility of Leopold maneuvers in screening for malpresentation. Obstet Gynecol 1991; 78:394.",
"     </a>",
"    </li>",
"    <li>",
"     Hofmeyr, GJ, Kulier, R. External cephalic version for breech presentation at term. Cochrane Library 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/19\">",
"      Centers for Disease Control. Births: Final data for 2001. National vital statistics reports 2002; 51:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/20\">",
"      Hutton EK, Hannah ME, Barrett J. Use of external cephalic version for breech pregnancy and mode of delivery for breech and twin pregnancy: a survey of Canadian practitioners. J Obstet Gynaecol Can 2002; 24:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/21\">",
"      Rietberg CC, Elferink-Stinkens PM, Visser GH. The effect of the Term Breech Trial on medical intervention behaviour and neonatal outcome in The Netherlands: an analysis of 35,453 term breech infants. BJOG 2005; 112:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/22\">",
"      Yogev Y, Horowitz E, Ben-Haroush A, et al. Changing attitudes toward mode of delivery and external cephalic version in breech presentations. Int J Gynaecol Obstet 2002; 79:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/23\">",
"      Hannah ME, Hannah WJ, Hewson SA, et al. Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial. Term Breech Trial Collaborative Group. Lancet 2000; 356:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/24\">",
"      Hartnack Tharin JE, Rasmussen S, Krebs L. Consequences of the Term Breech Trial in Denmark. Acta Obstet Gynecol Scand 2011; 90:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/25\">",
"      Glezerman M. Five years to the term breech trial: the rise and fall of a randomized controlled trial. Am J Obstet Gynecol 2006; 194:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/26\">",
"      Lockwood CJ. The term, singleton, vaginal breech delivery controversy. J Matern Fetal Neonatal Med 2002; 12:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/27\">",
"      Kotaska A. Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery. BMJ 2004; 329:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/28\">",
"      Hauth JC, Cunningham FG. Vaginal breech delivery is still justified. Obstet Gynecol 2002; 99:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/29\">",
"      van Roosmalen J, Rosendaal F. There is still room for disagreement about vaginal delivery of breech infants at term. BJOG 2002; 109:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/30\">",
"      Menticoglou SM. Why vaginal breech delivery should still be offered. J Obstet Gynaecol Can 2006; 28:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/31\">",
"      Whyte H, Hannah ME, Saigal S, et al. Outcomes of children at 2 years after planned cesarean birth versus planned vaginal birth for breech presentation at term: the International Randomized Term Breech Trial. Am J Obstet Gynecol 2004; 191:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/32\">",
"      Negele K, Heinrich J, Borte M, et al. Mode of delivery and development of atopic disease during the first 2 years of life. Pediatr Allergy Immunol 2004; 15:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/33\">",
"      Laubereau B, Filipiak-Pittroff B, von Berg A, et al. Caesarean section and gastrointestinal symptoms, atopic dermatitis, and sensitisation during the first year of life. Arch Dis Child 2004; 89:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/34\">",
"      Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol 2011; 38:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/35\">",
"      Schutte JM, Steegers EA, Santema JG, et al. Maternal deaths after elective cesarean section for breech presentation in the Netherlands. Acta Obstet Gynecol Scand 2007; 86:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/36\">",
"      Lawson GW. Report of a breech cesarean section maternal death. Birth 2011; 38:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/37\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 340. Mode of term singleton breech delivery. Obstet Gynecol 2006; 108:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/38\">",
"      Devarajan K, Seaward PG, Farine D. Attitudes among Toronto obstetricians towards vaginal breech delivery. J Obstet Gynaecol Can 2011; 33:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/39\">",
"      Hofmeyr GJ, Hannah ME. Planned caesarean section for term breech delivery. Cochrane Database Syst Rev 2003; :CD000166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/40\">",
"      Collea JV, Chein C, Quilligan EJ. The randomized management of term frank breech presentation: a study of 208 cases. Am J Obstet Gynecol 1980; 137:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/41\">",
"      Gimovsky ML, Wallace RL, Schifrin BS, Paul RH. Randomized management of the nonfrank breech presentation at term: a preliminary report. Am J Obstet Gynecol 1983; 146:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/42\">",
"      Hannah ME, Hannah WJ, Hodnett ED, et al. Outcomes at 3 months after planned cesarean vs planned vaginal delivery for breech presentation at term: the international randomized Term Breech Trial. JAMA 2002; 287:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/43\">",
"      Hannah ME, Whyte H, Hannah WJ, et al. Maternal outcomes at 2 years after planned cesarean section versus planned vaginal birth for breech presentation at term: the international randomized Term Breech Trial. Am J Obstet Gynecol 2004; 191:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/44\">",
"      Su M, McLeod L, Ross S, et al. Factors associated with adverse perinatal outcome in the Term Breech Trial. Am J Obstet Gynecol 2003; 189:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/45\">",
"      Su M, Hannah WJ, Willan A, et al. Planned caesarean section decreases the risk of adverse perinatal outcome due to both labour and delivery complications in the Term Breech Trial. BJOG 2004; 111:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/46\">",
"      Palencia R, Gafni A, Hannah ME, et al. The costs of planned cesarean versus planned vaginal birth in the Term Breech Trial. CMAJ 2006; 174:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/47\">",
"      Henderson J, Petrou S. The economic case for planned cesarean section for breech presentation at term. CMAJ 2006; 174:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/48\">",
"      Goffinet F, Carayol M, Foidart JM, et al. Is planned vaginal delivery for breech presentation at term still an option? Results of an observational prospective survey in France and Belgium. Am J Obstet Gynecol 2006; 194:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/49\">",
"      Azria E, Le Meaux JP, Khoshnood B, et al.. Factors associated with adverse perinatal outcomes for term breech fetuses with planned vaginal delivery. Am J Obstet Gynecol 2012; 207:285.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/50\">",
"      Maier B, Georgoulopoulos A, Zajc M, et al. Fetal outcome for infants in breech by method of delivery: experiences with a stand-by service system of senior obstetricians and women's choices of mode of delivery. J Perinat Med 2011; 39:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/51\">",
"      Michel S, Drain A, Closset E, et al. Evaluation of a decision protocol for type of delivery of infants in breech presentation at term. Eur J Obstet Gynecol Reprod Biol 2011; 158:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/52\">",
"      Robilio PA, Boe NM, Danielsen B, Gilbert WM. Vaginal vs. cesarean delivery for preterm breech presentation of singleton infants in California: a population-based study. J Reprod Med 2007; 52:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/53\">",
"      Kayem G, Baumann R, Goffinet F, et al. Early preterm breech delivery: is a policy of planned vaginal delivery associated with increased risk of neonatal death? Am J Obstet Gynecol 2008; 198:289.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/54\">",
"      Penn ZJ, Steer PJ, Grant A. A multicentre randomised controlled trial comparing elective and selective caesarean section for the delivery of the preterm breech infant. Br J Obstet Gynaecol 1996; 103:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/55\">",
"      Zlatnik FJ. The Iowa premature breech trial. Am J Perinatol 1993; 10:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/56\">",
"      Hsieh YY, Tsai FJ, Lin CC, et al. Breech deformation complex in neonates. J Reprod Med 2000; 45:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/57\">",
"      Fox AE, Paton RW. The relationship between mode of delivery and developmental dysplasia of the hip in breech infants: a four-year prospective cohort study. J Bone Joint Surg Br 2010; 92:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/58\">",
"      Schutte MF, van Hemel OJ, van de Berg C, van de Pol A. Perinatal mortality in breech presentations as compared to vertex presentations in singleton pregnancies: an analysis based upon 57819 computer-registered pregnancies in The Netherlands. Eur J Obstet Gynecol Reprod Biol 1985; 19:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13448/abstract/59\">",
"      Eide MG, &Oslash;yen N, Skjaerven R, et al. Breech delivery and intelligence: a population-based study of 8,738 breech infants. Obstet Gynecol 2005; 105:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6776 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-2A680BD67D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13448=[""].join("\n");
var outline_f13_8_13448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      External cephalic version",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cesarean versus vaginal delivery at term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15336833\">",
"      Systematic review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15336847\">",
"      Term Breech Trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15336854\">",
"      PREMODA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cesarean versus vaginal delivery preterm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABOR AND DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6776\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6776|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/7/34943\" title=\"figure 1\">",
"      Frank breech presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/27/35263\" title=\"figure 2\">",
"      Complete breech presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/18/14624\" title=\"figure 3\">",
"      Incomplete breech presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/38/21092\" title=\"figure 4\">",
"      External cephalic version",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6776|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/32/4619\" title=\"table 1\">",
"      PREMODA criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=related_link\">",
"      Congenital muscular torticollis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=related_link\">",
"      Delivery of the fetus in breech presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=related_link\">",
"      Epidemiology and pathogenesis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8281?source=related_link\">",
"      External cephalic version",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/62/18402?source=related_link\">",
"      Patient information: Breech pregnancy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_8_13449="Cryptococcal infection outside the central nervous system";
var content_f13_8_13449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cryptococcal infection outside the central nervous system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13449/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13449/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13449/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13449/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13449/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13449/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13449/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/8/13449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal pneumonia and other sites of infection outside the central nervous system in immunocompetent and immunosuppressed patients will be reviewed here.",
"   </p>",
"   <p>",
"    Issues related to cryptococcal meningoencephalitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PULMONARY INFECTION IN IMMUNOCOMPETENT ADULTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans likely become infected with C. neoformans by inhaling the basidiospore form of the fungus or small poorly encapsulated yeasts. Basidiospores are smaller than the yeast forms obtained from clinical samples and have much smaller polysaccharide capsules, facilitating deposition in the alveoli and terminal bronchioles after inhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/1\">",
"     1",
"    </a>",
"    ]. Following inhalation, C. neoformans likely causes a focal pneumonitis that may or may not be symptomatic. The immune status is the most important determinant of the subsequent course of the infection (eg, whether the pneumonitis resolves or progresses to symptomatic dissemination) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large segment of the population has been exposed to C. neoformans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/4\">",
"     4",
"    </a>",
"    ]. Subclinical primary infections are common and most are asymptomatic. Postmortem studies on immunocompetent persons without antecedent respiratory complaints have demonstrated small areas of granulomatous inflammation in the lung parenchyma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hilar lymph nodes due to C. neoformans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The foci are generally smaller than those seen in tuberculosis and do not appear to calcify as frequently as seen with histoplasmosis. Infection can persist in a latent state; if the host immune system becomes compromised, organisms may be liberated from the granulomatous complexes and cause active infection.",
"   </p>",
"   <p>",
"    There are also descriptions of pulmonary cryptococcosis in apparently immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a review of approximately 90 immunocompetent hosts with pulmonary cryptococcosis, 32 percent of the patients were asymptomatic, and pulmonary infection was discovered as an incidental finding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/7\">",
"     7",
"    </a>",
"    ]. Asymptomatic patients with chest radiograph findings suspicious for malignancy who undergo biopsy are occasionally found to have cryptococcosis.",
"   </p>",
"   <p>",
"    The factors that determine whether an exposed person develops symptomatic infection are uncertain but may include the inoculum of fungi (eg, burden of exposure)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    virulence factors of the infecting strain. Common symptoms include cough, sputum production, hemoptysis, dyspnea, chest pain, fever, malaise, night sweats, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ]. Less common symptoms include rash and gastrointestinal complaints. Rare manifestations include obstruction of the superior vena cava, Pancoast's syndrome due to granulomatous inflammation from the host response to C. neoformans, eosinophilic pneumonia, and extension from the lung to the chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tools for pulmonary cryptococcosis include histology, fungal culture, serum cryptococcal antigen, and radiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Culture and histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of encapsulated yeast forms in sputum, bronchoalveolar lavage or tissue specimens is suggestive of cryptococcal pulmonary infection. The diagnosis is established by culturing the organism from sputum or another specimen. Biopsy specimens of asymptomatic nodules may have yeast on histopathologic inspection but the culture may be negative.",
"   </p>",
"   <p>",
"    Associated pleural effusions are usually exudative [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Yeast forms may be seen in the pleural effusion, and cultures are usually positive.",
"   </p>",
"   <p>",
"    Routine blood cultures are appropriate for patients who have extensive infiltrates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cryptococcal antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum cryptococcal antigen should be performed. Although positive results are often found in immunocompromised hosts with cryptococcal pneumonia, antigen detection is not a sensitive test for diagnosis of pulmonary infection in immunocompetent patients. However, antigen testing may be more useful for diagnosis of cryptococcal pneumonia due to C. gattii among immunocompetent hosts in regions where C. gattii is endemic (eg, the Pacific Northwest and British Columbia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=see_link&amp;anchor=H11#H11\">",
"     \"Microbiology and epidemiology of cryptococcal infection\", section on 'C. gattii'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no role for monitoring serum cryptococcal antigen titers to determine duration of therapy in either immunosuppressed or immunocompetent hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic features of pulmonary cryptococcosis in immunocompetent patients are variable. The most common findings are solitary or few well-defined, non-calcified nodules that are often pleural-based (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64815 \" href=\"UTD.htm?8/51/9012\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Other radiographic findings include lobar infiltrates, hilar and mediastinal adenopathy, and pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/16,17,21-24\">",
"     16,17,21-24",
"    </a>",
"    ]. In a case series of 12 immunocompetent hosts, 10 patients had nodules and masses (eight were peripheral); three had cavitation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissemination from the lungs to the central nervous system in immunocompetent patients is rare, and routine lumbar puncture to evaluate for cryptococcal meningoencephalitis is generally not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, lumbar puncture is warranted for patients with neurologic symptoms or an underlying condition that predisposes to dissemination. Lumbar puncture is also appropriate for immunocompetent patients with a very high serum cryptococcal antigen titer (&gt;1:512); such patients appear to have a higher burden of infection with risk for extrapulmonary spread and seeding of the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is to control signs and symptoms of cryptococcal pneumonia and minimize risk of dissemination to the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ]. Literature for management of pulmonary cryptococcal infection consists of retrospective reports; the approach is extrapolated from literature describing management of patients with HIV infection and CNS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/9,28-31\">",
"     9,28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompetent patients with cryptococcal pneumonia and neurologic symptoms should undergo lumbar puncture to evaluate for meningitis. Normal hosts with no CNS symptoms and low serum cryptococcal antigen titer (&lt;1:512) need not undergo lumbar puncture.",
"   </p>",
"   <p>",
"    Pleural effusions rarely require drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Surgical excision of infected pulmonary tissue is only indicated in cases of masses that impinge on adjacent structures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Principles of therapy are comparable for infection due to C. neoformans and C. gattii.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites) or a cryptococcal antigen titer &ge;1:512 (a known poor prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/32\">",
"     32",
"    </a>",
"    ]) should be managed as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on extrapolation from literature describing management of patients with HIV infection, treatment for immunocompetent patients with mild to moderate pulmonary cryptococcosis in the absence of diffuse pulmonary infiltrates or disseminated infection consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg [6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    per day orally) for 6 to 12 months (",
"    <a class=\"graphic graphic_table graphicRef82028 \" href=\"UTD.htm?35/23/36219\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ]. If fluconazole is not available or is contraindicated, acceptable alternatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg twice per day orally),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (200 mg twice per day orally) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (400 mg twice per day orally), although there are minimal data available regarding the latter agents.",
"   </p>",
"   <p>",
"    Asymptomatic patients who have cryptococcal infection diagnosed incidentally in the setting of pulmonary nodule resection to rule out malignancy and who have negative cultures and cryptococcal antigen titers may not require antifungal therapy. There are reports of immunocompetent, asymptomatic patients with positive culture, serology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histopathology who improved radiographically with observation alone in the absence of antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/9,29,31\">",
"     9,29,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic patients with detectable serum cryptococcal antigen probably have a very low likelihood of symptomatic systemic dissemination. However, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is appropriate since it is likely to be curative and the risk of adverse effects is low [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no role for monitoring serum cryptococcal antigen titers to guide duration of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1029509529\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, localized cryptococcal infections of the lung not responding to medical therapy may need surgical resection for cure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PULMONARY INFECTION IN IMMUNOCOMPROMISED ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of pulmonary cryptococcosis in the immunocompromised host are likely due to reactivation of latent infection. However, primary infection in a naive host or reinfection with a new strain is also possible. Immunocompromised hosts with pulmonary cryptococcosis generally have more symptoms than immunocompetent hosts and are more likely to present with extrapulmonary disease.",
"   </p>",
"   <p>",
"    Conditions that increase risk for pulmonary cryptococcosis include HIV infection, malignancies, stem cell and solid organ transplantation, cirrhosis, renal failure, chronic lung disease, diabetes, Cushing's syndrome, sarcoidosis, and treatment with glucocorticoids or tumor necrosis factor-alpha antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/9,31,33-39\">",
"     9,31,33-39",
"    </a>",
"    ]. Cryptococcal pneumonia in a lung transplant patient due to asymptomatic C. neoformans carriage in the donor lung has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HIV negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations due to pulmonary cryptococcosis range from asymptomatic pneumonia to acute respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/9,28,31,41\">",
"     9,28,31,41",
"    </a>",
"    ]. Among 34 immunocompromised patients with cryptococcal pneumonia, 28 developed extrapulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/31\">",
"     31",
"    </a>",
"    ]. The most common symptoms were fever (63 percent), chest pain (44 percent), dyspnea (27 percent), cough (17 percent), and hemoptysis (7 percent).",
"   </p>",
"   <p>",
"    Cryptococcal pneumonia and acute respiratory distress syndrome (ARDS) occur more frequently among organ transplant recipients than other hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/28,42,43\">",
"     28,42,43",
"    </a>",
"    ]. In this setting ARDS is often associated with disseminated infection; mortality is high and urgent treatment is required [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/28,41\">",
"     28,41",
"    </a>",
"    ]. Such patients should be managed as outlined separately for cryptococcal meningoencephalitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     HIV positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of pulmonary cryptococcosis in patients with HIV is more acute and severe than in other hosts. The severity of symptoms and extent of dissemination are inversely proportional to the CD4 lymphocyte count; most symptomatic cases occur in patients with CD4 counts less than",
"    <span class=\"nowrap\">",
"     100/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Clinical",
"    manifestations include fever (81 to 94 percent), cough (63 to 71 percent), dyspnea (5 to 50 percent) and headache (41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/37\">",
"     37",
"    </a>",
"    ]. Some patients are hypoxic; some present with acute respiratory distress syndrome (ARDS). Dissemination from the lungs to the central nervous system occurs in 65 to 94 percent of cases of HIV-associated pulmonary cryptococcosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/30,37,44,45\">",
"     30,37,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other opportunistic infections with manifestations similar to pulmonary cryptococcosis include those due to P. jirovecii, Mycobacterium avium complex, M. tuberculosis, CMV, and Histoplasma capsulatum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/37,45\">",
"     37,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tools for pulmonary cryptococcosis include histology, fungal culture, serum cryptococcal antigen, and radiography.",
"   </p>",
"   <p>",
"    Evaluation of immunocompromised patients with pulmonary cryptococcosis should include evaluation for disseminated infection; this includes blood and cerebrospinal fluid (CSF) cultures as well as blood and CSF cryptococcal polysaccharide antigen testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cryptococcal antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum cryptococcal antigen is positive in virtually all patients with HIV infection and pulmonary cryptococcosis, and in 56 to 70 percent of patients with other underlying immunocompromising conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/9,30,35,36,46\">",
"     9,30,35,36,46",
"    </a>",
"    ]. Therefore, it is as an excellent screening test in immunocompromised patients with respiratory symptoms. False positive serum cryptococcal antigen tests can occur in the setting of infections due to the fungus Trichosporon asahii (formerly T. beigelii) or the bacterial genera Stomatococcus or Capnocytophaga [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. False negative serum cryptococcal antigen tests can occur with samples that contain a large amount of antigen (the prozone phenomenon) if the laboratory is using a latex agglutination assay and doesn&rsquo;t pretreat the sample with pronase [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/50\">",
"     50",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    In solid organ transplant recipients with pulmonary cryptococcosis, a positive serum cryptococcal antigen test frequently reflects advanced lung involvement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extrapulmonary disease, such as fungemia or central nervous system infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/51\">",
"     51",
"    </a>",
"    ]. In one series including solid organ transplant recipients, a positive serum cryptococcal antigen titer was documented in 38 percent of patients with pulmonary cryptococcosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/29\">",
"     29",
"    </a>",
"    ]. In a prospective study of 60 solid organ transplant recipients with pulmonary cryptococcosis, positive serum cryptococcal antigen results were observed in 84 percent of those with any pulmonary involvement; the test was positive in 73 percent of those with disease limited to the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/51\">",
"     51",
"    </a>",
"    ]. However, a negative cryptococcal antigen result does not exclude the diagnosis of cryptococcosis.",
"   </p>",
"   <p>",
"    Given the high rate of extrapulmonary disease among immunocompromised patients with cryptococcal pneumonia, a positive serum cryptococcal antigen result should prompt investigation for disseminated infection with blood culture, cerebrospinal fluid (CSF) cryptococcal antigen assay and CSF culture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/32\">",
"     32",
"    </a>",
"    ]. Positive results should prompt management as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Culture and histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of expectorated sputum samples is often positive in immunocompromised patients. C. neoformans in respiratory tract specimens from transplant patients should be considered to represent a true pathogen. Bronchoscopy may be indicated in patients with advanced HIV infection to rule out other opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy is necessary only if malignancy is suspected. Histology can help to establish the diagnosis by demonstrating encapsulated yeast forms (",
"    <a class=\"graphic graphic_picture graphicRef64561 \" href=\"UTD.htm?13/5/13400\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Routine blood cultures are appropriate for patients with severe immunosuppression, extensive infiltrates,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic findings are usually more severe than those seen in apparently immunocompetent patients. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with HIV, alveolar infiltrates, lymphadenopathy, mass lesions, and small pleural effusions have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/37\">",
"     37",
"    </a>",
"    ]. Interstitial infiltrates may mimic the radiographic presentation of Pneumocystis jirovecii pneumonia (PCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/37,53\">",
"     37,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture to evaluate for cryptococcal meningoencephalitis is warranted for patients with neurologic symptoms or an underlying condition that predisposes to dissemination. In a study of HIV seronegative patients with pulmonary cryptococcal disease, those with disseminated disease were more likely to have cirrhosis, headache, weight loss, fever, altered mental status,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to be receiving high-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the definition of the immunocompromised state is imprecise, a lumbar puncture to rule out central nervous system disease should be performed in those with pulmonary cryptococcosis who are considered to be immunosuppressed even in the absence of neurologic signs or symptoms. Such patients appear to have a higher burden of infection with risk for extrapulmonary spread and seeding of the central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites) or a serum cryptococcal antigen titer &ge;1:512 (a known poor prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/32\">",
"     32",
"    </a>",
"    ]) should be managed as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal treatment of cryptococcal pneumonia is uncertain; management is extrapolated from literature describing management of patients with HIV infection and CNS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/9,29,30\">",
"     9,29,30",
"    </a>",
"    ]. In general, treatment for immunocompromised patients with mild to moderate pulmonary cryptococcosis in the absence of diffuse pulmonary infiltrates or disseminated infection consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg [6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    per day) for 6 to 12 months (",
"    <a class=\"graphic graphic_table graphicRef82028 \" href=\"UTD.htm?35/23/36219\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ]. If fluconazole is not available or contraindicated, acceptable alternatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg twice per day orally),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (200 mg twice per day orally), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (400 mg twice per day orally) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], although there are minimal data for the latter agents.",
"   </p>",
"   <p>",
"    The efficacy of this approach was illustrated in a study of 39 solid organ transplant recipients with extraneural cryptococcosis who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or a regimen containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ; the mortality was comparable (10 to 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/56\">",
"     56",
"    </a>",
"    ]. Among 109 HIV negative immunocompromised patients with pulmonary cryptococcosis treated with fluconazole, the 12 month survival was 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/9\">",
"     9",
"    </a>",
"    ]. In a retrospective review of 14 solid organ transplant recipients with extraneural cryptococcosis who received fluconazole as primary therapy for a median of 60 days, no therapeutic failures were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-infected patients should continue chronic suppressive therapy with 200 mg per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . In patients with HIV who are receiving HAART and have CD4 count &gt;100",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    suppressed viral load, and a cryptococcal antigen titer &le;1:512 that is not increasing, it may be reasonable to discontinue maintenance fluconazole after 1 year of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have responded to therapy for pulmonary cryptococcosis and subsequently must undergo chemotherapy or intensive therapy for graft rejection within two years of the diagnosis should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    during these intervals to prevent recurrent cryptococcal infection.",
"   </p>",
"   <p>",
"    There is no role for monitoring serum cryptococcal antigen titers to determine duration of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H951399052\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, localized cryptococcal infections of the lung not responding to medical therapy may need surgical resection for cure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PULMONARY INFECTION IN PREGNANT WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been cases of cryptococcal pneumonia described in pregnancy, although there are insufficient epidemiologic data to implicate pregnancy as a predisposing condition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\", section on 'Pregnant women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women with stable pulmonary cryptococcosis should be followed closely and may initiate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    therapy following delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ]. Immune reconstitution inflammatory syndrome can occur in the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Indeed, nearly half of the Cryptococcus cases reported in pregnancy presented with symptomatic disease in the third trimester or postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PULMONARY INFECTION IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcus has been reported in children with primary immunodeficiencies such as hyper-immunoglobulin M syndrome and severe combined immunodeficiency syndrome, as well as children with HIV, connective tissue diseases, and solid organ transplant recipients. Cryptococcosis has also been described in children with no recognized immunodeficiency.",
"   </p>",
"   <p>",
"    Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or serum cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\", section on 'Children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of children with mild to moderate pulmonary cryptococcosis consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally) for 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     NONMENINGEAL, NONPULMONARY CRYPTOCOCCOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonmeningeal, nonpulmonary cryptococcosis generally reflects disseminated infection, even if clinical manifestations are confined to a single anatomic site (such as skin, soft tissue or osteoarticular infection).",
"   </p>",
"   <p>",
"    Cryptococcal skin lesions are seen in up to 15 percent of patients with disseminated infection; they manifest as papules (",
"    <a class=\"graphic graphic_picture graphicRef69214 \" href=\"UTD.htm?34/15/35058\">",
"     picture 2",
"    </a>",
"    ), plaques, purpura, ulcers, cellulitis, superficial plaques, abscesses and sinus tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/62\">",
"     62",
"    </a>",
"    ]. Patients with advanced HIV infection may have umbilicated papules resembling molluscum contagiosum; in transplant patients, cellulitis may occur without evidence of dissemination. Although the majority of cryptococcal skin lesions result from disseminated infection, primary cryptococcal skin infections by direct inoculation may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryptococcal lesions of the skeletal system occur in &lt;10 percent of patients with disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/64\">",
"     64",
"    </a>",
"    ]. The vertebrae are the most common site of osteoarticular infection. Radiography typically demonstrates a well circumscribed osteolytic lesion resembling malignancy. Septic arthritis is rare.",
"   </p>",
"   <p>",
"    Cryptococcal infection can involve any body site or structure following dissemination, including the liver, lymph nodes, peritoneum, urogenital tract, adrenal glands and eyes. Involvement of the eyes frequently reflects central nervous system infection, which should be sought in all cases. The prostate may serve as a reservoir of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among 175 solid organ transplant recipients with cryptococcosis, nine patients (5 percent) presented very early following transplantation (defined as &le;30 days post-transplant; mean 5.7 days post-transplant) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients who presented very early were more likely to have disease at unusual locations, including in the transplanted allograft or in the surgical fossa. These locations suggest that the infections were donor-derived. Five of the nine patients (56 percent) with very early onset disease were liver transplant recipients compared with 43 of 166 patients (26 percent) with disease occurring &gt;30 days post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/66\">",
"     66",
"    </a>",
"    ], suggesting that some of these patients may have had unrecognized infection prior to transplantation as a result of the impaired host defenses that accompany cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies evaluating treatment of cryptococcal infection involving sites other than lungs and CNS. In general, infection at a single site in the absence of CNS disease, fungemia or risk factors for immunosuppression may be managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg [6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    per day orally) for 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13449/abstract/27,68,69\">",
"     27,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of ocular infections must be managed in consultation with ophthalmologic expertise and tailored to individual circumstances depending on the extent of eye structure involvement and whether CNS involvement has been documented. Therapeutic possibilities include systemic therapy with high penetration into the eye such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adjunctive intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large segment of the population has been exposed to C. neoformans. Subclinical primary infections are common and most are asymptomatic. Infection can persist in a latent state; if the host immune system becomes compromised organisms may be liberated from the granulomatous complexes and cause active infection. Symptomatic pulmonary cryptococcosis can also occur in apparently immunocompetent patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pulmonary infection in immunocompetent adults'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Pulmonary infection in immunocompromised adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations due to cryptococcal pneumonia range from asymptomatic pneumonia to acute respiratory failure. The presentation of pulmonary cryptococcosis in patients with HIV is more acute and severe than in other hosts. Most symptomatic cases occur in patients with CD4 counts less than 100",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H14\">",
"       'HIV positive patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cryptococcal pneumonia in immunocompetent hosts is established by culturing the organism from sputum or another specimen. Visualization of encapsulated yeast forms in sputum, bronchoalveolar lavage, or tissue specimens is suggestive of cryptococcal pulmonary infection. The most common radiographic findings are solitary or few well-defined, non-calcified nodules. Lumbar puncture is warranted for patients with neurologic symptoms and for patients with serum cryptococcal antigen titer &gt;1:512. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serum cryptococcal antigen titer is often positive in immunocompromised patients with cryptococcal pneumonia. Culture of respiratory specimens is also a useful tool. A lumbar puncture to rule out central nervous system disease should be performed in those with pulmonary cryptococcosis who are considered to be immunosuppressed even in the absence of neurologic signs or symptoms.(See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with mild to moderate pulmonary cryptococcosis in the absence of diffuse pulmonary infiltrates or disseminated infection be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is fluconazole 400 mg (6",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      per day for 6 to 12 months (",
"      <a class=\"graphic graphic_table graphicRef82028 \" href=\"UTD.htm?35/23/36219\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"       \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/1\">",
"      Valegapudi, R, Hsueh, YP, Geunes Boyer, S, et al. Spores as infectious propagules of Cryptococcus neoformans. Infect Immunol 2009; 77:4345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/2\">",
"      Salkowski CA, Balish E. Role of natural killer cells in resistance to systemic cryptococcosis. J Leukoc Biol 1991; 50:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/3\">",
"      Huffnagle GB, Traynor TR, McDonald RA, et al. Leukocyte recruitment during pulmonary Cryptococcus neoformans infection. Immunopharmacology 2000; 48:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/4\">",
"      Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001; 107:E66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/5\">",
"      BAKER RD, HAUGEN RK. Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases. Am J Clin Pathol 1955; 25:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/6\">",
"      Baker RD. The primary pulmonary lymph node complex of crytptococcosis. Am J Clin Pathol 1976; 65:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/7\">",
"      Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966; 94:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/8\">",
"      Chu HQ, Li HP, He GJ. Analysis of 23 cases of pulmonary cryptococcosis. Chin Med J (Engl) 2004; 117:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/9\">",
"      Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/10\">",
"      Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 2006; 129:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/11\">",
"      Shirley RM, Baddley JW. Cryptococcal lung disease. Curr Opin Pulm Med 2009; 15:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/12\">",
"      Menon A, Rajamani R. Giant 'cryptococcoma' of the lung. Br J Dis Chest 1976; 70:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/13\">",
"      Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis 1992; 14:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/14\">",
"      Starr JC, Che H, Montgomery J. Cryptococcal pneumonia simulating chronic eosinophilic pneumonia. South Med J 1995; 88:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/15\">",
"      Mitsuoka S, Kanazawa H. Images in Thorax. An unique case of primary pulmonary cryptococcosis with extensive chest wall invasion. Thorax 2005; 60:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/16\">",
"      McAllister CK, Davis CE Jr, Ognibene AJ, Carpenter JL. Cryptococcal pleuro-pulmonary disease: infection of the pleural fluid in the absence of disseminated cryptococcosis. Case report. Mil Med 1984; 149:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/17\">",
"      Young EJ, Hirsh DD, Fainstein V, Williams TW. Pleural effusions due to Cryptococcus neoformans: a review of the literature and report of two cases with cryptococcal antigen determinations. Am Rev Respir Dis 1980; 121:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/18\">",
"      Zlupko GM, Fochler FJ, Goldschmidt ZH. Pulmonary cryptococcosis presenting with multiple pulmonary nodules. Chest 1980; 77:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/19\">",
"      Lindell RM, Hartman TE, Nadrous HF, Ryu JH. Pulmonary cryptococcosis: CT findings in immunocompetent patients. Radiology 2005; 236:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/20\">",
"      Yang CJ, Hwang JJ, Wang TH, et al. Clinical and radiographic presentations of pulmonary cryptococcosis in immunocompetent patients. Scand J Infect Dis 2006; 38:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/21\">",
"      Hunt KK, Enquist RW, Bowen TE. Multiple pulmonary nodules with central cavitation. Chest 1976; 69:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/22\">",
"      Feigin DS. Pulmonary cryptococcosis: radiologic-pathologic correlates of its three forms. AJR Am J Roentgenol 1983; 141:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/23\">",
"      Khoury MB, Godwin JD, Ravin CE, et al. Thoracic cryptococcosis: immunologic competence and radiologic appearance. AJR Am J Roentgenol 1984; 142:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/24\">",
"      Murata K, Khan A, Herman PG. Pulmonary parenchymal disease: evaluation with high-resolution CT. Radiology 1989; 170:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/25\">",
"      Fox DL, M&uuml;ller NL. Pulmonary cryptococcosis in immunocompetent patients: CT findings in 12 patients. AJR Am J Roentgenol 2005; 185:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/26\">",
"      Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008; 27:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/27\">",
"      Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/28\">",
"      Vilchez RA, Linden P, Lacomis J, et al. Acute respiratory failure associated with pulmonary cryptococcosis in non-aids patients. Chest 2001; 119:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/29\">",
"      Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/30\">",
"      Meyohas MC, Roux P, Bollens D, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 1995; 21:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/31\">",
"      Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981; 94:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/32\">",
"      Dromer F, Mathoulin-P&eacute;lissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/33\">",
"      Whitley TH, Graybill JR, Alford RH. Pulmonary cryptococcosis in chronic lymphocytic leukemia. South Med J 1976; 69:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/34\">",
"      Kramer M, Corrado ML, Bacci V, et al. Pulmonary cryptococcosis and Cushing's syndrome. Arch Intern Med 1983; 143:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/35\">",
"      Finke R, Strobel ES, Kroepelin T, et al. Disseminated cryptococcosis in a patient with malignant lymphoma. Mycoses 1988; Suppl 1:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/36\">",
"      Christoph I. Pulmonary Cryptococcus neoformans and disseminated Nocardia brasiliensis in an immunocompromised host. Case report. N C Med J 1990; 51:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/37\">",
"      Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991; 13:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/38\">",
"      Arend SM, Kuijper EJ, Allaart CF, et al. Cavitating pneumonia after treatment with infliximab and prednisone. Eur J Clin Microbiol Infect Dis 2004; 23:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/39\">",
"      Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis 2009; 48:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/40\">",
"      Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996; 75:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/41\">",
"      Visnegarwala F, Graviss EA, Lacke CE, et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis 1998; 27:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/42\">",
"      Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/43\">",
"      Shaariah W, Morad Z, Suleiman AB. Cryptococcosis in renal transplant recipients. Transplant Proc 1992; 24:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/44\">",
"      Wasser L, Talavera W. Pulmonary cryptococcosis in AIDS. Chest 1987; 92:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/45\">",
"      Clark RA, Greer DL, Valainis GT, Hyslop NE. Cryptococcus neoformans pulmonary infection in HIV-1-infected patients. J Acquir Immune Defic Syndr 1990; 3:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/46\">",
"      Jensen WA, Rose RM, Hammer SM, Karchmer AW. Serologic diagnosis of focal pneumonia caused by Cryptococcus neoformans. Am Rev Respir Dis 1985; 132:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/47\">",
"      Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993; 342:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/48\">",
"      McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/49\">",
"      Westerink MA, Amsterdam D, Petell RJ, et al. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987; 83:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/50\">",
"      Tanner DC, Weinstein MP, Fedorciw B, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994; 32:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/51\">",
"      Singh N, Alexander BD, Lortholary O, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/52\">",
"      Malabonga VM, Basti J, Kamholz SL. Utility of bronchoscopic sampling techniques for cryptococcal disease in AIDS. Chest 1991; 99:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/53\">",
"      Friedman EP, Miller RF, Severn A, et al. Cryptococcal pneumonia in patients with the acquired immunodeficiency syndrome. Clin Radiol 1995; 50:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/54\">",
"      Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/55\">",
"      Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/56\">",
"      Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996; 23:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/57\">",
"      Mart&iacute;nez E, Garc&iacute;a-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14:2615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/58\">",
"      Ely EW, Peacock JE Jr, Haponik EF, Washburn RG. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998; 77:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/59\">",
"      Costeas PA, Koumouli A, Giantsiou-Kyriakou A, et al. Th2/Th3 cytokine genotypes are associated with pregnancy loss. Hum Immunol 2004; 65:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/60\">",
"      Annapureddy SR, Masterson SW, David HG, Greig JR. Post partum osteomyelitis due to Cryptococcus neoformans. Scand J Infect Dis 2007; 39:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/61\">",
"      Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis 2007; 45:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/62\">",
"      Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/63\">",
"      Neuville S, Dromer F, Morin O, et al. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/64\">",
"      Behrman RE, Masci JR, Nicholas P. Cryptococcal skeletal infections: case report and review. Rev Infect Dis 1990; 12:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/65\">",
"      Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989; 111:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/66\">",
"      Sun HY, Alexander BD, Lortholary O, et al. Unrecognized pretransplant and donorderived cryptococcal disease in organ transplant recipients. Clin Infect Dis 2010; 51:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/67\">",
"      Singh N, Husain S, De Vera M, et al. Cryptococcus neoformans Infection in Patients With Cirrhosis, Including Liver Transplant Candidates. Medicine (Baltimore) 2004; 83:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/68\">",
"      Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13449/abstract/69\">",
"      Singh N, Gayowski T, Marino IR. Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. Transpl Int 1998; 11:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2421 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13449=[""].join("\n");
var outline_f13_8_13449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PULMONARY INFECTION IN IMMUNOCOMPETENT ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Culture and histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cryptococcal antigen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1029509529\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PULMONARY INFECTION IN IMMUNOCOMPROMISED ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HIV negative patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - HIV positive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cryptococcal antigen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Culture and histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H951399052\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PULMONARY INFECTION IN PREGNANT WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PULMONARY INFECTION IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NONMENINGEAL, NONPULMONARY CRYPTOCOCCOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2421\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2421|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/51/9012\" title=\"diagnostic image 1\">",
"      Chest CT cryptococcal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2421|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/5/13400\" title=\"picture 1\">",
"      Crypto H and E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/15/35058\" title=\"picture 2\">",
"      Disseminated cryptococcosis - papules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2421|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/23/36219\" title=\"table 1\">",
"      Rx nonmeningeal crypto",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=related_link\">",
"      Microbiology and epidemiology of cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_8_13450="Treatment of acute diverticulitis";
var content_f13_8_13450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute diverticulitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13450/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13450/contributors\">",
"     Tonia Young-Fadok, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13450/contributors\">",
"     John H Pemberton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13450/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/8/13450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/8/13450/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/8/13450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticulitis represents acute inflammation of the diverticular bearing portion of colon, likely caused by microscopic or macroscopic perforation of one or several diverticula which sets up an inflammatory reaction involving principally the colon wall and surrounding pericolonic tissue. This reaction is self-limiting in patients with simple diverticulitis and is immediately walled off and thus no abscess or peritonitis ensues. Macro- or gross perforation can result in peritonitis (purulent or fecal), abscess, or fistula; and continued or recurrent inflammation can result in stricture. All these manifestations are referred to as complicated diverticulitis.",
"   </p>",
"   <p>",
"    It was previously believed that obstruction of diverticula, eg, by fecaliths, increased diverticular pressure and caused perforation; such obstruction is now thought to be rare. The primary process is thought to be erosion of the diverticular wall by increased intraluminal pressure or inspissated food particles. Inflammation and focal necrosis ensue, resulting in perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36854?source=see_link\">",
"     \"Epidemiology and pathophysiology of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on the management of patients with acute diverticulitis. Several major medical organizations have also proposed recommendations, which are available online [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Society of Colon and Rectal Surgeons (",
"      <a class=\"external\" href=\"file://www.fascrs.org/\">",
"       www.fascrs.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Society for Surgery of the Alimentary Tract (",
"      <a class=\"external\" href=\"file://www.ssat.com/\">",
"       www.ssat.com",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The American College of Gastroenterology (",
"      <a class=\"external\" href=\"file://www.acg.gi.org/\">",
"       www.acg.gi.org/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      European Association of Endoscopic Surgeons (",
"      <a class=\"external\" href=\"file://www.eaes.eu/Home.aspx\">",
"       www.eaes.eu/Home.aspx",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Association of Coloproctology of Great Britain and Ireland (",
"      <a class=\"external\" href=\"file://www.acpgbi.org.uk/\">",
"       www.acpgbi.org.uk/",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines from the American Society of Colon and Rectal Surgeons and the American College of Gastroenterology are particularly useful in providing the supporting documentation used by the panels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88798216\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;From a therapeutic viewpoint, diverticulitis can be divided into complicated and uncomplicated presentations (",
"    <a class=\"graphic graphic_figure graphicRef65206 \" href=\"UTD.htm?15/61/16350\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Complicated diverticulitis",
"      </strong>",
"      refers to the presence of a perforation, obstruction, an abscess, or a fistula. Approximately 25 percent of patients diagnosed with diverticulitis for the first time present with complicated diverticulitis. Nearly all of these patients require surgery.",
"     </li>",
"     <li>",
"      <strong>",
"       Uncomplicated diverticulitis",
"      </strong>",
"      , accounting for 75 percent of cases, refers to diverticulitis without the complications noted above. The majority of these patients respond to medical therapy, although up to 30 percent require surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute diverticulitis is often suspected based upon the history and the physical examination. In the acute stage, further studies are performed to confirm the diagnosis and to rule out other sources of acute abdominal signs. Computer tomographic scanning has become the optimal method of investigation in patients suspected of having acute diverticulitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UNCOMPLICATED DIVERTICULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success rate of conservative treatment, bowel rest and antibiotics, ranges from 70 to 100 percent for patients with acute uncomplicated diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/7-15\">",
"     7-15",
"    </a>",
"    ]. A CT scan can be helpful for identifying patients who are likely to respond to conservative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This was illustrated in a study that included 56 patients with acute diverticulitis, 37 of whom were identified as having uncomplicated disease by CT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/10\">",
"     10",
"    </a>",
"    ]. All of these 37 were treated successfully with nonsurgical therapy and discharged in an average of 6.8 days. Nineteen patients had complicated disease (abscess, fistula, peritonitis, obstruction) and were treated appropriately. Three of the initial cohort of 59 patients (5 percent) had a mistaken clinical diagnosis of acute diverticulitis. Similar findings were noted in another series in which medical therapy was successful in 97 percent of patients with uncomplicated diverticulitis by CT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several issues must be addressed when caring for patients with uncomplicated diverticulitis, including whether treatment can be achieved safely in an outpatient setting, the need and selection of specific antibiotics, dietary recommendations, the need for follow-up investigation, the likelihood of recurrence, and the choice and timing of operative intervention in those who do not respond adequately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Selection for outpatient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision regarding whether to hospitalize a patient with diverticulitis depends upon several factors, including the severity of presentation, the ability to tolerate oral intake, the presence of comorbid diseases, and the available support system. Patients selected for outpatient management should be reliable and understand the indications for seeking immediate medical attention. These include an increase in fever or abdominal pain or the inability to consume adequate fluids. As a general rule, the elderly, immunosuppressed, those with significant comorbidities, and those with high fever or significant leukocytosis should be hospitalized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice and duration of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticulitis represents a localized infection that is traditionally treated with antibiotics, based upon retrospective studies and expert opinion. In the uncomplicated patient with acute diverticulitis, antibiotics are continued for 7 to 10 days, depending upon resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The choice of antibiotics should be based upon the usual bacteria, which are principally Gram-negative rods and anaerobes (particularly E. coli and B. fragilis). Reasonable choices include a quinolone with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    with metronidazole. The selection may be influenced by the patient's history of allergies or previous use of antibiotics.",
"   </p>",
"   <p>",
"    Our usual outpatient regimen includes a 10 to 14 day course of antibiotics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (500 mg PO twice daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg PO three times daily).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      <span class=\"nowrap\">",
"       (875/125",
"      </span>",
"      mg twice daily) is an acceptable alternative. Oral ciprofloxacin achieves levels similar to those with intravenous administration, has broad coverage of enteric Gram-negative pathogens, and (similar to amoxicillin-clavulanate) requires only twice daily dosing, thus improving compliance.",
"     </li>",
"     <li>",
"      For patients intolerant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      may be an acceptable alternative. For patients intolerant to metronidazole as well as beta lactam agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      has reasonable gram-negative and anaerobic coverage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients requiring hospitalization should receive empiric broad-spectrum intravenous antibiotics with activity against gram negative rods and anaerobic organisms pending culture results of any abscess obtained by percutaneous aspirate or surgical drainage.",
"   </p>",
"   <p>",
"    For",
"    <strong>",
"     complicated diverticulitis",
"    </strong>",
"    , intravenous antibiotics are administered until the inflammation is stabilized and pain and tenderness are resolving. The patient is then transitioned to oral antibiotics for a 10 to 14 day course.",
"   </p>",
"   <p>",
"    We suggest one of the following intravenous regimens (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monotherapy with a",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      (3 g every six hours) OR",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"        piperacillin",
"       </a>",
"       /tazobactam",
"      </span>",
"      (3.375 g IV every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      (3.1 g every six hours)",
"     </li>",
"     <li>",
"      A third generation cephalosporin such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 g IV every 24 hours) PLUS",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every 8 hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with beta-lactam intolerance, alternative empiric regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A fluoroquinolone (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      400 mg IV every 12 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      500 mg or 750 IV daily) PLUS",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every 8 hours)",
"     </li>",
"     <li>",
"      Monotherapy with a carbapenem, such as imipenem (500 mg every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g every eight hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      (1 g daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the initial empiric regimen, the therapeutic regimen should be revisited once culture and susceptibility results are available. Recovery of more than one organism should suggest polymicrobial infection including anaerobes, even if no anaerobes are isolated in culture. In such circumstances, anaerobic coverage should be continued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88798508\">",
"    <span class=\"h3\">",
"     Challenge to conventional antibiotic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the conventional management of",
"    <strong>",
"     uncomplicated",
"    </strong>",
"    acute diverticulitis with antibiotics was challenged by a multicenter randomized trial that included 623 patients with CT-scan-proven uncomplicated diverticulitis, and found no statistical difference in complication rates based upon use of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/18\">",
"     18",
"    </a>",
"    ]. There was no difference in rate of bowel perforation for patients treated with intravenous fluids without antibiotics compared with patients receiving intravenous fluids and antibiotics (three patients per group, &lt;1 percent). Patients treated without antibiotics also had a similar rate of recurrent diverticulitis (16.2 versus 15.8 percent). However, three patients randomized to treatment without antibiotics developed an intra-abdominal abscess. If these findings are confirmed, selected patients who are diagnosed with",
"    <strong>",
"     uncomplicated",
"    </strong>",
"    diverticulitis may be safely managed with close observation without antibiotic therapy.",
"   </p>",
"   <p>",
"    However, pain is a common presentation of acute diverticulitis and time to relief of pain with antibiotics was not addressed in this trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\", section on 'Clinical manifestations'",
"    </a>",
"    .) Cross-over to the antibiotic arm occurred for 10 patients (3.2 percent) because of increasing abdominal pain, fever, or increasing C-reactive protein (CRP). The value of antibiotics to relieve inflammation and resultant pain may be sufficient to maintain use of antibiotics as the treatment approach of choice for most patients, even if the rate of bowel perforation and recurrent diverticulitis is comparable without antibiotics. Observation only strategies for patients with uncomplicated diverticulitis awaits further prospective investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dietary recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatients should be instructed to consume clear liquids only. Clinical improvement should be evident after two to three days, after which the diet can be advanced slowly. Patients requiring hospitalization can be treated with clear liquids or NPO with intravenous hydration, depending upon the severity of symptoms.",
"   </p>",
"   <p>",
"    The role of dietary therapy in the prevention of recurrence has not been established in well-designed randomized controlled trials with long-term follow-up. Nevertheless, patients should generally be advised to consume a high fiber diet once the acute phase has resolved. This recommendation is based mostly upon uncontrolled studies, which have suggested that long-term fiber supplementation may reduce the incidence of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/12,19\">",
"     12,19",
"    </a>",
"    ]. Indirect support for fiber supplementation can also be inferred from studies that have demonstrated a protective effect from diets high in fiber on the development of diverticular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/20\">",
"     20",
"    </a>",
"    ]. Two small controlled trials on fiber supplementation for prevention of recurrence had conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Seeds and nuts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diverticular disease have historically been advised to avoid whole pieces of fiber (such as seeds, corn, and nuts) because of concern that the undigested fragments could become lodged within a diverticulum, thereby inciting an episode of diverticulitis. The commonly heard advice to avoid small undigestible foods (such as seeds) because they may theoretically become lodged in a diverticulum is completely unproven and is probably little more than an old wives' tale. However, there continues to be considerable practice variation with regard to this recommendation. In a survey of colorectal surgeons, one-half believed that the avoidance of seeds and nuts was of no value [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors have seen tens of thousands of diverticula and never seen a single seed. Furthermore, in a large observational study (The Health Professionals Follow-up Study) there was an inverse association between nut and popcorn consumption and the risk of diverticulitis and diverticular bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, no association was found between consumption of corn and diverticulitis or between nut, corn, or popcorn consumption and diverticular bleeding or uncomplicated diverticulosis. Thus, we do not suggest that patients with diverticulosis avoid seeds, corn, and nuts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monitoring the clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatients should be advised to call for increasing pain, fever, or the inability to tolerate fluids, all of which may be an indication for hospitalization. Complications should be sought in all patients with clinical deterioration or those who fail to improve within two to three days. Abscesses amenable to percutaneous drainage should be treated. Laparotomy is necessary if there is no reversible condition, if abscesses cannot be drained, or if drainage does not result in improvement (",
"    <a class=\"graphic graphic_table graphicRef65296 \" href=\"UTD.htm?19/52/20299\">",
"     table 2",
"    </a>",
"    ). Surgery should proceed without delay if a patient's condition deteriorates (increased pain, more localized peritonitis or diffuse tenderness, increased white count), and there is no reversible condition.",
"   </p>",
"   <p>",
"    Alternative diagnoses should also be considered. These include acute appendicitis; Crohn's disease; colon cancer; ischemic colitis; pseudomembranous colitis; complicated ulcer disease; ovarian cyst, abscesses, or torsion; and ectopic pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recommendations following resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two to six weeks after recovery, patients should undergo an evaluation of the colon to exclude other diagnoses (such as colonic neoplasia) and to evaluate the extent of the diverticulosis (information that may be important to direct therapy, should future complications of diverticulosis occur). This is usually accomplished with a colonoscopy, although a flexible sigmoidoscopy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema is a reasonable alternative, if the patient had a colonoscopy within one year. In a retrospective review of 319 patients with left sided diverticulitis, a follow-up colonoscopy confirmed the diagnosis in 89 percent, and 26 percent of those had previously undiagnosed polyps identified [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/24\">",
"     24",
"    </a>",
"    ]. For the 35 patients who did not have confirmation of diverticulitis, 9 patients were diagnosed with colorectal cancer, 5 with colitis, 3 procedures failed, and 18 patients were normal. As noted above, patients should be advised to consume a diet high in fiber. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?17/32/17922?source=see_link\">",
"     \"Patient information: Diverticular disease (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prognosis after resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following successful conservative therapy for a first attack of diverticulitis, approximately one-third of patients will remain asymptomatic, one-third will have episodic abdominal cramps without frank diverticulitis, and one-third will proceed to a second attack of diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/12,25-28\">",
"     12,25-28",
"    </a>",
"    ]. Recurrent attacks are generally not severe. This was illustrated in a retrospective review of 672 patients in which 36 percent had a recurrence at five years, but only 4 percent had a complicated recurrence (eg, fistula, abscess, free perforation) when treated medically [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/28\">",
"     28",
"    </a>",
"    ]. The major risk factors for a recurrence were retroperitoneal abscess in the initial episode, a family history of diverticulitis, and more than 5 cm of colon involved in the initial episode.",
"   </p>",
"   <p>",
"    It was generally believed that the prognosis is worse with a second attack of diverticulitis. Early studies described rates of complicated diverticulitis in recurrent disease of almost 60 percent and a doubling of the mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ]. These data have been the foundation for recommending an operation after a second attack.",
"   </p>",
"   <p>",
"    However, later studies suggest that the prognosis after a second attack may be better than previously reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This was illustrated in a series of 110 patients who were treated conservatively for a first episode of diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/31\">",
"     31",
"    </a>",
"    ]. Follow-up was complete in 83 patients, 15 of whom (18 percent) recurred once and six of whom (7 percent) recurred twice or more during a median of 10.5 years. Only nine patients required inpatient therapy during a recurrence, two underwent operation, and none required an emergency procedure. The authors concluded that recurrent diverticulitis can be treated in a similar fashion to a first episode and that medical therapy remains a valuable alternative to surgery. In another report, morbidity and mortality were not significantly different between patients with more than two episodes of diverticulitis compared with those with one or two prior attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these later observations, elective surgery is",
"    <strong>",
"     not",
"    </strong>",
"    necessary for all patients who respond to medical therapy. However, the possible increased risk of complications with a second episode emphasizes the importance of identifying patients who are more likely to have a recurrence after a first attack of diverticulitis and those who are at increased risk for complications. Patients in whom elective surgery has been recommended following a single attack of diverticulitis include younger patients (variously defined in the literature as less than 40 or 50 years of age) and those who are immunosuppressed. However, the role of bowel resection in younger patients is controversial (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Young patients'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients who are treated operatively are usually cured, with the development of new diverticula in the remaining colon occurring in only 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/33\">",
"     33",
"    </a>",
"    ], and a need for further surgery in 2 to 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. However, up to 27 percent of these patients may describe abdominal pain postoperatively in the same location; these persistent symptoms may be explained by coexistent irritable bowel syndrome rather than recurrent diverticulitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875525214\">",
"    <span class=\"h3\">",
"     Smoldering diverticulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of patients who develop acute diverticulitis do not follow the classic pattern of resolving with either antibiotics or after surgical resection. Such patients have been described as having \"smoldering\" diverticulitis. In a series of 930 patients who underwent sigmoid resection for diverticular disease, 47 (5 percent) had symptoms consistent with smoldering diverticular disease; all had chronic left lower quadrant pain for more than six months (mean 93 months) and some had an alteration in bowel habits or rectal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/36\">",
"     36",
"    </a>",
"    ]. Acute or chronic inflammatory changes were present in 76 percent of resected specimens. Complete resolution of symptoms occurred in 77 percent, with 88 percent becoming pain free.",
"   </p>",
"   <p>",
"    The authors concluded that smoldering diverticular disease is uncommon and poorly defined but that resection can be beneficial. Since all patients were treated surgically, the natural history of this disorder could not be determined. The diagnosis of smoldering diverticulitis must be made carefully, since less stringently selected patients may have irritable bowel syndrome or other causes of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of anti-inflammatory treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the theory that chronic inflammation plays a role in diverticulitis, there is increasing interest in use of anti-inflammatory agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    in the management of diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. While this strategy appears promising, there are no controlled studies and no information on the long-term efficacy and safety of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATED DIVERTICULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional factors must be considered in patients with one of the complications of diverticulitis, such as obstruction, perforation, abscess formation, or fistula formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse peritonitis mandates resuscitation, broad-spectrum antibiotics, and emergency exploration; diagnostic studies are rarely necessary. Examples of antibiotic regimens we have used are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      (2 g IV every six hours),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (1.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every 8 hours)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Imipenem/cilastin",
"      </span>",
"      (500 mg IV every six hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (3.375 g IV every six hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perforated diverticulitis has a mortality rate of 6 percent for purulent peritonitis and 35 percent for fecal peritonitis (peritonitis with fecal soilage) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of administering an appropriate initial empiric antibiotic regimen was illustrated in a review of 425 patients who required surgery for community-acquired secondary peritonitis, including patients with diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/40\">",
"     40",
"    </a>",
"    ]. In 13 percent of patients, the initial antibiotic regimen was inappropriate, defined as not covering all bacteria subsequently isolated or not covering both aerobic and anaerobic organisms in the absence of culture results. Resolution of the infection with initial or step-down therapy after primary surgery was significantly less likely with an inappropriate regimen (53 versus 79 percent); failure to achieve such clinical success was associated with a six day prolongation in hospitalization (20 versus 14 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticular obstruction is rarely complete, usually allowing for bowel preparation. A primary concern is differentiation from carcinoma; even with negative biopsies, resection is mandatory in lesions in which there is suspicion for malignancy based upon their appearance alone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67258 \" href=\"UTD.htm?14/43/15039\">",
"     image 1",
"    </a>",
"    ). Resection with primary anastomosis is usually possible; a colostomy is required if the preparation is inadequate or on table colonic lavage can be considered to permit primary anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free intraperitoneal rupture of diverticulitis is unusual; however, such patients have high mortality rates of 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. Treatment usually involves a two-stage procedure as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abscesses occur in 16 percent of patients with acute diverticulitis without peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/42\">",
"     42",
"    </a>",
"    ] and in 31 to 56 percent of those requiring surgery for diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/27\">",
"     27",
"    </a>",
"    ]. Prior to interventional radiologic techniques, abscesses mandated operative intervention, often with two-stage procedures. Percutaneous drainage now permits elective single stage surgery in 60 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]; furthermore, in selected patients with contraindications to surgery, catheter drainage may be sufficient to relieve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/44\">",
"     44",
"    </a>",
"    ]. Drainage is usually performed through the anterior abdominal wall; abscesses deep in the pelvis or obscured by other organs may be accessed transgluteally, or through the rectum or vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The catheter is left in place until drainage is less than 10 mL in 24 hours; this may take as long as 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/44\">",
"     44",
"    </a>",
"    ]. Catheter sinograms during this period can show persistent communication between fistula and bowel, and permit assessment of resolution of the abscess cavity. Surgical intervention is mandatory if improvement does not occur.",
"   </p>",
"   <p>",
"    Until recently, all abscesses have been considered to represent complicated diverticulitis, and surgery has typically been recommended once resolution has occurred. However, with continued improvements in CT scan technology, smaller abscesses can be identified. Some of these are so small (ie, less than 3 cm) that they are not amenable to CT guided drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In addition to size limitations, the presence of small bowel loops adjacent to the collection may preclude drainage. Abscess recurrence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fistula formation after percutaneous drainage may also complicate the patient's course and compromise the surgical approach. Accordingly, there has been interest in treating small abscesses with systemic antibiotics alone.",
"   </p>",
"   <p>",
"    In a retrospective study of 22 patients with 23 diverticular abscesses less than 3 cm in diameter and no evidence of free air, all resolved the acute episode with antibiotic treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/48\">",
"     48",
"    </a>",
"    ]. In subsequent follow up, 36 percent required eventual surgery, 41 percent reported full resolution of symptoms, and 23 percent had mild recurrent or persistent symptoms that did not warrant surgery. Limitations of the study are the small sample size and the lack of proof that these collections were actually abscesses as opposed to localized reactive peritoneal fluid collections.",
"   </p>",
"   <p>",
"    Patients with acute diverticulitis should be evaluated by a surgeon. CT scan findings should be reviewed with the interventional radiologist to determine if any collections are amenable to percutaneous drainage. Indications for immediate surgery include free intraperitoneal air. A patient with a fluid collection less than 3 cm and not amenable to catheter drainage can be treated with intravenous antibiotics and monitored carefully for any worsening of symptoms. Patients with worsening symptoms require surgical intervention.",
"   </p>",
"   <p>",
"    For patients who are treated by CT-guided percutaneous drainage, surgery is indicated if the drain does not control symptoms by the third or fifth day. For patients successfully treated by percutaneous drainage, a clinical assessment is made to determine if the patient can be safely observed, or as in the case of high risk patients (eg, advanced age, debility, and chronic immunosuppressive therapy), an operative intervention is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticulitis involves the sigmoid colon in approximately 90 percent of cases. Thus, fistulas arising from diverticulitis usually involve the sigmoid colon. The approach to this problem is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42819?source=see_link\">",
"     \"Acute diverticulitis complicated by fistula formation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery in patients who respond to conservative therapy depends upon the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/50\">",
"     50",
"    </a>",
"    ]. After successful medical treatment of one attack of acute diverticulitis, approximately one third of patients will develop a later second attack [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/1\">",
"     1",
"    </a>",
"    ]. After a second attack, another one third of patients will have yet a third attack. Among all patients with acute diverticulitis, approximately 20 percent will require surgical intervention at some time during the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/51\">",
"     51",
"    </a>",
"    ]. Nearly all patients who undergo an operation have either had complicated diverticulitis or alternatively, experienced several episodes of recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While operative management has been advised after a first attack of complicated diverticulitis or after two or more episodes of uncomplicated diverticulitis, there is increasing evidence that arbitrary guidelines for surgical management, particularly for recurrent attacks, are inappropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The exceptions to that statement are certain groups of patients, such as those who are immunocompromised. As always, the risks and benefits of surgery should be tailored to the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9998547\">",
"    <span class=\"h2\">",
"     Surgical goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of surgery are to remove the septic focus by resection of the colon, to treat obstruction or fistula, and to restore bowel continuity while minimizing morbidity and mortality. Surgical mortality rate is approximately 1.3 to 5 percent depending upon the severity of illness and the presence of comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/29,54\">",
"     29,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9997103\">",
"    <span class=\"h2\">",
"     Laparoscopic versus open resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growing experience with laparoscopic techniques for performing colonic resections suggests that it is associated with a shorter recovery time than traditional open approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/5,55-62\">",
"     5,55-62",
"    </a>",
"    ]. Laparoscopic resection appears to be best suited for patients in whom the episode of acute diverticulitis has resolved and in patients with stage I or II disease according to the Hinchey classification (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Intraoperative assessment'",
"    </a>",
"    below) provided that a surgeon experienced with laparoscopic surgery of the colon is available [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fast-track recovery protocols may incrementally improve perioperative outcomes in patients for whom elective laparoscopic surgery is performed. A retrospective review of 334 patients undergoing a laparoscopic sigmoidectomy for diverticulitis found that patients managed by a fast-track postoperative protocol (n=99) had significantly shorter times to consuming a soft diet (2.3 versus 3.6 days), first bowel movement (2.6 versus 3.5 days), median length of hospital stay (3 versus 5 days), and lower morbidity (15 versus 26 percent) compared with patients managed with traditional postoperative care [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the number of experienced laparoscopic surgeons increases, the indications for and acceptance of laparoscopic resection of diverticulitis are increasing. As shown in the following studies, nearly all patients requiring resection for diverticular disease can potentially be approached laparoscopically, with the exception of patients with generalized peritonitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only prospective trial comparing laparoscopic sigmoid resection to open sigmoid resection for sigmoid diverticulitis (the Sigma trial) reported on 104 patients from five centers [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/64\">",
"       64",
"      </a>",
"      ]. Half of the patients underwent laparoscopic surgery and the other half underwent open surgery for sigmoid diverticulitis. The conversion rate was 19 percent. In this series, laparoscopic sigmoid resection took longer but resulted in less blood loss, fewer major complications, less pain, and shorter hospital stays.",
"     </li>",
"     <li>",
"      A meta-analysis of 19 comparative studies of 1014 patients undergoing an elective laparoscopic sigmoidectomy for diverticular disease reported significantly fewer wound infections (RR = 1.85, 95% CI 1.25-2.78), blood transfusions (RR = 4.0, 95% CI 1.67-10.0), postoperative ileus rates (RR = 2.70, 95% CI 1.52-5.0), and incisional hernias (RR = 3.70, 95% CI 1.56-8.33) compared with 1369 patients undergoing an elective open sigmoidectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/65\">",
"       65",
"      </a>",
"      ]. There was no significant difference in anastomotic leak rate, anastomotic stricture rate, inadvertent enterotomy, small bowel obstruction, or intra-abdominal bleeding or abscess formation.",
"     </li>",
"     <li>",
"      A retrospective analysis of 500 patients who underwent laparoscopic resection for uncomplicated and complicated diverticulitis at a single center from 1991 to 2007 demonstrated that laparoscopic resection was safe and effective even in complicated cases of diverticulitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/66\">",
"       66",
"      </a>",
"      ]. Indications for surgery were at least two attacks of confirmed diverticulitis with evidence of inflammation requiring antibiotic treatment (77 percent), evidence of diverticular associated stenosis (3 percent), or fistulization to skin, bladder, or vagina (9 percent), and localized perforation or abscess. Median operating time was 120 minutes, median hospital stay was four days, and conversion rate was 2.8 percent. Perioperative complications included one postoperative death from myocardial infarction, three anastomotic bleeds, three intraabdominal hematomas, seven anastomotic leaks, six wound infections, and three pulmonary emboli. Late complications included one anastomotic structure, one small bowel obstruction and two incisional hernias. There were no cases of recurrent diverticulitis after laparoscopic resection.",
"     </li>",
"     <li>",
"      A retrospective review evaluated short term outcomes for 361 patients who underwent either an open or laparoscopic resection for complicated (n=136) diverticulitis compared with uncomplicated (n=225) diverticulitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients with complicated diverticulitis had a similar mean return to bowel function (3.1 versus 3.2 days), and no significant difference for morbidity (28 versus 20 percent), or mean length of hospital stay (5.4 versus 4.8 days). There were no 30-day deaths.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients receive antibiotics, a second or third generation cephalosporin or more broad-spectrum antibiotics, depending upon the degree of contamination. Examples of regimens we have used are:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 g IV every eight hours) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg IV every 8 hours);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    (1.5 g IV every six hours); or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    (3.1 g IV every six hours). For patients with more extensive contamination, we use the regimens described above for peritonitis.",
"   </p>",
"   <p>",
"    Bowel preparation is often possible in nonemergent situations. Patients should be advised before surgery of the possibility of a stoma and the abdominal wall should be marked. The modified lithotomy position allows the use of a circular stapler if an anastomosis is possible. Intraoperative proctoscopy permits assessment and emptying of the rectum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intraoperative assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the emergency setting, the abdomen is explored through a midline incision; in the elective setting (usually at least six weeks after the episode of diverticulitis has resolved) a laparoscopic approach may be possible. Assessment of peritoneal contamination using Hinchey's classification determines the advisability of a primary anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; pericolic or mesenteric abscess",
"     </li>",
"     <li>",
"      Stage II &mdash; walled-off pelvic abscess",
"     </li>",
"     <li>",
"      Stage III &mdash; generalized purulent peritonitis",
"     </li>",
"     <li>",
"      Stage IV &mdash; generalized fecal peritonitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In elective or semielective situations, resection and primary anastomosis are often possible, since the disease is well-localized or has significantly resolved. Patients with Hinchey stages I and II disease can usually have a bowel preparation preoperatively. The bowel must be well-vascularized, nonedematous, tension-free, and well-prepared. The distal resection margin is in the upper third of the rectum, where the taenia coalesce; the proximal margin is where the colon becomes soft and nonedematous. It is not necessary to remove",
"    <strong>",
"     all",
"    </strong>",
"    diverticula-bearing colon proximal to the intended anastomosis to prevent recurrence since diverticula proximal to the",
"    <span class=\"nowrap\">",
"     descending/sigmoid",
"    </span>",
"    colon are unlikely to result in further symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/35\">",
"     35",
"    </a>",
"    ]. Contraindications to primary anastomosis are fecal or purulent peritonitis, associated medical conditions, poor nutrition, and immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two-stage procedures are typically used in emergency situations with peritoneal contamination (",
"    <a class=\"graphic graphic_figure graphicRef61440 \" href=\"UTD.htm?10/32/10758\">",
"     figure 2",
"    </a>",
"    ). A common approach is the Hartmann procedure, which involves resection of the diseased colon, an end-colostomy, and creation of a rectal stump; this is followed by colostomy closure three months later [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach entails resection, primary anastomosis, and proximal diverting stoma (colostomy or ileostomy); the second stage is stoma closure (",
"    <a class=\"graphic graphic_figure graphicRef70246 \" href=\"UTD.htm?17/24/17792\">",
"     figure 3",
"    </a>",
"    ). This approach is used when there are relative contraindications to primary anastomosis, but no purulent or fecal peritonitis and the bowel is nonedematous. It is preferred to the first approach in these settings because of the difficulty of reversing a Hartmann procedure after generalized peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Although still very controversial, there is increasing experience with primary anastomosis in the acute setting in the presence of an unprepared colon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/71\">",
"     71",
"    </a>",
"    ]. As an alternative, on-table colonic lavage may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resection, diverting colostomy and a Hartmann rectal stump is the preferred approach in patients with fecal peritonitis and in most cases with purulent peritonitis (",
"    <a class=\"graphic graphic_figure graphicRef61440 \" href=\"UTD.htm?10/32/10758\">",
"     figure 2",
"    </a>",
"    ). A mucous fistula, in which the distal end of the transected bowel is brought through the abdominal wall, is often not possible after resection of the entire sigmoid. Many surgeons mark the rectal stump with a long nonabsorbable suture and tack it to the anterior abdominal wall or sacral promontory.",
"   </p>",
"   <p>",
"    The classic three-stage procedure is now rarely indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/73\">",
"     73",
"    </a>",
"    ] because it is associated with a higher mortality rate (26 versus 7 percent after resection) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/39\">",
"     39",
"    </a>",
"    ]. The first stage is drainage of the diseased segment, plus a proximal diverting stoma, without resection. This is followed by resection with primary anastomosis, and then by closure of the stoma. In exceptional cases, when inflammation precludes safe dissection of iliac vessels and ureters or the patient is unstable, it may be necessary to drain the area and create a proximal stoma. Drainage and diversion may also be performed to stabilize the patient prior to transfer to a large center.",
"   </p>",
"   <p>",
"    If a mucous fistula is created, a portion of the rectosigmoid and possibly the sigmoid must, by definition, remain for it to reach the anterior abdominal wall. Thus, any patient with a mucus fistula will require additional resection of the rectosigmoid down to the proximal rectum at the time of colostomy closure (reversal of Hartmann's procedure) to avoid retention of diverticula that may subsequently cause further symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach recommended thus far may need to be amended in selected patients, including those under age 40, those who are immunosuppressed, and those with right-sided diverticulitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Young patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of patients with acute diverticulitis who are under age 40 is controversial. Resection had traditionally been recommended after one episode, an approach that was based upon two premises: these patients have more virulent disease; and those who respond to medical therapy are more likely to have recurrent diverticulitis and ultimately require surgical intervention. However, although certain features are common to most series, there is dissent as to the virulence of the disease and its natural history.",
"   </p>",
"   <p>",
"    Young patients with diverticulitis comprise 12 to 29 percent of large series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/69,74-77\">",
"     69,74-77",
"    </a>",
"    ]. There is a male predominance, ranging from 2:1 to 4:1; in addition, the great majority of patients are obese [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/29,41\">",
"     29,41",
"    </a>",
"    ]. Large series of all patients with diverticulitis note an operative rate of 27 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. The thought that diverticulitis is more virulent in the young arises from studies with operative rates of 48 to 88 percent in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/69,75,77,78\">",
"     69,75,77,78",
"    </a>",
"    ]; however, others describe rates of surgery similar to those in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/74,76,79\">",
"     74,76,79",
"    </a>",
"    ]. In a review of 1019 consecutive patients with acute diverticulitis, patients 40 years and younger had a similar risk of a covered (30.4 versus 29.5 percent) or a free perforation (26.1 versus 23.9 percent) at presentation compared with older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/79\">",
"     79",
"    </a>",
"    ]. There was no significant difference for the rate of emergency surgery (26.1 versus 23.9 percent) or failure of conservative treatment for the younger patients (3.4 versus 4.9 percent).",
"   </p>",
"   <p>",
"    One problem may be that many young patients undergo urgent surgery because of an incorrect preoperative diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/80\">",
"     80",
"    </a>",
"    ]; in some series with high rates of surgery, the incidence of incorrect diagnosis has been as high as 41 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/69,75\">",
"     69,75",
"    </a>",
"    ]. If CT or contrast studies are used to establish the diagnosis, the operative rate in young patients may actually be lower than that in older patients (15 versus 33 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history after medical management of young patients is also disputed. Some studies report rates of readmission of 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/81,82\">",
"     81,82",
"    </a>",
"    ] and subsequent operative rates of 20 to 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/80,81,83\">",
"     80,81,83",
"    </a>",
"    ]; others report no subsequent surgery after four years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/84\">",
"     84",
"    </a>",
"    ]. When total operative rates are examined, the data become more consistent, with an eventual operative risk, on first admission or later, of about 50 percent. Thus, some series have high initial operative rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/69,75,77\">",
"     69,75,77",
"    </a>",
"    ], while others have a lower rate on admission of 15 to 25 percent, but with poor outcome or later surgery in approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/74,83,85\">",
"     74,83,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, it is unclear if young patients suffer more virulent disease. The literature suggests an ultimate operative rate of about 50 percent; with wider use of CT, it is possible that, although the rate of surgery on the first admission may fall, a larger proportion of patients treated medically may ultimately require resection.",
"   </p>",
"   <p>",
"    There are no convincing arguments to insist on resection after resolution of uncomplicated diverticulitis in a young patient. Once the patient is advised of risks, the issue becomes one of patient evaluation of risk and lifestyle concerns. In patients with no comorbid conditions, elective surgery after one episode remains a reasonable recommendation; others with the same risk are equally justified in wishing to wait.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression is associated with an increased incidence of perforated diverticulitis. Such patients include those on chemotherapy or long-term corticosteroid therapy, but this problem is also apparent in diabetics, those with renal failure, and patients with collagen-vascular disorders such as lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunosuppressed patients may present with minimal symptoms or signs even with frank peritonitis, and diagnosis is frequently delayed. Surgery is necessary in almost all immunocompromised patients, and early surgical intervention should be considered. In one study, for example, medical therapy for acute diverticulitis was successful in 76 percent of 76 nonimmunocompromised patients versus none of 10 immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the limits of currently available data, most surgeons would give serious consideration to surgical resection after a single attack of diverticulitis in any patient who is already immunosuppressed or about to start taking immunosuppressive medications (eg, pretransplant patients). This is probably not the case, however, for patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    where further data are needed. It is also not the case for patients undergoing a limited course of chemotherapy, where elective resection would require one month off chemotherapy before operation and another month for recovery before chemotherapy is resumed. In these cases, completion of the course of chemotherapy is probably more pressing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Right-sided (cecal) diverticulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right-sided (cecal) diverticula account for about 5 percent of diverticulosis in Western countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/89\">",
"     89",
"    </a>",
"    ] and 1.5 percent of cases of diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/90\">",
"     90",
"    </a>",
"    ]. However, right-sided disease is much more common in Asia, accounting for up to 20 percent of cases of diverticular disease and 75 percent of those with diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Most right-sided lesions are thought to be false diverticula [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with right-sided diverticulitis tend to be younger than those with left-sided disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. In published series, the correct preoperative diagnosis is made in only 4 to 16 percent of cases; most patients are thought to have acute appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/92-94\">",
"     92-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations range from medical therapy if the diagnosis is made preoperatively, to appendectomy and antibiotic therapy if the diagnosis is made at laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/91,92\">",
"     91,92",
"    </a>",
"    ], to diverticulectomy for minimal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/91\">",
"     91",
"    </a>",
"    ], and to right hemicolectomy for extensive inflammation or a mass suggestive of carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/94\">",
"     94",
"    </a>",
"    ]. If carcinoma cannot be ruled out at operation, resection may proceed if there are no contraindications to anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/94\">",
"     94",
"    </a>",
"    ]. More extensive evaluation should be performed after recovery from the acute phase. Recommendations for medical therapy were supported by a study from the Netherlands that included 41 patients with right-sided diverticulitis who were treated conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/8/13450/abstract/95\">",
"     95",
"    </a>",
"    ]. During up to 11 years of follow-up, only five patients developed recurrent symptoms, two of whom underwent elective surgery. Of interest, serial ultrasound and CT examinations demonstrated the eventual spontaneous evacuation of the contents of the inflamed diverticulum into the colonic lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/6/1122?source=see_link\">",
"       \"Patient information: Diverticulitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/32/17922?source=see_link\">",
"       \"Patient information: Diverticular disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest conservative treatment (bowel rest and antibiotics) rather than surgery in patients with uncomplicated diverticulitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The success rate for this approach ranges from 70 to 100 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Uncomplicated diverticulitis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The typical outpatient regimen includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , 500 mg PO twice daily plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , 500 mg PO three times daily, although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      <span class=\"nowrap\">",
"       (875/125",
"      </span>",
"      mg twice daily) is an acceptable alternative. Treatment should be continued for 7 to 10 days, depending upon resolution of symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Choice and duration of antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two to six weeks after recovery, patients should undergo a colonoscopy to exclude other diagnostic considerations (such as colonic neoplasia) and to evaluate the extent of the diverticulosis (information that may be important to direct therapy should future complications of diverticulosis occur).",
"     </li>",
"     <li>",
"      Diverticulitis complicated by such clinical findings such as peritonitis, obstruction, or nonlocalized perforation, mandates resuscitation, broad-spectrum antibiotics eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (2 g IV every six hours),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (1.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every 8 hours), as well as emergency exploration. For patients with penicillin allergy,",
"      <span class=\"nowrap\">",
"       imipenem/cilastin",
"      </span>",
"      (500 mg IV every six hours) should be used. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complicated diverticulitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For diverticulitis complicated by a localized abscess formation without peritonitis, we perform radiographic imaging and percutaneous drainage of the fluid collection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Abscess'",
"      </a>",
"      above.) The catheter remains in place until drainage is less than 10 mL in 24 hours. Surgical intervention is mandatory when resolution of the abscess cannot be accomplished by percutaneous drainage.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/1\">",
"      Rafferty J, Shellito P, Hyman NH, et al. Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 2006; 49:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/2\">",
"      Wong WD, Wexner SD, Lowry A, et al. Practice parameters for the treatment of sigmoid diverticulitis--supporting documentation. The Standards Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 2000; 43:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/3\">",
"      Surgical treatment of diverticulitis. Patient Care Committee of the Society for Surgery of the Alimentary Tract (SSAT). J Gastrointest Surg 1999; 3:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/4\">",
"      Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/5\">",
"      K&ouml;hler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg Endosc 1999; 13:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/6\">",
"      Fozard JB, Armitage NC, Schofield JB, et al. ACPGBI position statement on elective resection for diverticulitis. Colorectal Dis 2011; 13 Suppl 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/7\">",
"      Thompson WG, Patel DG. Clinical picture of diverticular disease of the colon. Clin Gastroenterol 1986; 15:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/8\">",
"      Cheskin LJ, Bohlman M, Schuster MM. Diverticular disease in the elderly. Gastroenterol Clin North Am 1990; 19:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/9\">",
"      Detry R, Jamez J, Kartheuser A, et al. Acute localized diverticulitis: optimum management requires accurate staging. Int J Colorectal Dis 1992; 7:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/10\">",
"      Hachigian MP, Honickman S, Eisenstat TE, et al. Computed tomography in the initial management of acute left-sided diverticulitis. Dis Colon Rectum 1992; 35:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/11\">",
"      Kellum JM, Sugerman HJ, Coppa GF, et al. Randomized, prospective comparison of cefoxitin and gentamicin-clindamycin in the treatment of acute colonic diverticulitis. Clin Ther 1992; 14:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/12\">",
"      Larson DM, Masters SS, Spiro HM. Medical and surgical therapy in diverticular disease: a comparative study. Gastroenterology 1976; 71:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/13\">",
"      Biondo S, Par&eacute;s D, Mart&iacute; Ragu&eacute; J, et al. Acute colonic diverticulitis in patients under 50 years of age. Br J Surg 2002; 89:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/14\">",
"      Young-Fadok TM, Roberts PL, Spencer MP, Wolff BG. Colonic diverticular disease. Curr Probl Surg 2000; 37:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/15\">",
"      Dharmarajan S, Hunt SR, Birnbaum EH, et al. The efficacy of nonoperative management of acute complicated diverticulitis. Dis Colon Rectum 2011; 54:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/16\">",
"      Schechter S, Mulvey J, Eisenstat TE. Management of uncomplicated acute diverticulitis: results of a survey. Dis Colon Rectum 1999; 42:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/17\">",
"      Salzman H, Lillie D. Diverticular disease: diagnosis and treatment. Am Fam Physician 2005; 72:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/18\">",
"      Chabok A, P&aring;hlman L, Hjern F, et al. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg 2012; 99:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/19\">",
"      Painter NS. Diverticular disease of the colon. The first of the Western diseases shown to be due to a deficiency of dietary fibre. S Afr Med J 1982; 61:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/20\">",
"      Aldoori WH, Giovannucci EL, Rockett HR, et al. A prospective study of dietary fiber types and symptomatic diverticular disease in men. J Nutr 1998; 128:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/21\">",
"      Brodribb AJ. Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet 1977; 1:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/22\">",
"      Ornstein MH, Littlewood ER, Baird IM, et al. Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J (Clin Res Ed) 1981; 282:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/23\">",
"      Strate LL, Liu YL, Syngal S, et al. Nut, corn, and popcorn consumption and the incidence of diverticular disease. JAMA 2008; 300:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/24\">",
"      Lau KC, Spilsbury K, Farooque Y, et al. Is colonoscopy still mandatory after a CT diagnosis of left-sided diverticulitis: can colorectal cancer be confidently excluded? Dis Colon Rectum 2011; 54:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/25\">",
"      Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/26\">",
"      Rege RV, Nahrwold DL. Diverticular disease. Curr Probl Surg 1989; 26:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/27\">",
"      Rodkey GV, Welch CE. Changing patterns in the surgical treatment of diverticular disease. Ann Surg 1984; 200:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/28\">",
"      Hall JF, Roberts PL, Ricciardi R, et al. Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence? Dis Colon Rectum 2011; 54:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/29\">",
"      Sarin S, Boulos PB. Long-term outcome of patients presenting with acute complications of diverticular disease. Ann R Coll Surg Engl 1994; 76:117.",
"     </a>",
"    </li>",
"    <li>",
"     Imbembo AL, Bailey RW. Diverticular disease of the colon. In: Textbook of Surgery, 14th ed, Sabiston DC Jr (Ed), Churchill Livingstone, 1992. p.910.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/31\">",
"      Chautems R, Ambrosetti P, Ludwig A. Long-term follow-up after first acute episode of sigmoid diverticulitis: Is surgery mandatory. Dis Colon Rectum 2001; 44:A5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/32\">",
"      Kaiser AM. Complicated diverticulitis: it is not yet time to rethink the rules! Ann Surg 2006; 243:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/33\">",
"      Wolff BG, Ready RL, MacCarty RL, et al. Influence of sigmoid resection on progression of diverticular disease of the colon. Dis Colon Rectum 1984; 27:645.",
"     </a>",
"    </li>",
"    <li>",
"     Corman, ML. Colon and Rectal Surgery, 3rd edition, JB Lippincott, Philadelphia 1993. p.817.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/35\">",
"      Benn PL, Wolff BG, Ilstrup DM. Level of anastomosis and recurrent colonic diverticulitis. Am J Surg 1986; 151:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/36\">",
"      Horgan AF, McConnell EJ, Wolff BG, et al. Atypical diverticular disease: surgical results. Dis Colon Rectum 2001; 44:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/37\">",
"      Floch MH, White JA. Management of diverticular disease is changing. World J Gastroenterol 2006; 12:3225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/38\">",
"      Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol 2008; 103:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/39\">",
"      Nagorney DM, Adson MA, Pemberton JH. Sigmoid diverticulitis with perforation and generalized peritonitis. Dis Colon Rectum 1985; 28:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/40\">",
"      Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/41\">",
"      Kriwanek S, Armbruster C, Beckerhinn P, Dittrich K. Prognostic factors for survival in colonic perforation. Int J Colorectal Dis 1994; 9:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/42\">",
"      Ambrosetti P, Robert J, Witzig JA, et al. Prognostic factors from computed tomography in acute left colonic diverticulitis. Br J Surg 1992; 79:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/43\">",
"      Doringer E. Computerized tomography of colonic diverticulitis. Crit Rev Diagn Imaging 1992; 33:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/44\">",
"      Neff CC, vanSonnenberg E, Casola G, et al. Diverticular abscesses: percutaneous drainage. Radiology 1987; 163:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/45\">",
"      Schechter S, Eisenstat TE, Oliver GC, et al. Computerized tomographic scan-guided drainage of intra-abdominal abscesses. Preoperative and postoperative modalities in colon and rectal surgery. Dis Colon Rectum 1994; 37:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/46\">",
"      Kuligowska E, Keller E, Ferrucci JT. Treatment of pelvic abscesses: value of one-step sonographically guided transrectal needle aspiration and lavage. AJR Am J Roentgenol 1995; 164:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/47\">",
"      Schiller VL, Schreiber L, Seaton C, Sarti DA. Transvaginal sonographic diagnosis of sigmoid diverticulitis. Abdom Imaging 1995; 20:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/48\">",
"      Siewert B, Tye G, Kruskal J, et al. Impact of CT-guided drainage in the treatment of diverticular abscesses: size matters. AJR Am J Roentgenol 2006; 186:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/49\">",
"      Brandt D, Gervaz P, Durmishi Y, et al. Percutaneous CT scan-guided drainage vs. antibiotherapy alone for Hinchey II diverticulitis: a case-control study. Dis Colon Rectum 2006; 49:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/50\">",
"      Stollman NH, Raskin JB. Diverticular disease of the colon. J Clin Gastroenterol 1999; 29:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/51\">",
"      Chappuis CW, Cohn I Jr. Acute colonic diverticulitis. Surg Clin North Am 1988; 68:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/52\">",
"      Janes S, Meagher A, Frizelle FA. Elective surgery after acute diverticulitis. Br J Surg 2005; 92:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/53\">",
"      Chapman JR, Dozois EJ, Wolff BG, et al. Diverticulitis: a progressive disease? Do multiple recurrences predict less favorable outcomes? Ann Surg 2006; 243:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/54\">",
"      Constantinides VA, Tekkis PP, Senapati A, Association of Coloproctology of Great Britain Ireland. Prospective multicentre evaluation of adverse outcomes following treatment for complicated diverticular disease. Br J Surg 2006; 93:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/55\">",
"      K&ouml;ckerling F, Schneider C, Reymond MA, et al. Laparoscopic resection of sigmoid diverticulitis. Results of a multicenter study. Laparoscopic Colorectal Surgery Study Group. Surg Endosc 1999; 13:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/56\">",
"      Franklin ME Jr, Dorman JP, Jacobs M, Plasencia G. Is laparoscopic surgery applicable to complicated colonic diverticular disease? Surg Endosc 1997; 11:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/57\">",
"      Stevenson AR, Stitz RW, Lumley JW, Fielding GA. Laparoscopically assisted anterior resection for diverticular disease: follow-up of 100 consecutive patients. Ann Surg 1998; 227:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/58\">",
"      Eijsbouts QA, Cuesta MA, de Brauw LM, Sietses C. Elective laparoscopic-assisted sigmoid resection for diverticular disease. Surg Endosc 1997; 11:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/59\">",
"      Dwivedi A, Chahin F, Agrawal S, et al. Laparoscopic colectomy vs. open colectomy for sigmoid diverticular disease. Dis Colon Rectum 2002; 45:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/60\">",
"      Scheidbach H, Schneider C, Rose J, et al. Laparoscopic approach to treatment of sigmoid diverticulitis: changes in the spectrum of indications and results of a prospective, multicenter study on 1,545 patients. Dis Colon Rectum 2004; 47:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/61\">",
"      Alves A, Panis Y, Slim K, et al. French multicentre prospective observational study of laparoscopic versus open colectomy for sigmoid diverticular disease. Br J Surg 2005; 92:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/62\">",
"      Purkayastha S, Constantinides VA, Tekkis PP, et al. Laparoscopic vs. open surgery for diverticular disease: a meta-analysis of nonrandomized studies. Dis Colon Rectum 2006; 49:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/63\">",
"      Larson DW, Batdorf NJ, Touzios JG, et al. A fast-track recovery protocol improves outcomes in elective laparoscopic colectomy for diverticulitis. J Am Coll Surg 2010; 211:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/64\">",
"      Klarenbeek BR, Veenhof AA, Bergamaschi R, et al. Laparoscopic sigmoid resection for diverticulitis decreases major morbidity rates: a randomized control trial: short-term results of the Sigma Trial. Ann Surg 2009; 249:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/65\">",
"      Siddiqui MR, Sajid MS, Qureshi S, et al. Elective laparoscopic sigmoid resection for diverticular disease has fewer complications than conventional surgery: a meta-analysis. Am J Surg 2010; 200:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/66\">",
"      Jones OM, Stevenson AR, Clark D, et al. Laparoscopic resection for diverticular disease: follow-up of 500 consecutive patients. Ann Surg 2008; 248:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/67\">",
"      Pendlimari R, Touzios JG, Azodo IA, et al. Short-term outcomes after elective minimally invasive colectomy for diverticulitis. Br J Surg 2011; 98:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/68\">",
"      Hinchey EJ, Schaal PG, Richards GK. Treatment of perforated diverticular disease of the colon. Adv Surg 1978; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/69\">",
"      Rothenberger DA, Wiltz O. Surgery for complicated diverticulitis. Surg Clin North Am 1993; 73:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/70\">",
"      Constantinides VA, Tekkis PP, Athanasiou T, et al. Primary resection with anastomosis vs. Hartmann's procedure in nonelective surgery for acute colonic diverticulitis: a systematic review. Dis Colon Rectum 2006; 49:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/71\">",
"      Trillo C, Paris MF, Brennan JT. Primary anastomosis in the treatment of acute disease of the unprepared left colon. Am Surg 1998; 64:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/72\">",
"      Lee EC, Murray JJ, Coller JA, et al. Intraoperative colonic lavage in nonelective surgery for diverticular disease. Dis Colon Rectum 1997; 40:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/73\">",
"      Roberts P, Abel M, Rosen L, et al. Practice parameters for sigmoid diverticulitis. The Standards Task Force American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1995; 38:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/74\">",
"      Ambrosetti P, Robert JH, Witzig JA, et al. Acute left colonic diverticulitis in young patients. J Am Coll Surg 1994; 179:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/75\">",
"      Schauer PR, Ramos R, Ghiatas AA, Sirinek KR. Virulent diverticular disease in young obese men. Am J Surg 1992; 164:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/76\">",
"      Acosta JA, Grebenc ML, Doberneck RC, et al. Colonic diverticular disease in patients 40 years old or younger. Am Surg 1992; 58:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/77\">",
"      Freischlag J, Bennion RS, Thompson JE Jr. Complications of diverticular disease of the colon in young people. Dis Colon Rectum 1986; 29:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/78\">",
"      Pautrat K, Bretagnol F, Huten N, de Calan L. Acute diverticulitis in very young patients: a frequent surgical management. Dis Colon Rectum 2007; 50:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/79\">",
"      Ritz JP, Lehmann KS, Stroux A, et al. Sigmoid diverticulitis in young patients--a more aggressive disease than in older patients? J Gastrointest Surg 2011; 15:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/80\">",
"      Chodak GW, Rangel DM, Passaro E Jr. Colonic diverticulitis in patients under age 40: need for earlier diagnosis. Am J Surg 1981; 141:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/81\">",
"      Ouriel K, Schwartz SI. Diverticular disease in the young patient. Surg Gynecol Obstet 1983; 156:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/82\">",
"      Chautems RC, Ambrosetti P, Ludwig A, et al. Long-term follow-up after first acute episode of sigmoid diverticulitis: is surgery mandatory?: a prospective study of 118 patients. Dis Colon Rectum 2002; 45:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/83\">",
"      Vignati PV, Welch JP, Cohen JL. Long-term management of diverticulitis in young patients. Dis Colon Rectum 1995; 38:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/84\">",
"      Simonowitz D, Paloyan D. Diverticular disease of the colon in patients under 40 years of age. Am J Gastroenterol 1977; 67:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/85\">",
"      Cunningham MA, Davis JW, Kaups KL. Medical versus surgical management of diverticulitis in patients under age 40. Am J Surg 1997; 174:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/86\">",
"      Mpofu S, Mpofu CM, Hutchinson D, et al. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 2004; 63:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/87\">",
"      Young-Fadok T, Sgambati S, Wolff B. Increased morbidity and mortality after colectomy in patients with lupus: A case-matched series (abstract). Dis Colon Rectum 2000; 43:A57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/88\">",
"      Perkins JD, Shield CF 3rd, Chang FC, Farha GJ. Acute diverticulitis. Comparison of treatment in immunocompromised and nonimmunocompromised patients. Am J Surg 1984; 148:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/89\">",
"      Hughes LE. Postmortem survey of diverticular disease of the colon. I. Diverticulosis and diverticulitis. Gut 1969; 10:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/90\">",
"      Fischer MG, Farkas AM. Diverticulitis of the cecum and ascending colon. Dis Colon Rectum 1984; 27:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/91\">",
"      Ngoi SS, Chia J, Goh MY, et al. Surgical management of right colon diverticulitis. Dis Colon Rectum 1992; 35:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/92\">",
"      Sugihara K, Muto T, Morioka Y, et al. Diverticular disease of the colon in Japan. A review of 615 cases. Dis Colon Rectum 1984; 27:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/93\">",
"      Markham NI, Li AK. Diverticulitis of the right colon--experience from Hong Kong. Gut 1992; 33:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/94\">",
"      Lo CY, Chu KW. Acute diverticulitis of the right colon. Am J Surg 1996; 171:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/8/13450/abstract/95\">",
"      Oudenhoven LF, Koumans RK, Puylaert JB. Right colonic diverticulitis: US and CT findings--new insights about frequency and natural history. Radiology 1998; 208:611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1380 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-201.211.0.116-308C262905-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13450=[""].join("\n");
var outline_f13_8_13450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88798216\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UNCOMPLICATED DIVERTICULITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Selection for outpatient management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice and duration of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88798508\">",
"      - Challenge to conventional antibiotic management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dietary recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Seeds and nuts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monitoring the clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recommendations following resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prognosis after resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H875525214\">",
"      - Smoldering diverticulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of anti-inflammatory treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATED DIVERTICULITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRINCIPLES OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9998547\">",
"      Surgical goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9997103\">",
"      Laparoscopic versus open resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intraoperative assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Young patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Right-sided (cecal) diverticulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1380|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/43/15039\" title=\"diagnostic image 1\">",
"      Divertic obstruct Hypaque enema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1380|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/61/16350\" title=\"figure 1\">",
"      Natural history diverticulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/32/10758\" title=\"figure 2\">",
"      Two stage resection divertic dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/24/17792\" title=\"figure 3\">",
"      Loop ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/21/7517\" title=\"table 1\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/52/20299\" title=\"table 2\">",
"      Indix surgery diverticulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42819?source=related_link\">",
"      Acute diverticulitis complicated by fistula formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36854?source=related_link\">",
"      Epidemiology and pathophysiology of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/32/17922?source=related_link\">",
"      Patient information: Diverticular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/6/1122?source=related_link\">",
"      Patient information: Diverticulitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_8_13451="Early symptomatic HIV";
var content_f13_8_13451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of B conditions in early symptomatic HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Thrush",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal candidiasis that is persistent, frequent, or difficult to manage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral hairy leukoplakia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes zoster involving two episodes or more than one dermatome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacillary angiomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constitutional symptoms such as fever (38.5&deg;C) or diarrhea for more than one month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic inflammatory disease, especially if complicated by a tubo-ovarian abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listeriosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13451=[""].join("\n");
var outline_f13_8_13451=null;
var title_f13_8_13452="Causes of diffuse alveolar damage";
var content_f13_8_13452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of diffuse alveolar damage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acute respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic acute interstitial pneumonia (Hamman Rich syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chemotherapeutic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ethchlorvynol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radiation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oxygen toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heroin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Toxic inhalants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chlorine gas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nitrogen dioxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Phosgene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Smoke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ingestants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paraquat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Kerosene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rapeseed oil-toxic oil syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polymyositis&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lupus pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Legionella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mycoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral, including influenza and severe acute respiratory syndrome (SARS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13452=[""].join("\n");
var outline_f13_8_13452=null;
var title_f13_8_13453="Second line TB drugs for adults";
var content_f13_8_13453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of second line antituberculosis drugs in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily adult dosage*",
"        <br/>",
"        (normal renal function)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main adverse affects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin",
"       </td>",
"       <td>",
"        1000 mg orally or IV",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        GI toxicity, CNS effects, rash, dysglycemia, tendonitis or tendon rupture, QT prolongation",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        400 mg orally or IV",
"       </td>",
"       <td>",
"        GI toxicity, CNS effects, rash, tendonitis or tendon rupture, QT prolongation, dysglycemia",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capreomycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Auditory and vestibular toxicity, nephrotoxicity, electrolyte disturbances",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kanamycin",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Ototoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Ototoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptomycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Vestibular and ototoxicity, neurotoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethionamide",
"       </td>",
"       <td>",
"        15 to 20 mg/kg orally as a single daily dose or 2 divided doses (max 500 mg twice daily)",
"       </td>",
"       <td>",
"        <p>",
"         GI and hepatic toxicity, neurotoxicity, hypothyroidism, optic neuritis.",
"        </p>",
"        Pyridoxine 50 to 100 mg orally per day may be useful in preventing or reducing neurotoxicity.",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cycloserine",
"       </td>",
"       <td>",
"        10 to 15 mg/kg orally in 2 divided doses (max 500 mg twice daily)",
"       </td>",
"       <td>",
"        <p>",
"         Psychiatric symptoms, headaches, seizures.",
"        </p>",
"        Pyridoxine 50 mg (oral once per day) for every 250 mg of cycloserine may be useful in preventing or reducing neurotoxicity.",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Para-aminosalicylic acid",
"       </td>",
"       <td>",
"        8 to 12 g orally in 2 or 3 divided doses",
"       </td>",
"       <td>",
"        GI toxicity, malabsorption, hypersensitivity, hepatitis, hypothyroidism",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscular; IV: intravenous; GI: gastrointestinal; CNS: central nervous system; max: maximum.",
"     <br/>",
"     * Dosage may need to be adjusted for renal impairment.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Greater efficacy has been observed with administration of 1000 mg (compared with 500 mg) for treatment of multidrug-resistant tuberculosis.",
"     <br/>",
"     &Delta; Generally given 5 to 7 times per week (15 mg/kg, or a maximum of 1 g per dose) for an initial 2 to 4 months, and then (if needed) 2 to 3 times per week (20 to 30 mg/kg, or a maximum of 1.5 g per dose). For patients &gt;59 years old, dosage is reduced to 10 mg/kg (max 750 mg per dose). Dosage should be decreased if renal function is diminished.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     For patients who are overweight or obese, dose is based on ideal body weight or dosing weight (see UpToDate calculator). Adjust dose based on serum concentration monitoring for target trough &lt;1 mcg/mL and target peak of 56 to 64 mcg/mL for once daily administration.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with special permission from: Treatment Guidelines from The Medical Letter, April 2012; Vol. 10 (116):29.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13453=[""].join("\n");
var outline_f13_8_13453=null;
var title_f13_8_13454="Pustular psoriasis";
var content_f13_8_13454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pustular psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 232px; height: 156px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pustular psoriasis is characterized by widespread erythema and scaling and sheets of superficial pustules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13454=[""].join("\n");
var outline_f13_8_13454=null;
var title_f13_8_13455="Walk up wall stretch PI";
var content_f13_8_13455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Walk-up-wall stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Face a wall and stand about three-quarters of an arm's length away. Put your fingers on the wall. Then walk your fingers up the wall until your arm is at shoulder level. Use your shoulder muscles as little as possible and keep your shoulders level (do not shrug them). Repeat this stretch 10 to 20 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_8_13455=[""].join("\n");
var outline_f13_8_13455=null;
